6	CD	6	6	6	N	O
ADVERSE	JJ	adverse	adverse	advers	N	O
REACTIONS	NN	reactions	reaction	reaction	N	O

The	DT	the	the	the	N	O
following	VBG	following	following	follow	N	O
serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
discussed	VBN	discussed	discussed	discuss	N	O
in	IN	in	in	in	N	O
greater	JJR	greater	greater	greater	N	O
detail	NN	detail	detail	detail	N	O
in	IN	in	in	in	N	O
another	DT	another	another	anoth	N	O
section	NN	section	section	section	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
label	NN	label	label	label	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
)]	NN	)]	)]	)]	N	O
:	:	:	:	:	N	O

Non	NNP	non	non	non	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
infectious	JJ	infectious	infectious	infecti	N	I-AdverseReaction
pneumonitis	NN	pneumonitis	pneumonitis	pneumon	Y	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Infections	NNS	infections	infection	infect	N	B-AdverseReaction
[	VBP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Angioedema	NN	angioedema	angioedema	angioedema	Y	B-AdverseReaction
with	IN	with	with	with	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
ACE	NNP	ace	ace	ace	N	O
inhibitors	NNS	inhibitors	inhibitor	inhibitor	N	O
[	VBD	[	[	[	N	O
see	JJ	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Oral	JJ	oral	oral	oral	N	B-AdverseReaction
ulceration	NN	ulceration	ulceration	ulcer	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Renal	JJ	renal	renal	renal	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Impaired	NNP	impaired	impaired	impair	N	B-AdverseReaction
wound	VBD	wound	wound	wound	Y	I-AdverseReaction
healing	VBG	healing	healing	heal	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
are	VBP	are	are	are	N	O
conducted	VBN	conducted	conducted	conduct	N	O
under	IN	under	under	under	N	O
widely	RB	widely	widely	wide	N	O
varying	VBG	varying	varying	vari	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
cannot	JJ	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
directly	RB	directly	directly	directli	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
rates	NNS	rates	rate	rate	N	O
in	IN	in	in	in	N	O
other	JJ	other	other	other	N	O
trials	NNS	trials	trial	trial	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
not	RB	not	not	not	N	O
reflect	VB	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
practice	NN	practice	practice	practic	N	O
.	.	.	.	.	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O

:	:	:	:	:	N	O
Advanced	NNP	advanced	advanced	advanc	N	O
HR	NNP	hr	hr	hr	N	O
BC	NNP	bc	bc	bc	N	O
,	,	,	,	,	N	O
advanced	VBD	advanced	advanced	advanc	N	O
PNET	NNP	pnet	pnet	pnet	N	O
,	,	,	,	,	N	O
advanced	VBD	advanced	advanced	advanc	N	O
RCC	NNP	rcc	rcc	rcc	N	O
:	:	:	:	:	N	O
Most	JJS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
incidence	VB	incidence	incidence	incid	N	O
30%	CD	30%	30%	30%	N	O
)	)	)	)	)	N	O
include	VBP	include	include	includ	N	O
stomatitis	NN	stomatitis	stomatitis	stomat	Y	B-AdverseReaction
,	,	,	,	,	N	O
infections	NNS	infections	infection	infect	N	B-AdverseReaction
,	,	,	,	,	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
,	,	,	,	,	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
,	,	,	,	,	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
edema	NN	edema	edema	edema	Y	B-AdverseReaction
,	,	,	,	,	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
fever	NN	fever	fever	fever	Y	B-AdverseReaction
,	,	,	,	,	N	O
asthenia	NN	asthenia	asthenia	asthenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
cough	NN	cough	cough	cough	Y	B-AdverseReaction
,	,	,	,	,	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
and	CC	and	and	and	N	O
decreased	VBD	decreased	decreased	decreas	N	B-AdverseReaction
appetite	NN	appetite	appetite	appetit	N	I-AdverseReaction
.	.	.	.	.	N	O

(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
,	,	,	,	,	N	O
6.2	CD	6.2	6.2	6.2	N	O
,	,	,	,	,	N	O
6.3	CD	6.3	6.3	6.3	N	O
)	)	)	)	)	N	O

Renal	JJ	renal	renal	renal	N	O
angiomyolipoma	NN	angiomyolipoma	angiomyolipoma	angiomyolipoma	Y	O
with	IN	with	with	with	N	O
TSC	NNP	tsc	tsc	tsc	N	O
:	:	:	:	:	N	O
Most	JJS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
(	(	(	(	(	N	O
incidence	VB	incidence	incidence	incid	N	O
30%	CD	30%	30%	30%	N	O
)	)	)	)	)	N	O
is	VBZ	is	is	is	N	O
stomatitis	JJ	stomatitis	stomatitis	stomat	Y	B-AdverseReaction
.	.	.	.	.	N	O

(	(	(	(	(	N	O
6.4	CD	6.4	6.4	6.4	N	O
)	)	)	)	)	N	O

SEGA	NN	sega	sega	sega	N	O
with	IN	with	with	with	N	O
TSC	NNP	tsc	tsc	tsc	N	O
:	:	:	:	:	N	O
Most	JJS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
incidence	VB	incidence	incidence	incid	N	O
30%	CD	30%	30%	30%	N	O
)	)	)	)	)	N	O
are	VBP	are	are	are	N	O
stomatitis	JJ	stomatitis	stomatitis	stomat	Y	B-AdverseReaction
and	CC	and	and	and	N	O
respiratory	JJ	respiratory	respiratory	respiratori	N	B-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
.	.	.	.	.	N	O

(	(	(	(	(	N	O
6.5	CD	6.5	6.5	6.5	N	O
)	)	)	)	)	N	O

To	TO	to	to	to	N	O
report	VB	report	report	report	N	O
SUSPECTED	NNP	suspected	suspected	suspect	N	O
ADVERSE	NNP	adverse	adverse	advers	N	O
REACTIONS	NNP	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
contact	NN	contact	contact	contact	N	O
Novartis	NNP	novartis	novartis	novarti	N	O
Pharmaceuticals	NNP	pharmaceuticals	pharmaceutical	pharmaceut	N	O
Corporation	NNP	corporation	corporation	corpor	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
888	CD	888	888	888	N	O
-	:	-	-	-	N	O
669	CD	669	669	669	N	O
-	:	-	-	-	N	O
6682	CD	6682	6682	6682	N	O
or	CC	or	or	or	N	O
FDA	NNP	fda	fda	fda	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
FDA	NNP	fda	fda	fda	N	O
-	:	-	-	-	N	O
1088	CD	1088	1088	1088	N	O
or	CC	or	or	or	N	O
www	VB	www	www	www	N	O
.	.	.	.	.	N	O
fda	NN	fda	fda	fda	N	O
.	.	.	.	.	N	O
gov	JJ	gov	gov	gov	N	O
medwatch	NN	medwatch	medwatch	medwatch	N	O
.	.	.	.	.	N	O

6.1	CD	6.1	6.1	6.1	N	O

Clinical	JJ	clinical	clinical	clinic	N	O
Study	NNP	study	study	studi	N	O
Experience	NNP	experience	experience	experi	N	O
in	IN	in	in	in	N	O
Advanced	NNP	advanced	advanced	advanc	N	O
Hormone	NNP	hormone	hormone	hormon	N	O
Receptor	NNP	receptor	receptor	receptor	N	O
-	:	-	-	-	N	O
Positive	NN	positive	positive	posit	N	O
,	,	,	,	,	N	O
HER2	NNP	her2	her2	her2	N	O
-	:	-	-	-	N	O
Negative	JJ	negative	negative	neg	N	O
Breast	NNP	breast	breast	breast	N	O
Cancer	NNP	cancer	cancer	cancer	Y	O

The	DT	the	the	the	N	O
efficacy	NN	efficacy	efficacy	efficaci	N	O
and	CC	and	and	and	N	O
safety	NN	safety	safety	safeti	N	O
of	IN	of	of	of	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
(	(	(	(	(	N	O
10	CD	10	10	10	N	O
mg	RB	mg	mg	mg	N	O
day	NN	day	day	day	N	O
)	)	)	)	)	N	O
plus	CC	plus	plus	plu	N	O
exemestane	NN	exemestane	exemestane	exemestan	N	O
(	(	(	(	(	N	O
25	CD	25	25	25	N	O
mg	RB	mg	mg	mg	N	O
day	NN	day	day	day	N	O
)	)	)	)	)	N	O
(	(	(	(	(	N	O
n	$	n	n	n	N	O
485	CD	485	485	485	N	O
)	)	)	)	)	N	O
versus	NN	versus	versus	versu	N	O
placebo	NN	placebo	placebo	placebo	N	O
plus	CC	plus	plus	plu	N	O
exemestane	NN	exemestane	exemestane	exemestan	N	O
(	(	(	(	(	N	O
25	CD	25	25	25	N	O
mg	RB	mg	mg	mg	N	O
day	NN	day	day	day	N	O
)	)	)	)	)	N	O
(	(	(	(	(	N	O
n	$	n	n	n	N	O
239	CD	239	239	239	N	O
)	)	)	)	)	N	O
was	VBD	was	wa	wa	N	O
evaluated	VBN	evaluated	evaluated	evalu	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
randomized	NN	randomized	randomized	random	N	O
,	,	,	,	,	N	O
controlled	VBN	controlled	controlled	control	N	O
trial	NN	trial	trial	trial	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
advanced	JJ	advanced	advanced	advanc	N	O
or	CC	or	or	or	N	O
metastatic	JJ	metastatic	metastatic	metastat	N	O
hormone	NN	hormone	hormone	hormon	N	O
receptor	NN	receptor	receptor	receptor	N	O
-	:	-	-	-	N	O
positive	JJ	positive	positive	posit	N	O
,	,	,	,	,	N	O
HER2	NNP	her2	her2	her2	N	O
-	:	-	-	-	N	O
negative	JJ	negative	negative	neg	N	O
breast	NN	breast	breast	breast	N	O
cancer	NN	cancer	cancer	cancer	Y	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
median	JJ	median	median	median	N	O
age	NN	age	age	age	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
was	VBD	was	wa	wa	N	O
61	CD	61	61	61	N	O
years	NNS	years	year	year	N	O
(	(	(	(	(	N	O
range	NN	range	range	rang	N	O
28	CD	28	28	28	N	O
-	:	-	-	-	N	O
93	CD	93	93	93	N	O
years	NNS	years	year	year	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
75%	CD	75%	75%	75%	N	O
were	VBD	were	were	were	N	O
Caucasian	JJ	caucasian	caucasian	caucasian	N	O
.	.	.	.	.	N	O

Safety	NN	safety	safety	safeti	N	O
results	NNS	results	result	result	N	O
are	VBP	are	are	are	N	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
a	DT	a	a	a	N	O
median	JJ	median	median	median	N	O
follow	NN	follow	follow	follow	N	O
-	:	-	-	-	N	O
up	IN	up	up	up	N	O
of	IN	of	of	of	N	O
approximately	RB	approximately	approximately	approxim	N	O
13	CD	13	13	13	N	O
months	NNS	months	month	month	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
incidence	VB	incidence	incidence	incid	N	O
30%	CD	30%	30%	30%	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
stomatitis	VBN	stomatitis	stomatitis	stomat	Y	B-AdverseReaction
,	,	,	,	,	N	O
infections	NNS	infections	infection	infect	N	B-AdverseReaction
,	,	,	,	,	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
,	,	,	,	,	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
,	,	,	,	,	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
decreased	VBD	decreased	decreased	decreas	N	B-AdverseReaction
appetite	NN	appetite	appetite	appetit	N	I-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
4	CD	4	4	4	N	I-Severity
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
incidence	VB	incidence	incidence	incid	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
stomatitis	VBN	stomatitis	stomatitis	stomat	Y	B-AdverseReaction
,	,	,	,	,	N	O
infections	NNS	infections	infection	infect	N	B-AdverseReaction
,	,	,	,	,	N	O
hyperglycemia	NN	hyperglycemia	hyperglycemia	hyperglycemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
,	,	,	,	,	N	O
dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
,	,	,	,	,	N	O
pneumonitis	NN	pneumonitis	pneumonitis	pneumon	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
(	(	(	(	(	N	O
incidence	VB	incidence	incidence	incid	N	O
50%	CD	50%	50%	50%	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
hypercholesterolemia	VBN	hypercholesterolemia	hypercholesterolemia	hypercholesterolemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
hyperglycemia	NN	hyperglycemia	hyperglycemia	hyperglycemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
increased	VBD	increased	increased	increas	N	B-AdverseReaction
aspartate	JJ	aspartate	aspartate	aspart	N	I-AdverseReaction
transaminase	NN	transaminase	transaminase	transaminas	N	I-AdverseReaction
(	(	(	(	(	N	O
AST	NNP	ast	ast	ast	N	I-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
anemia	RB	anemia	anemia	anemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
leukopenia	NN	leukopenia	leukopenia	leukopenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
thrombocytopenia	NN	thrombocytopenia	thrombocytopenia	thrombocytopenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
lymphopenia	NN	lymphopenia	lymphopenia	lymphopenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
increased	VBD	increased	increased	increas	N	B-AdverseReaction
alanine	JJ	alanine	alanine	alanin	N	I-AdverseReaction
transaminase	NN	transaminase	transaminase	transaminas	N	I-AdverseReaction
(	(	(	(	(	N	O
ALT	NNP	alt	alt	alt	N	I-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
hypertriglyceridemia	NN	hypertriglyceridemia	hypertriglyceridemia	hypertriglyceridemia	Y	B-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
4	CD	4	4	4	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
(	(	(	(	(	N	O
incidence	VB	incidence	incidence	incid	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
lymphopenia	JJ	lymphopenia	lymphopenia	lymphopenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
hyperglycemia	NN	hyperglycemia	hyperglycemia	hyperglycemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
anemia	NN	anemia	anemia	anemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
decreased	VBD	decreased	decreased	decreas	N	B-AdverseReaction
potassium	NN	potassium	potassium	potassium	Y	I-AdverseReaction
,	,	,	,	,	N	O
increased	VBD	increased	increased	increas	N	B-AdverseReaction
AST	NNP	ast	ast	ast	N	I-AdverseReaction
,	,	,	,	,	N	O
increased	VBD	increased	increased	increas	N	B-AdverseReaction
ALT	NNP	alt	alt	alt	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
thrombocytopenia	NN	thrombocytopenia	thrombocytopenia	thrombocytopenia	Y	B-AdverseReaction
.	.	.	.	.	N	O

Fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
occurred	VBD	occurred	occurred	occur	N	O
more	RBR	more	more	more	N	O
frequently	RB	frequently	frequently	frequent	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
plus	CC	plus	plus	plu	N	O
exemestane	NN	exemestane	exemestane	exemestan	N	O
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
patients	NNS	patients	patient	patient	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
plus	CC	plus	plus	plu	N	O
exemestane	NN	exemestane	exemestane	exemestan	N	O
arm	NN	arm	arm	arm	N	O
(	(	(	(	(	N	O
0.4%	CD	0.4%	0.4%	0.4%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
emergent	JJ	emergent	emergent	emerg	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
resulting	VBG	resulting	resulting	result	N	O
in	IN	in	in	in	N	O
permanent	JJ	permanent	permanent	perman	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
were	VBD	were	were	were	N	O
24%	CD	24%	24%	24%	N	O
and	CC	and	and	and	N	O
5%	CD	5%	5%	5%	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
plus	CC	plus	plus	plu	N	O
exemestane	NN	exemestane	exemestane	exemestan	N	O
and	CC	and	and	and	N	O
placebo	NN	placebo	placebo	placebo	N	O
plus	CC	plus	plus	plu	N	O
exemestane	JJ	exemestane	exemestane	exemestan	N	O
treatment	NN	treatment	treatment	treatment	N	O
groups	NNS	groups	group	group	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O

Dose	JJ	dose	dose	dose	N	O
adjustments	NNS	adjustments	adjustment	adjust	N	O
(	(	(	(	(	N	O
interruptions	NNS	interruptions	interruption	interrupt	N	O
or	CC	or	or	or	N	O
reductions	NNS	reductions	reduction	reduct	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
more	RBR	more	more	more	N	O
frequent	JJ	frequent	frequent	frequent	N	O
among	IN	among	among	among	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
plus	CC	plus	plus	plu	N	O
exemestane	NN	exemestane	exemestane	exemestan	N	O
arm	NN	arm	arm	arm	N	O
than	IN	than	than	than	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
plus	CC	plus	plus	plu	N	O
exemestane	NN	exemestane	exemestane	exemestan	N	O
arm	NN	arm	arm	arm	N	O
(	(	(	(	(	N	O
63%	CD	63%	63%	63%	N	O
versus	IN	versus	versus	versu	N	O
14%	CD	14%	14%	14%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
compares	VBZ	compares	compare	compar	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
emergent	JJ	emergent	emergent	emerg	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
reported	VBN	reported	reported	report	N	O
with	IN	with	with	with	N	O
an	DT	an	an	an	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
10%	CD	10%	10%	10%	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
10	CD	10	10	10	N	O
mg	JJ	mg	mg	mg	N	O
daily	JJ	daily	daily	daili	N	O
versus	NN	versus	versus	versu	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
:	:	:	:	:	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
Reported	VBD	reported	reported	report	N	O
10%	CD	10%	10%	10%	N	O
of	IN	of	of	of	N	O
Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Advanced	NNP	advanced	advanced	advanc	N	O
HR	NNP	hr	hr	hr	N	O
BC	NNP	bc	bc	bc	N	O

Grading	VBG	grading	grading	grade	N	O
according	VBG	according	according	accord	N	O
to	TO	to	to	to	N	O
CTCAE	NNP	ctcae	ctcae	ctcae	N	O
Version	NNP	version	version	version	N	O
3.0	CD	3.0	3.0	3.0	N	O
160	CD	160	160	160	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
33.2%	CD	33.2%	33.2%	33.2%	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
exposed	VBN	exposed	exposed	expos	N	O
to	TO	to	to	to	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
therapy	NN	therapy	therapy	therapi	N	O
for	IN	for	for	for	N	O
a	DT	a	a	a	N	O
period	NN	period	period	period	N	O
of	IN	of	of	of	N	O
32	CD	32	32	32	N	O
weeks	NNS	weeks	week	week	N	O
a	DT	a	a	a	N	O
Exemestane	NNP	exemestane	exemestane	exemestan	N	O
(	(	(	(	(	N	O
25	CD	25	25	25	N	O
mg	RB	mg	mg	mg	N	O
day	NN	day	day	day	N	O
)	)	)	)	)	N	O
b	NN	b	b	b	N	O
Includes	NNP	includes	includes	includ	N	O
stomatitis	NN	stomatitis	stomatitis	stomat	Y	B-AdverseReaction
,	,	,	,	,	N	O
mouth	JJ	mouth	mouth	mouth	N	B-AdverseReaction
ulceration	NN	ulceration	ulceration	ulcer	N	I-AdverseReaction
,	,	,	,	,	N	O
aphthous	JJ	aphthous	aphthous	aphthou	N	B-AdverseReaction
stomatitis	NN	stomatitis	stomatitis	stomat	Y	I-AdverseReaction
,	,	,	,	,	N	O
glossodynia	NN	glossodynia	glossodynia	glossodynia	Y	B-AdverseReaction
,	,	,	,	,	N	O
gingival	NN	gingival	gingival	gingiv	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
glossitis	NN	glossitis	glossitis	glossiti	Y	B-AdverseReaction
and	CC	and	and	and	N	O
lip	NN	lip	lip	lip	N	B-AdverseReaction
ulceration	NN	ulceration	ulceration	ulcer	N	I-AdverseReaction
c	SYM	c	c	c	N	O
Includes	VBZ	includes	includes	includ	N	O
all	DT	all	all	all	N	O
preferred	JJ	preferred	preferred	prefer	N	O
terms	NNS	terms	term	term	N	O
within	IN	within	within	within	N	O
the	DT	the	the	the	N	O
infections	NNS	infections	infection	infect	N	O
and	CC	and	and	and	N	O
infestations	NNS	infestations	infestation	infest	N	O
system	NN	system	system	system	N	O
organ	JJ	organ	organ	organ	N	O
class	NN	class	class	class	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
being	VBG	being	being	be	N	O
nasopharyngitis	NN	nasopharyngitis	nasopharyngitis	nasopharyng	Y	B-AdverseReaction
(	(	(	(	(	N	O
10%	CD	10%	10%	10%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
(	(	(	(	(	N	O
10%	CD	10%	10%	10%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
upper	JJ	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
(	(	(	(	(	N	O
4%	CD	4%	4%	4%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
bronchitis	NN	bronchitis	bronchitis	bronchiti	Y	B-AdverseReaction
(	(	(	(	(	N	O
4%	CD	4%	4%	4%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
cystitis	NN	cystitis	cystitis	cystiti	Y	B-AdverseReaction
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
sinusitis	NN	sinusitis	sinusitis	sinus	Y	B-AdverseReaction
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
also	RB	also	also	also	N	O
including	VBG	including	including	includ	N	O
candidiasis	NN	candidiasis	candidiasis	candidiasi	Y	B-AdverseReaction
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
sepsis	NN	sepsis	sepsis	sepsi	Y	B-AdverseReaction
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
hepatitis	NN	hepatitis	hepatitis	hepat	Y	B-AdverseReaction
C	NNP	c	c	c	N	I-AdverseReaction
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

d	NN	d	d	d	N	O
Includes	NNP	includes	includes	includ	N	O
pneumonitis	NN	pneumonitis	pneumonitis	pneumon	Y	B-AdverseReaction
,	,	,	,	,	N	O
interstitial	JJ	interstitial	interstitial	interstiti	N	B-AdverseReaction
lung	NN	lung	lung	lung	N	I-AdverseReaction
disease	NN	disease	disease	diseas	N	I-AdverseReaction
,	,	,	,	,	N	O
lung	NN	lung	lung	lung	N	B-AdverseReaction
infiltration	NN	infiltration	infiltration	infiltr	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	B-AdverseReaction
fibrosis	NN	fibrosis	fibrosis	fibrosi	Y	I-AdverseReaction
e	NN	e	e	e	N	O
Exposure	NNP	exposure	exposure	exposur	N	O
to	TO	to	to	to	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
or	CC	or	or	or	N	O
placebo	NN	placebo	placebo	placebo	N	O

AFINITOR	NN	afinitor	afinitor	afinitor	N	O

(	(	(	(	(	N	O
10	CD	10	10	10	N	O
mg	RB	mg	mg	mg	N	O
day	NN	day	day	day	N	O
)	)	)	)	)	N	O
exemestane	VBZ	exemestane	exemestane	exemestan	N	O
a	DT	a	a	a	N	O
N	NNP	n	n	n	N	O
482	CD	482	482	482	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
exemestane	NN	exemestane	exemestane	exemestan	N	O
a	DT	a	a	a	N	O
N	NNP	n	n	n	N	O
238	CD	238	238	238	N	O

All	DT	all	all	all	N	O
grades	NNS	grades	grade	grade	N	O
Grade	VBD	grade	grade	grade	N	O
3	CD	3	3	3	N	O
Grade	NNP	grade	grade	grade	N	O
4	CD	4	4	4	N	O
All	NNP	all	all	all	N	O
grades	NNS	grades	grade	grade	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
Grade	NNP	grade	grade	grade	N	O
4	CD	4	4	4	N	O

Any	DT	any	any	ani	N	O

adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
100	CD	100	100	100	N	O
41	CD	41	41	41	N	O
9	CD	9	9	9	N	O
90	CD	90	90	90	N	O
22	CD	22	22	22	N	O
5	CD	5	5	5	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
disorders	NNS	disorders	disorder	disord	N	O

Stomatitis	NN	stomatitis	stomatitis	stomat	Y	B-AdverseReaction
b	VBD	b	b	b	N	O
67	CD	67	67	67	N	O
8	CD	8	8	8	N	O
0	CD	0	0	0	N	O
11	CD	11	11	11	N	O
0.8	CD	0.8	0.8	0.8	N	O
0	CD	0	0	0	N	O

Diarrhea	NNP	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
33	CD	33	33	33	N	O
2	CD	2	2	2	N	O
0.2	CD	0.2	0.2	0.2	N	O
18	CD	18	18	18	N	O
0.8	CD	0.8	0.8	0.8	N	O
0	CD	0	0	0	N	O

Nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
29	CD	29	29	29	N	O
0.2	CD	0.2	0.2	0.2	N	O
0.2	CD	0.2	0.2	0.2	N	O
28	CD	28	28	28	N	O
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O

Vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
17	CD	17	17	17	N	O
0.8	CD	0.8	0.8	0.8	N	O
0.2	CD	0.2	0.2	0.2	N	O
12	CD	12	12	12	N	O
0.8	CD	0.8	0.8	0.8	N	O
0	CD	0	0	0	N	O

Constipation	NN	constipation	constipation	constip	Y	B-AdverseReaction
14	CD	14	14	14	N	O
0.4	CD	0.4	0.4	0.4	N	O
0	CD	0	0	0	N	O
13	CD	13	13	13	N	O
0.4	CD	0.4	0.4	0.4	N	O
0	CD	0	0	0	N	O

Dry	NNP	dry	dry	dri	N	B-AdverseReaction
mouth	VBD	mouth	mouth	mouth	N	I-AdverseReaction
11	CD	11	11	11	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
7	CD	7	7	7	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

General	NNP	general	general	gener	N	O
disorders	NNS	disorders	disorder	disord	N	O
and	CC	and	and	and	N	O
administration	NN	administration	administration	administr	N	O
site	NN	site	site	site	N	O
conditions	NNS	conditions	condition	condit	N	O

Fatigue	NNP	fatigue	fatigue	fatigu	Y	B-AdverseReaction
36	CD	36	36	36	N	O
4	CD	4	4	4	N	O
0.4	CD	0.4	0.4	0.4	N	O
27	CD	27	27	27	N	O
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O

Edema	NNP	edema	edema	edema	Y	B-AdverseReaction
peripheral	JJ	peripheral	peripheral	peripher	N	I-AdverseReaction
19	CD	19	19	19	N	O
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O
6	CD	6	6	6	N	O
0.4	CD	0.4	0.4	0.4	N	O
0	CD	0	0	0	N	O

Pyrexia	NNP	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
15	CD	15	15	15	N	O
0.2	CD	0.2	0.2	0.2	N	O
0	CD	0	0	0	N	O
7	CD	7	7	7	N	O
0.4	CD	0.4	0.4	0.4	N	O
0	CD	0	0	0	N	O

Asthenia	NNP	asthenia	asthenia	asthenia	Y	B-AdverseReaction
13	CD	13	13	13	N	O
2	CD	2	2	2	N	O
0.2	CD	0.2	0.2	0.2	N	O
4	CD	4	4	4	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Infections	NNS	infections	infection	infect	N	O
and	CC	and	and	and	N	O
infestations	NNS	infestations	infestation	infest	N	O

Infections	NNS	infections	infection	infect	N	B-AdverseReaction
c	VBP	c	c	c	N	O
50	CD	50	50	50	N	O
4	CD	4	4	4	N	O
1	CD	1	1	1	N	O
25	CD	25	25	25	N	O
2	CD	2	2	2	N	O
0	CD	0	0	0	N	O

Investigations	NNS	investigations	investigation	investig	N	O

Weight	NNP	weight	weight	weight	Y	B-AdverseReaction
decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
25	CD	25	25	25	N	O
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O
6	CD	6	6	6	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Metabolism	NN	metabolism	metabolism	metabol	N	O
and	CC	and	and	and	N	O
nutrition	NN	nutrition	nutrition	nutrit	N	O
disorders	NNS	disorders	disorder	disord	N	O

Decreased	VBN	decreased	decreased	decreas	N	B-AdverseReaction
appetite	RB	appetite	appetite	appetit	N	I-AdverseReaction
30	CD	30	30	30	N	O
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O
12	CD	12	12	12	N	O
0.4	CD	0.4	0.4	0.4	N	O
0	CD	0	0	0	N	O

Hyperglycemia	NNP	hyperglycemia	hyperglycemia	hyperglycemia	Y	B-AdverseReaction
14	CD	14	14	14	N	O
5	CD	5	5	5	N	O
0.4	CD	0.4	0.4	0.4	N	O
2	CD	2	2	2	N	O
0.4	CD	0.4	0.4	0.4	N	O
0	CD	0	0	0	N	O

Musculoskeletal	NNP	musculoskeletal	musculoskeletal	musculoskelet	N	O
and	CC	and	and	and	N	O
connective	JJ	connective	connective	connect	N	O
tissue	NN	tissue	tissue	tissu	N	O
disorders	NNS	disorders	disorder	disord	N	O

Arthralgia	NNP	arthralgia	arthralgia	arthralgia	Y	B-AdverseReaction
20	CD	20	20	20	N	O
0.8	CD	0.8	0.8	0.8	N	O
0	CD	0	0	0	N	O
17	CD	17	17	17	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Back	RB	back	back	back	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
14	CD	14	14	14	N	O
0.2	CD	0.2	0.2	0.2	N	O
0	CD	0	0	0	N	O
10	CD	10	10	10	N	O
0.8	CD	0.8	0.8	0.8	N	O
0	CD	0	0	0	N	O

Pain	NN	pain	pain	pain	Y	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
extremity	NN	extremity	extremity	extrem	N	I-AdverseReaction
9	CD	9	9	9	N	O
0.4	CD	0.4	0.4	0.4	N	O
0	CD	0	0	0	N	O
11	CD	11	11	11	N	O
2	CD	2	2	2	N	O
0	CD	0	0	0	N	O

Nervous	JJ	nervous	nervous	nervou	Y	O
system	NN	system	system	system	N	O
disorders	NNS	disorders	disorder	disord	N	O

Dysgeusia	NNP	dysgeusia	dysgeusia	dysgeusia	Y	B-AdverseReaction
22	CD	22	22	22	N	O
0.2	CD	0.2	0.2	0.2	N	O
0	CD	0	0	0	N	O
6	CD	6	6	6	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Headache	NNP	headache	headache	headach	Y	B-AdverseReaction
21	CD	21	21	21	N	O
0.4	CD	0.4	0.4	0.4	N	O
0	CD	0	0	0	N	O
14	CD	14	14	14	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Psychiatric	JJ	psychiatric	psychiatric	psychiatr	N	O
disorders	NNS	disorders	disorder	disord	N	O

Insomnia	NNP	insomnia	insomnia	insomnia	Y	B-AdverseReaction
13	CD	13	13	13	N	O
0.2	CD	0.2	0.2	0.2	N	O
0	CD	0	0	0	N	O
8	CD	8	8	8	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Respiratory	NNP	respiratory	respiratory	respiratori	N	O
,	,	,	,	,	N	O
thoracic	NN	thoracic	thoracic	thorac	N	O
and	CC	and	and	and	N	O
mediastinal	JJ	mediastinal	mediastinal	mediastin	N	O
disorders	NNS	disorders	disorder	disord	N	O

Cough	NNP	cough	cough	cough	Y	B-AdverseReaction
24	CD	24	24	24	N	O
0.6	CD	0.6	0.6	0.6	N	O
0	CD	0	0	0	N	O
12	CD	12	12	12	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Dyspnea	NNP	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
21	CD	21	21	21	N	O
4	CD	4	4	4	N	O
0.2	CD	0.2	0.2	0.2	N	O
11	CD	11	11	11	N	O
0.8	CD	0.8	0.8	0.8	N	O
0.4	CD	0.4	0.4	0.4	N	O

Epistaxis	NNP	epistaxis	epistaxis	epistaxi	Y	B-AdverseReaction
17	CD	17	17	17	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Pneumonitis	NNP	pneumonitis	pneumonitis	pneumon	Y	B-AdverseReaction
d	VBD	d	d	d	N	O
19	CD	19	19	19	N	O
4	CD	4	4	4	N	O
0.2	CD	0.2	0.2	0.2	N	O
0.4	CD	0.4	0.4	0.4	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Skin	NNP	skin	skin	skin	N	O
and	CC	and	and	and	N	O
subcutaneous	JJ	subcutaneous	subcutaneous	subcutan	N	O
tissue	NN	tissue	tissue	tissu	N	O
disorders	NNS	disorders	disorder	disord	N	O

Rash	NNP	rash	rash	rash	Y	B-AdverseReaction
39	CD	39	39	39	N	O
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O
6	CD	6	6	6	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Pruritus	NNP	pruritus	pruritus	pruritu	Y	B-AdverseReaction
13	CD	13	13	13	N	O
0.2	CD	0.2	0.2	0.2	N	O
0	CD	0	0	0	N	O
5	CD	5	5	5	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Alopecia	NNP	alopecia	alopecia	alopecia	Y	B-AdverseReaction
10	CD	10	10	10	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
5	CD	5	5	5	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Vascular	JJ	vascular	vascular	vascular	N	O
disorders	NNS	disorders	disorder	disord	N	O

Hot	NNP	hot	hot	hot	N	B-AdverseReaction
flush	VBD	flush	flush	flush	N	I-AdverseReaction
6	CD	6	6	6	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
14	CD	14	14	14	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Median	JJ	median	median	median	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
e	RB	e	e	e	N	O
23.9	CD	23.9	23.9	23.9	N	O
weeks	NNS	weeks	week	week	N	O
13.4	CD	13.4	13.4	13.4	N	O
weeks	NNS	weeks	week	week	N	O

Key	NNP	key	key	key	N	O
observed	VBD	observed	observed	observ	N	O
laboratory	JJ	laboratory	laboratory	laboratori	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
are	VBP	are	are	are	N	O
presented	VBN	presented	presented	present	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
3	CD	3	3	3	N	O
.	.	.	.	.	N	O

Table	NN	table	table	tabl	N	O

3	CD	3	3	3	N	O
:	:	:	:	:	N	O
Key	NNP	key	key	key	N	O
Laboratory	NNP	laboratory	laboratory	laboratori	N	O
Abnormalities	NNP	abnormalities	abnormality	abnorm	N	O
Reported	NNP	reported	reported	report	N	O
in	IN	in	in	in	N	O
10%	CD	10%	10%	10%	N	O
of	IN	of	of	of	N	O
Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Advanced	NNP	advanced	advanced	advanc	N	O
HR	NNP	hr	hr	hr	N	O
BC	NNP	bc	bc	bc	N	O

Grading	VBG	grading	grading	grade	N	O
according	VBG	according	according	accord	N	O
to	TO	to	to	to	N	O
CTCAE	NNP	ctcae	ctcae	ctcae	N	O
Version	NNP	version	version	version	N	O
3.0	CD	3.0	3.0	3.0	N	O
a	DT	a	a	a	N	O
Exemestane	NNP	exemestane	exemestane	exemestan	N	O
(	(	(	(	(	N	O
25	CD	25	25	25	N	O
mg	RB	mg	mg	mg	N	O
day	NN	day	day	day	N	O
)	)	)	)	)	N	O
b	NN	b	b	b	N	O
Reflects	NNPS	reflects	reflects	reflect	N	O
corresponding	JJ	corresponding	corresponding	correspond	N	O
adverse	JJ	adverse	adverse	advers	N	O
drug	NN	drug	drug	drug	N	O
reaction	NN	reaction	reaction	reaction	N	O
reports	NNS	reports	report	report	N	O
of	IN	of	of	of	N	O
anemia	NN	anemia	anemia	anemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
leukopenia	NN	leukopenia	leukopenia	leukopenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
lymphopenia	NN	lymphopenia	lymphopenia	lymphopenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
thrombocytopenia	NN	thrombocytopenia	thrombocytopenia	thrombocytopenia	Y	B-AdverseReaction
(	(	(	(	(	N	O
collectively	RB	collectively	collectively	collect	N	O
as	IN	as	a	as	N	O
pancytopenia	NN	pancytopenia	pancytopenia	pancytopenia	Y	B-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
which	WDT	which	which	which	N	O
occurred	VBD	occurred	occurred	occur	N	O
at	IN	at	at	at	N	O
lower	JJR	lower	lower	lower	N	O
frequency	NN	frequency	frequency	frequenc	N	O
.	.	.	.	.	N	O

Laboratory	NN	laboratory	laboratory	laboratori	N	O

parameter	NN	parameter	parameter	paramet	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
(	(	(	(	(	N	O
10	CD	10	10	10	N	O
mg	RB	mg	mg	mg	N	O
day	NN	day	day	day	N	O
)	)	)	)	)	N	O
exemestane	VBZ	exemestane	exemestane	exemestan	N	O
a	DT	a	a	a	N	O
N	NNP	n	n	n	N	O
482	CD	482	482	482	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
exemestane	NN	exemestane	exemestane	exemestan	N	O
a	DT	a	a	a	N	O
N	NNP	n	n	n	N	O
238	CD	238	238	238	N	O

All	DT	all	all	all	N	O
grades	NNS	grades	grade	grade	N	O
Grade	VBD	grade	grade	grade	N	O
3	CD	3	3	3	N	O
Grade	NNP	grade	grade	grade	N	O
4	CD	4	4	4	N	O
All	NNP	all	all	all	N	O
grades	NNS	grades	grade	grade	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
Grade	NNP	grade	grade	grade	N	O
4	CD	4	4	4	N	O

Hematology	NN	hematology	hematology	hematolog	N	O

b	NN	b	b	b	N	O

Hemoglobin	NNP	hemoglobin	hemoglobin	hemoglobin	Y	B-AdverseReaction
decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
68	CD	68	68	68	N	O
6	CD	6	6	6	N	O
0.6	CD	0.6	0.6	0.6	N	O
40	CD	40	40	40	N	O
0.8	CD	0.8	0.8	0.8	N	O
0.4	CD	0.4	0.4	0.4	N	O

WBC	NNP	wbc	wbc	wbc	Y	B-AdverseReaction
decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
58	CD	58	58	58	N	O
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O
28	CD	28	28	28	N	O
5	CD	5	5	5	N	O
0.8	CD	0.8	0.8	0.8	N	O

Platelets	NNS	platelets	platelet	platelet	N	B-AdverseReaction
decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
54	CD	54	54	54	N	O
3	CD	3	3	3	N	O
0.2	CD	0.2	0.2	0.2	N	O
5	CD	5	5	5	N	O
0	CD	0	0	0	N	O
0.4	CD	0.4	0.4	0.4	N	O

Lymphocytes	NNS	lymphocytes	lymphocyte	lymphocyt	Y	B-AdverseReaction
decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
54	CD	54	54	54	N	O
11	CD	11	11	11	N	O
0.6	CD	0.6	0.6	0.6	N	O
37	CD	37	37	37	N	O
5	CD	5	5	5	N	O
0.8	CD	0.8	0.8	0.8	N	O

Neutrophils	NNS	neutrophils	neutrophil	neutrophil	Y	B-AdverseReaction
decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
31	CD	31	31	31	N	O
2	CD	2	2	2	N	O
0	CD	0	0	0	N	O
11	CD	11	11	11	N	O
0.8	CD	0.8	0.8	0.8	N	O
0.8	CD	0.8	0.8	0.8	N	O

Clinical	JJ	clinical	clinical	clinic	N	O
chemistry	NN	chemistry	chemistry	chemistri	N	O

Glucose	NNP	glucose	glucose	glucos	Y	B-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
69	CD	69	69	69	N	O
9	CD	9	9	9	N	O
0.4	CD	0.4	0.4	0.4	N	O
44	CD	44	44	44	N	O
0.8	CD	0.8	0.8	0.8	N	O
0.4	CD	0.4	0.4	0.4	N	O

Cholesterol	NNP	cholesterol	cholesterol	cholesterol	Y	B-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
70	CD	70	70	70	N	O
0.6	CD	0.6	0.6	0.6	N	O
0.2	CD	0.2	0.2	0.2	N	O
38	CD	38	38	38	N	O
0.8	CD	0.8	0.8	0.8	N	O
0.8	CD	0.8	0.8	0.8	N	O

Aspartate	NNP	aspartate	aspartate	aspart	N	B-AdverseReaction
transaminase	NN	transaminase	transaminase	transaminas	N	I-AdverseReaction
(	(	(	(	(	N	O
AST	NNP	ast	ast	ast	N	B-AdverseReaction
)	)	)	)	)	N	O
increased	VBD	increased	increased	increas	N	I-AdverseReaction
69	CD	69	69	69	N	O
4	CD	4	4	4	N	O
0.2	CD	0.2	0.2	0.2	N	O
45	CD	45	45	45	N	O
3	CD	3	3	3	N	O
0.4	CD	0.4	0.4	0.4	N	O

Alanine	NNP	alanine	alanine	alanin	N	B-AdverseReaction
transaminase	NN	transaminase	transaminase	transaminas	N	I-AdverseReaction
(	(	(	(	(	N	O
ALT	NNP	alt	alt	alt	N	B-AdverseReaction
)	)	)	)	)	N	O
increased	VBD	increased	increased	increas	N	I-AdverseReaction
51	CD	51	51	51	N	O
4	CD	4	4	4	N	O
0.2	CD	0.2	0.2	0.2	N	O
29	CD	29	29	29	N	O
5	CD	5	5	5	N	O
0	CD	0	0	0	N	O

Triglycerides	NNS	triglycerides	triglyceride	triglycerid	Y	B-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
50	CD	50	50	50	N	O
0.8	CD	0.8	0.8	0.8	N	O
0	CD	0	0	0	N	O
26	CD	26	26	26	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Albumin	NNP	albumin	albumin	albumin	Y	B-AdverseReaction
decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
33	CD	33	33	33	N	O
0.8	CD	0.8	0.8	0.8	N	O
0	CD	0	0	0	N	O
16	CD	16	16	16	N	O
0.8	CD	0.8	0.8	0.8	N	O
0	CD	0	0	0	N	O

Potassium	NN	potassium	potassium	potassium	Y	B-AdverseReaction
decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
29	CD	29	29	29	N	O
4	CD	4	4	4	N	O
0.2	CD	0.2	0.2	0.2	N	O
7	CD	7	7	7	N	O
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O

Creatinine	NNP	creatinine	creatinine	creatinin	Y	B-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
24	CD	24	24	24	N	O
2	CD	2	2	2	N	O
0.2	CD	0.2	0.2	0.2	N	O
13	CD	13	13	13	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

6.2	CD	6.2	6.2	6.2	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Study	NNP	study	study	studi	N	O
Experience	NNP	experience	experience	experi	N	O
in	IN	in	in	in	N	O
Advanced	NNP	advanced	advanced	advanc	N	O
Pancreatic	NNP	pancreatic	pancreatic	pancreat	N	O
Neuroendocrine	NNP	neuroendocrine	neuroendocrine	neuroendocrin	N	O
Tumors	NNS	tumors	tumor	tumor	N	O

In	IN	in	in	in	N	O
a	DT	a	a	a	N	O
randomized	NN	randomized	randomized	random	N	O
,	,	,	,	,	N	O
controlled	VBD	controlled	controlled	control	N	O
trial	NN	trial	trial	trial	N	O
of	IN	of	of	of	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
204	CD	204	204	204	N	O
)	)	)	)	)	N	O
versus	NN	versus	versus	versu	N	O
placebo	NN	placebo	placebo	placebo	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
203	CD	203	203	203	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
advanced	JJ	advanced	advanced	advanc	N	O
PNET	NNP	pnet	pnet	pnet	N	O
the	DT	the	the	the	N	O
median	JJ	median	median	median	N	O
age	NN	age	age	age	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
was	VBD	was	wa	wa	N	O
58	CD	58	58	58	N	O
years	NNS	years	year	year	N	O
(	(	(	(	(	N	O
range	NN	range	range	rang	N	O
20	CD	20	20	20	N	O
-	:	-	-	-	N	O
87	CD	87	87	87	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
79%	CD	79%	79%	79%	N	O
were	VBD	were	were	were	N	O
Caucasian	JJ	caucasian	caucasian	caucasian	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
55%	CD	55%	55%	55%	N	O
were	VBD	were	were	were	N	O
male	NN	male	male	male	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
arm	NN	arm	arm	arm	N	O
could	MD	could	could	could	N	O
cross	VB	cross	cross	cross	N	O
over	IN	over	over	over	N	O
to	TO	to	to	to	N	O
open	VB	open	open	open	N	O
-	:	-	-	-	N	O
label	NN	label	label	label	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
upon	IN	upon	upon	upon	N	O
disease	NN	disease	disease	diseas	N	O
progression	NN	progression	progression	progress	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
incidence	VB	incidence	incidence	incid	N	O
30%	CD	30%	30%	30%	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
stomatitis	VBN	stomatitis	stomatitis	stomat	Y	B-AdverseReaction
,	,	,	,	,	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
,	,	,	,	,	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
,	,	,	,	,	N	O
edema	NN	edema	edema	edema	Y	B-AdverseReaction
,	,	,	,	,	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
fever	NN	fever	fever	fever	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
-	:	-	-	-	N	I-Severity
4	CD	4	4	4	N	I-Severity
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
incidence	VB	incidence	incidence	incid	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
stomatitis	VBN	stomatitis	stomatitis	stomat	Y	B-AdverseReaction
and	CC	and	and	and	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
(	(	(	(	(	N	O
incidence	VB	incidence	incidence	incid	N	O
50%	CD	50%	50%	50%	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
decreased	VBN	decreased	decreased	decreas	N	B-AdverseReaction
hemoglobin	NN	hemoglobin	hemoglobin	hemoglobin	Y	I-AdverseReaction
,	,	,	,	,	N	O
hyperglycemia	NN	hyperglycemia	hyperglycemia	hyperglycemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
alkaline	JJ	alkaline	alkaline	alkalin	N	B-AdverseReaction
phosphatase	NN	phosphatase	phosphatase	phosphatas	N	I-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
,	,	,	,	,	N	O
hypercholesterolemia	NN	hypercholesterolemia	hypercholesterolemia	hypercholesterolemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
bicarbonate	NN	bicarbonate	bicarbonate	bicarbon	Y	B-AdverseReaction
decreased	VBN	decreased	decreased	decreas	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
increased	VBD	increased	increased	increas	N	B-AdverseReaction
aspartate	NN	aspartate	aspartate	aspart	N	I-AdverseReaction
transaminase	NN	transaminase	transaminase	transaminas	N	I-AdverseReaction
(	(	(	(	(	N	O
AST	NNP	ast	ast	ast	N	I-AdverseReaction
)	)	)	)	)	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
-	:	-	-	-	N	I-Severity
4	CD	4	4	4	N	I-Severity
laboratory	NN	laboratory	laboratory	laboratori	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
(	(	(	(	(	N	O
incidence	VB	incidence	incidence	incid	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
hyperglycemia	VBN	hyperglycemia	hyperglycemia	hyperglycemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
lymphopenia	NN	lymphopenia	lymphopenia	lymphopenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
decreased	VBD	decreased	decreased	decreas	N	B-AdverseReaction
hemoglobin	NN	hemoglobin	hemoglobin	hemoglobin	Y	I-AdverseReaction
,	,	,	,	,	N	O
hypophosphatemia	NN	hypophosphatemia	hypophosphatemia	hypophosphatemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
increased	VBD	increased	increased	increas	N	B-AdverseReaction
alkaline	JJ	alkaline	alkaline	alkalin	N	I-AdverseReaction
phosphatase	NN	phosphatase	phosphatase	phosphatas	N	I-AdverseReaction
,	,	,	,	,	N	O
neutropenia	RB	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
increased	VBD	increased	increased	increas	N	B-AdverseReaction
aspartate	JJ	aspartate	aspartate	aspart	N	I-AdverseReaction
transaminase	NN	transaminase	transaminase	transaminas	N	I-AdverseReaction
(	(	(	(	(	N	O
AST	NNP	ast	ast	ast	N	I-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
potassium	NN	potassium	potassium	potassium	Y	B-AdverseReaction
decreased	VBN	decreased	decreased	decreas	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
thrombocytopenia	NN	thrombocytopenia	thrombocytopenia	thrombocytopenia	Y	B-AdverseReaction
.	.	.	.	.	N	O

Deaths	NNS	deaths	death	death	N	B-AdverseReaction
during	IN	during	during	dure	N	O
double	JJ	double	double	doubl	N	O
-	:	-	-	-	N	O
blind	NN	blind	blind	blind	Y	O
treatment	NN	treatment	treatment	treatment	N	O
where	WRB	where	where	where	N	O
an	DT	an	an	an	N	O
adverse	JJ	adverse	adverse	advers	N	O
event	NN	event	event	event	N	O
was	VBD	was	wa	wa	N	O
the	DT	the	the	the	N	O
primary	JJ	primary	primary	primari	N	O
cause	NN	cause	cause	caus	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
seven	CD	seven	seven	seven	N	O
patients	NNS	patients	patient	patient	N	O
on	IN	on	on	on	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
and	CC	and	and	and	N	O
one	CD	one	one	one	N	O
patient	NN	patient	patient	patient	N	O
on	IN	on	on	on	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

Causes	NNS	causes	cause	caus	N	O
of	IN	of	of	of	N	O
death	NN	death	death	death	Y	B-AdverseReaction
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
arm	NN	arm	arm	arm	N	O
included	VBD	included	included	includ	N	O
one	CD	one	one	one	N	O
case	NN	case	case	case	N	O
of	IN	of	of	of	N	O
each	DT	each	each	each	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
following	NN	following	following	follow	N	O
:	:	:	:	:	N	O
acute	JJ	acute	acute	acut	N	B-AdverseReaction
renal	JJ	renal	renal	renal	N	I-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
,	,	,	,	,	N	O
acute	JJ	acute	acute	acut	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
distress	NN	distress	distress	distress	N	I-AdverseReaction
,	,	,	,	,	N	O
cardiac	JJ	cardiac	cardiac	cardiac	N	B-AdverseReaction
arrest	NN	arrest	arrest	arrest	N	I-AdverseReaction
,	,	,	,	,	N	O
death	NN	death	death	death	Y	B-AdverseReaction
(	(	(	(	(	N	O
cause	VB	cause	cause	caus	N	O
unknown	NN	unknown	unknown	unknown	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
hepatic	JJ	hepatic	hepatic	hepat	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
,	,	,	,	,	N	O
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
sepsis	NN	sepsis	sepsis	sepsi	Y	B-AdverseReaction
.	.	.	.	.	N	O

There	EX	there	there	there	N	O
was	VBD	was	wa	wa	N	O
one	CD	one	one	one	N	O
death	NN	death	death	death	Y	B-AdverseReaction
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	B-AdverseReaction
embolism	NN	embolism	embolism	embol	Y	I-AdverseReaction
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	B-Factor
arm	NN	arm	arm	arm	N	O
.	.	.	.	.	N	O

After	IN	after	after	after	N	O
cross	SYM	cross	cross	cross	N	O
-	:	-	-	-	N	O
over	IN	over	over	over	N	O
to	TO	to	to	to	N	O
open	VB	open	open	open	N	O
-	:	-	-	-	N	O
label	NN	label	label	label	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
,	,	,	,	,	N	O
there	EX	there	there	there	N	O
were	VBD	were	were	were	N	O
three	CD	three	three	three	N	O
additional	JJ	additional	additional	addit	N	O
deaths	NNS	deaths	death	death	N	B-AdverseReaction
,	,	,	,	,	N	O
one	CD	one	one	one	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	B-AdverseReaction
and	CC	and	and	and	N	O
cardiac	JJ	cardiac	cardiac	cardiac	N	B-AdverseReaction
arrest	NN	arrest	arrest	arrest	N	I-AdverseReaction
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
patient	NN	patient	patient	patient	N	O
with	IN	with	with	with	N	O
insulinoma	NN	insulinoma	insulinoma	insulinoma	Y	O
,	,	,	,	,	N	O
one	CD	one	one	one	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
myocardial	JJ	myocardial	myocardial	myocardi	N	B-AdverseReaction
infarction	NN	infarction	infarction	infarct	Y	I-AdverseReaction
with	IN	with	with	with	N	O
congestive	JJ	congestive	congestive	congest	N	B-AdverseReaction
heart	NN	heart	heart	heart	N	I-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
other	JJ	other	other	other	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
sudden	JJ	sudden	sudden	sudden	N	B-AdverseReaction
death	NN	death	death	death	Y	I-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
emergent	JJ	emergent	emergent	emerg	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
resulting	VBG	resulting	resulting	result	N	O
in	IN	in	in	in	N	O
permanent	JJ	permanent	permanent	perman	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
were	VBD	were	were	were	N	O
20%	CD	20%	20%	20%	N	O
and	CC	and	and	and	N	O
6%	CD	6%	6%	6%	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
and	CC	and	and	and	N	O
placebo	VB	placebo	placebo	placebo	N	O
treatment	NN	treatment	treatment	treatment	N	O
groups	NNS	groups	group	group	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O

Dose	NNP	dose	dose	dose	N	O
delay	NN	delay	delay	delay	N	O
or	CC	or	or	or	N	O
reduction	NN	reduction	reduction	reduct	N	O
was	VBD	was	wa	wa	N	O
necessary	JJ	necessary	necessary	necessari	N	O
in	IN	in	in	in	N	O
61%	CD	61%	61%	61%	N	O
of	IN	of	of	of	N	O
everolimus	NN	everolimus	everolimus	everolimu	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
29%	CD	29%	29%	29%	N	O
of	IN	of	of	of	N	O
placebo	NN	placebo	placebo	placebo	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Grade	$	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
-	:	-	-	-	N	O
4	CD	4	4	4	N	I-Severity
renal	JJ	renal	renal	renal	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
six	CD	six	six	six	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
everolimus	NN	everolimus	everolimus	everolimu	N	O
arm	NN	arm	arm	arm	N	O
and	CC	and	and	and	N	O
three	CD	three	three	three	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
arm	NN	arm	arm	arm	N	O
.	.	.	.	.	N	O

Thrombotic	JJ	thrombotic	thrombotic	thrombot	N	B-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
included	VBD	included	included	includ	N	O
five	CD	five	five	five	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	B-AdverseReaction
embolus	NN	embolus	embolus	embolu	Y	I-AdverseReaction
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
everolimus	NN	everolimus	everolimus	everolimu	N	O
arm	NN	arm	arm	arm	N	O
and	CC	and	and	and	N	O
one	CD	one	one	one	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
arm	NN	arm	arm	arm	N	O
as	RB	as	a	as	N	O
well	RB	well	well	well	N	O
as	IN	as	a	as	N	O
three	CD	three	three	three	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
thrombosis	NN	thrombosis	thrombosis	thrombosi	Y	B-AdverseReaction
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
everolimus	NN	everolimus	everolimus	everolimu	N	O
arm	NN	arm	arm	arm	N	O
and	CC	and	and	and	N	O
two	CD	two	two	two	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
arm	NN	arm	arm	arm	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
4	CD	4	4	4	N	O
compares	VBZ	compares	compare	compar	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
emergent	JJ	emergent	emergent	emerg	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
reported	VBN	reported	reported	report	N	O
with	IN	with	with	with	N	O
an	DT	an	an	an	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
10%	CD	10%	10%	10%	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
10	CD	10	10	10	N	O
mg	JJ	mg	mg	mg	N	O
daily	JJ	daily	daily	daili	N	O
versus	NN	versus	versus	versu	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
4	CD	4	4	4	N	O
:	:	:	:	:	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
Reported	VBD	reported	reported	report	N	O
10%	CD	10%	10%	10%	N	O
of	IN	of	of	of	N	O
Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Advanced	NNP	advanced	advanced	advanc	N	O
PNET	NNP	pnet	pnet	pnet	N	O

Grading	VBG	grading	grading	grade	N	O
according	VBG	according	according	accord	N	O
to	TO	to	to	to	N	O
CTCAE	NNP	ctcae	ctcae	ctcae	N	O
Version	NNP	version	version	version	N	O
3.0	CD	3.0	3.0	3.0	N	O
a	DT	a	a	a	N	O
Includes	NNP	includes	includes	includ	N	O
stomatitis	NN	stomatitis	stomatitis	stomat	Y	B-AdverseReaction
,	,	,	,	,	N	O
aphthous	JJ	aphthous	aphthous	aphthou	N	B-AdverseReaction
stomatitis	NN	stomatitis	stomatitis	stomat	Y	I-AdverseReaction
,	,	,	,	,	N	O
gingival	NN	gingival	gingival	gingiv	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
swelling	VBG	swelling	swelling	swell	Y	I-AdverseReaction
ulceration	NN	ulceration	ulceration	ulcer	N	I-AdverseReaction
,	,	,	,	,	N	O
glossitis	NN	glossitis	glossitis	glossiti	Y	B-AdverseReaction
,	,	,	,	,	N	O
glossodynia	NN	glossodynia	glossodynia	glossodynia	Y	B-AdverseReaction
,	,	,	,	,	N	O
lip	JJ	lip	lip	lip	N	B-AdverseReaction
ulceration	NN	ulceration	ulceration	ulcer	N	I-AdverseReaction
,	,	,	,	,	N	O
mouth	JJ	mouth	mouth	mouth	N	B-AdverseReaction
ulceration	NN	ulceration	ulceration	ulcer	N	I-AdverseReaction
,	,	,	,	,	N	O
tongue	NN	tongue	tongue	tongu	N	B-AdverseReaction
ulceration	NN	ulceration	ulceration	ulcer	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
mucosal	JJ	mucosal	mucosal	mucos	N	B-AdverseReaction
inflammation	NN	inflammation	inflammation	inflamm	Y	I-AdverseReaction
.	.	.	.	.	N	O

b	NN	b	b	b	N	O
Includes	NNP	includes	includes	includ	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
enteritis	NN	enteritis	enteritis	enter	Y	B-AdverseReaction
,	,	,	,	,	N	O
enterocolitis	NN	enterocolitis	enterocolitis	enterocol	Y	B-AdverseReaction
,	,	,	,	,	N	O
colitis	NN	colitis	colitis	coliti	Y	B-AdverseReaction
,	,	,	,	,	N	O
defecation	NN	defecation	defecation	defec	N	B-AdverseReaction
urgency	NN	urgency	urgency	urgenc	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
steatorrhea	NN	steatorrhea	steatorrhea	steatorrhea	Y	B-AdverseReaction
.	.	.	.	.	N	O

c	SYM	c	c	c	N	O
Includes	NNP	includes	includes	includ	N	O
pneumonitis	NN	pneumonitis	pneumonitis	pneumon	Y	B-AdverseReaction
,	,	,	,	,	N	O
interstitial	JJ	interstitial	interstitial	interstiti	N	B-AdverseReaction
lung	NN	lung	lung	lung	N	I-AdverseReaction
disease	NN	disease	disease	diseas	N	I-AdverseReaction
,	,	,	,	,	N	O
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	B-AdverseReaction
fibrosis	NN	fibrosis	fibrosis	fibrosi	Y	I-AdverseReaction
and	CC	and	and	and	N	O
restrictive	JJ	restrictive	restrictive	restrict	N	B-AdverseReaction
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	I-AdverseReaction
disease	NN	disease	disease	diseas	N	I-AdverseReaction
.	.	.	.	.	N	O

AFINITOR	NN	afinitor	afinitor	afinitor	N	O

N	NNP	n	n	n	N	O
204	CD	204	204	204	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
N	NNP	n	n	n	N	O
203	CD	203	203	203	N	O

All	DT	all	all	all	N	O
grades	NNS	grades	grade	grade	N	O
Grade	VBD	grade	grade	grade	N	O
3	CD	3	3	3	N	O
Grade	NNP	grade	grade	grade	N	O
4	CD	4	4	4	N	O
All	NNP	all	all	all	N	O
grades	NNS	grades	grade	grade	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
Grade	NNP	grade	grade	grade	N	O
4	CD	4	4	4	N	O

Any	DT	any	any	ani	N	O

adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
100	CD	100	100	100	N	O
49	CD	49	49	49	N	O
13	CD	13	13	13	N	O
98	CD	98	98	98	N	O
32	CD	32	32	32	N	O
8	CD	8	8	8	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
disorders	NNS	disorders	disorder	disord	N	O

Stomatitis	VB	stomatitis	stomatitis	stomat	Y	B-AdverseReaction
a	DT	a	a	a	N	O
70	CD	70	70	70	N	O
7	CD	7	7	7	N	O
0	CD	0	0	0	N	O
20	CD	20	20	20	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Diarrhea	NNP	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
b	VBD	b	b	b	N	O
50	CD	50	50	50	N	O
5	CD	5	5	5	N	O
0.5	CD	0.5	0.5	0.5	N	O
25	CD	25	25	25	N	O
3	CD	3	3	3	N	O
0	CD	0	0	0	N	O

Abdominal	NNP	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
36	CD	36	36	36	N	O
4	CD	4	4	4	N	O
0	CD	0	0	0	N	O
32	CD	32	32	32	N	O
6	CD	6	6	6	N	O
1	CD	1	1	1	N	O

Nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
32	CD	32	32	32	N	O
2	CD	2	2	2	N	O
0	CD	0	0	0	N	O
33	CD	33	33	33	N	O
2	CD	2	2	2	N	O
0	CD	0	0	0	N	O

Vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
29	CD	29	29	29	N	O
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O
21	CD	21	21	21	N	O
2	CD	2	2	2	N	O
0	CD	0	0	0	N	O

Constipation	NN	constipation	constipation	constip	Y	B-AdverseReaction
14	CD	14	14	14	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
13	CD	13	13	13	N	O
0.5	CD	0.5	0.5	0.5	N	O
0	CD	0	0	0	N	O

Dry	NNP	dry	dry	dri	N	B-AdverseReaction
mouth	VBD	mouth	mouth	mouth	N	I-AdverseReaction
11	CD	11	11	11	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
4	CD	4	4	4	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

General	NNP	general	general	gener	N	O
disorders	NNS	disorders	disorder	disord	N	O
and	CC	and	and	and	N	O
administration	NN	administration	administration	administr	N	O
site	NN	site	site	site	N	O
conditions	NNS	conditions	condition	condit	N	O

Fatigue	NNP	fatigue	fatigue	fatigu	Y	B-AdverseReaction
malaise	NN	malaise	malaise	malais	Y	B-AdverseReaction
45	CD	45	45	45	N	O
3	CD	3	3	3	N	O
0.5	CD	0.5	0.5	0.5	N	O
27	CD	27	27	27	N	O
2	CD	2	2	2	N	O
0.5	CD	0.5	0.5	0.5	N	O

Edema	NNP	edema	edema	edema	Y	B-AdverseReaction
(	(	(	(	(	N	O
general	JJ	general	general	gener	N	I-AdverseReaction
and	CC	and	and	and	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	I-AdverseReaction
)	)	)	)	)	N	O
39	CD	39	39	39	N	O
1	CD	1	1	1	N	O
0.5	CD	0.5	0.5	0.5	N	O
12	CD	12	12	12	N	O
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O

Fever	RB	fever	fever	fever	Y	B-AdverseReaction
31	CD	31	31	31	N	O
0.5	CD	0.5	0.5	0.5	N	O
0.5	CD	0.5	0.5	0.5	N	O
13	CD	13	13	13	N	O
0.5	CD	0.5	0.5	0.5	N	O
0	CD	0	0	0	N	O

Asthenia	NNP	asthenia	asthenia	asthenia	Y	B-AdverseReaction
19	CD	19	19	19	N	O
3	CD	3	3	3	N	O
0	CD	0	0	0	N	O
20	CD	20	20	20	N	O
3	CD	3	3	3	N	O
0	CD	0	0	0	N	O

Infections	NNS	infections	infection	infect	N	O
and	CC	and	and	and	N	O
infestations	NNS	infestations	infestation	infest	N	O

Nasopharyngitis	NNP	nasopharyngitis	nasopharyngitis	nasopharyng	Y	B-AdverseReaction
rhinitis	NN	rhinitis	rhinitis	rhiniti	Y	B-AdverseReaction
URI	NNP	uri	uri	uri	N	B-AdverseReaction
25	CD	25	25	25	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
13	CD	13	13	13	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
16	CD	16	16	16	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
6	CD	6	6	6	N	O
0.5	CD	0.5	0.5	0.5	N	O
0	CD	0	0	0	N	O

Investigations	NNS	investigations	investigation	investig	N	O

Weight	NNP	weight	weight	weight	Y	B-AdverseReaction
decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
28	CD	28	28	28	N	O
0.5	CD	0.5	0.5	0.5	N	O
0	CD	0	0	0	N	O
11	CD	11	11	11	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Metabolism	NN	metabolism	metabolism	metabol	N	O
and	CC	and	and	and	N	O
nutrition	NN	nutrition	nutrition	nutrit	N	O
disorders	NNS	disorders	disorder	disord	N	O

Decreased	VBN	decreased	decreased	decreas	N	B-AdverseReaction
appetite	RB	appetite	appetite	appetit	N	I-AdverseReaction
30	CD	30	30	30	N	O
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O
18	CD	18	18	18	N	O
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O

Diabetes	NNS	diabetes	diabetes	diabet	Y	B-AdverseReaction
mellitus	VBP	mellitus	mellitus	mellitu	N	I-AdverseReaction
10	CD	10	10	10	N	O
2	CD	2	2	2	N	O
0	CD	0	0	0	N	O
0.5	CD	0.5	0.5	0.5	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Musculoskeletal	NNP	musculoskeletal	musculoskeletal	musculoskelet	N	O
and	CC	and	and	and	N	O
connective	JJ	connective	connective	connect	N	O
tissue	NN	tissue	tissue	tissu	N	O
disorders	NNS	disorders	disorder	disord	N	O

Arthralgia	NNP	arthralgia	arthralgia	arthralgia	Y	B-AdverseReaction
15	CD	15	15	15	N	O
1	CD	1	1	1	N	O
0.5	CD	0.5	0.5	0.5	N	O
7	CD	7	7	7	N	O
0.5	CD	0.5	0.5	0.5	N	O
0	CD	0	0	0	N	O

Back	RB	back	back	back	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
15	CD	15	15	15	N	O
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O
11	CD	11	11	11	N	O
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O

Pain	NN	pain	pain	pain	Y	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
extremity	NN	extremity	extremity	extrem	N	I-AdverseReaction
14	CD	14	14	14	N	O
0.5	CD	0.5	0.5	0.5	N	O
0	CD	0	0	0	N	O
6	CD	6	6	6	N	O
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O

Muscle	NNP	muscle	muscle	muscl	N	B-AdverseReaction
spasms	VBD	spasms	spasm	spasm	Y	I-AdverseReaction
10	CD	10	10	10	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
4	CD	4	4	4	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Nervous	JJ	nervous	nervous	nervou	Y	O
system	NN	system	system	system	N	O
disorders	NNS	disorders	disorder	disord	N	O

Headache	NNP	headache	headache	headach	Y	B-AdverseReaction
migraine	VBD	migraine	migraine	migrain	Y	B-AdverseReaction
30	CD	30	30	30	N	O
0.5	CD	0.5	0.5	0.5	N	O
0	CD	0	0	0	N	O
15	CD	15	15	15	N	O
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O

Dysgeusia	NNP	dysgeusia	dysgeusia	dysgeusia	Y	B-AdverseReaction
19	CD	19	19	19	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
5	CD	5	5	5	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Dizziness	NNP	dizziness	dizziness	dizzi	Y	B-AdverseReaction
12	CD	12	12	12	N	O
0.5	CD	0.5	0.5	0.5	N	O
0	CD	0	0	0	N	O
7	CD	7	7	7	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Psychiatric	JJ	psychiatric	psychiatric	psychiatr	N	O
disorders	NNS	disorders	disorder	disord	N	O

Insomnia	NNP	insomnia	insomnia	insomnia	Y	B-AdverseReaction
14	CD	14	14	14	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
8	CD	8	8	8	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Respiratory	NNP	respiratory	respiratory	respiratori	N	O
,	,	,	,	,	N	O
thoracic	NN	thoracic	thoracic	thorac	N	O
and	CC	and	and	and	N	O
mediastinal	JJ	mediastinal	mediastinal	mediastin	N	O
disorders	NNS	disorders	disorder	disord	N	O

Cough	NNP	cough	cough	cough	Y	B-AdverseReaction
productive	JJ	productive	productive	product	N	B-AdverseReaction
cough	NN	cough	cough	cough	Y	I-AdverseReaction
25	CD	25	25	25	N	O
0.5	CD	0.5	0.5	0.5	N	O
0	CD	0	0	0	N	O
13	CD	13	13	13	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Epistaxis	NNP	epistaxis	epistaxis	epistaxi	Y	B-AdverseReaction
22	CD	22	22	22	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Dyspnea	NNP	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
dyspnea	VBD	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
exertional	JJ	exertional	exertional	exert	N	I-AdverseReaction
20	CD	20	20	20	N	O
2	CD	2	2	2	N	O
0.5	CD	0.5	0.5	0.5	N	O
7	CD	7	7	7	N	O
0.5	CD	0.5	0.5	0.5	N	O
0	CD	0	0	0	N	O

Pneumonitis	NNP	pneumonitis	pneumonitis	pneumon	Y	B-AdverseReaction
c	VBD	c	c	c	N	O
17	CD	17	17	17	N	O
3	CD	3	3	3	N	O
0.5	CD	0.5	0.5	0.5	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Oropharyngeal	NNP	oropharyngeal	oropharyngeal	oropharyng	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
11	CD	11	11	11	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
6	CD	6	6	6	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Skin	NNP	skin	skin	skin	N	O
and	CC	and	and	and	N	O
subcutaneous	JJ	subcutaneous	subcutaneous	subcutan	N	O
disorders	NNS	disorders	disorder	disord	N	O

Rash	NNP	rash	rash	rash	Y	B-AdverseReaction
59	CD	59	59	59	N	O
0.5	CD	0.5	0.5	0.5	N	O
0	CD	0	0	0	N	O
19	CD	19	19	19	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Nail	NNP	nail	nail	nail	N	B-AdverseReaction
disorders	NNS	disorders	disorder	disord	N	I-AdverseReaction
22	CD	22	22	22	N	O
0.5	CD	0.5	0.5	0.5	N	O
0	CD	0	0	0	N	O
2	CD	2	2	2	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Pruritus	NNP	pruritus	pruritus	pruritu	Y	B-AdverseReaction
pruritus	NN	pruritus	pruritus	pruritu	Y	B-AdverseReaction
generalized	VBD	generalized	generalized	gener	N	I-AdverseReaction
21	CD	21	21	21	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
13	CD	13	13	13	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Dry	NNP	dry	dry	dri	N	B-AdverseReaction
skin	NN	skin	skin	skin	N	I-AdverseReaction
xeroderma	VBD	xeroderma	xeroderma	xeroderma	Y	B-AdverseReaction
13	CD	13	13	13	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
6	CD	6	6	6	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Vascular	JJ	vascular	vascular	vascular	N	O
disorders	NNS	disorders	disorder	disord	N	O

Hypertension	NNP	hypertension	hypertension	hypertens	Y	B-AdverseReaction
13	CD	13	13	13	N	O
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O
6	CD	6	6	6	N	O
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O

Median	JJ	median	median	median	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
(	(	(	(	(	N	O
wks	NN	wks	wks	wk	N	O
)	)	)	)	)	N	O
37	CD	37	37	37	N	O
16	CD	16	16	16	N	O

In	IN	in	in	in	N	O
female	JJ	female	female	femal	N	O
patients	NNS	patients	patient	patient	N	O
aged	VBD	aged	aged	age	N	O
18	CD	18	18	18	N	O
to	TO	to	to	to	N	O
55	CD	55	55	55	N	O
years	NNS	years	year	year	N	O
,	,	,	,	,	N	O
irregular	JJ	irregular	irregular	irregular	N	B-AdverseReaction
menstruation	NN	menstruation	menstruation	menstruat	N	I-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
5	CD	5	5	5	N	O
of	IN	of	of	of	N	O
46	CD	46	46	46	N	O
(	(	(	(	(	N	O
11%	CD	11%	11%	11%	N	O
)	)	)	)	)	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
females	NNS	females	female	femal	N	O
and	CC	and	and	and	N	O
none	NN	none	none	none	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
33	CD	33	33	33	N	O
females	NNS	females	female	femal	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
group	NN	group	group	group	N	O
.	.	.	.	.	N	O

Key	NN	key	key	key	N	O

observed	JJ	observed	observed	observ	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
are	VBP	are	are	are	N	O
presented	VBN	presented	presented	present	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
5	CD	5	5	5	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
5	CD	5	5	5	N	O
:	:	:	:	:	N	O
Key	NNP	key	key	key	N	O
Laboratory	NNP	laboratory	laboratory	laboratori	N	O
Abnormalities	NNP	abnormalities	abnormality	abnorm	N	O
Reported	NNP	reported	reported	report	N	O
in	IN	in	in	in	N	O
10%	CD	10%	10%	10%	N	O
of	IN	of	of	of	N	O
Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Advanced	NNP	advanced	advanced	advanc	N	O
PNET	NNP	pnet	pnet	pnet	N	O

Grading	VBG	grading	grading	grade	N	O
according	VBG	according	according	accord	N	O
to	TO	to	to	to	N	O
CTCAE	NNP	ctcae	ctcae	ctcae	N	O
Version	NNP	version	version	version	N	O
3.0	CD	3.0	3.0	3.0	N	O

Laboratory	NN	laboratory	laboratory	laboratori	N	O

parameter	NN	parameter	parameter	paramet	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
N	NNP	n	n	n	N	O
204	CD	204	204	204	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
N	NNP	n	n	n	N	O
203	CD	203	203	203	N	O

All	DT	all	all	all	N	O
grades	NNS	grades	grade	grade	N	O
Grade	VBD	grade	grade	grade	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
4	CD	4	4	4	N	O
All	DT	all	all	all	N	O
grades	NNS	grades	grade	grade	N	O
Grade	VBD	grade	grade	grade	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
4	CD	4	4	4	N	O

Hematology	NN	hematology	hematology	hematolog	N	O

Hemoglobin	NN	hemoglobin	hemoglobin	hemoglobin	Y	B-AdverseReaction

decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
86	CD	86	86	86	N	O
15	CD	15	15	15	N	O
63	CD	63	63	63	N	O
1	CD	1	1	1	N	O

Lymphocytes	NNS	lymphocytes	lymphocyte	lymphocyt	Y	B-AdverseReaction
decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
45	CD	45	45	45	N	O
16	CD	16	16	16	N	O
22	CD	22	22	22	N	O
4	CD	4	4	4	N	O

Platelets	NNS	platelets	platelet	platelet	N	B-AdverseReaction
decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
45	CD	45	45	45	N	O
3	CD	3	3	3	N	O
11	CD	11	11	11	N	O
0	CD	0	0	0	N	O

WBC	NNP	wbc	wbc	wbc	Y	B-AdverseReaction
decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
43	CD	43	43	43	N	O
2	CD	2	2	2	N	O
13	CD	13	13	13	N	O
0	CD	0	0	0	N	O

Neutrophils	NNS	neutrophils	neutrophil	neutrophil	Y	B-AdverseReaction
decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
30	CD	30	30	30	N	O
4	CD	4	4	4	N	O
17	CD	17	17	17	N	O
2	CD	2	2	2	N	O

Clinical	JJ	clinical	clinical	clinic	N	O

chemistry	NN	chemistry	chemistry	chemistri	N	O

Alkaline	JJ	alkaline	alkaline	alkalin	N	B-AdverseReaction
phosphatase	NN	phosphatase	phosphatase	phosphatas	N	I-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
74	CD	74	74	74	N	O
8	CD	8	8	8	N	O
66	CD	66	66	66	N	O
8	CD	8	8	8	N	O

Glucose	NNP	glucose	glucose	glucos	Y	B-AdverseReaction
(	(	(	(	(	N	I-AdverseReaction
fasting	VBG	fasting	fasting	fast	Y	I-AdverseReaction
)	)	)	)	)	N	I-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
75	CD	75	75	75	N	O
17	CD	17	17	17	N	O
53	CD	53	53	53	N	O
6	CD	6	6	6	N	O

Cholesterol	NNP	cholesterol	cholesterol	cholesterol	Y	B-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
66	CD	66	66	66	N	O
0.5	CD	0.5	0.5	0.5	N	O
22	CD	22	22	22	N	O
0	CD	0	0	0	N	O

Bicarbonate	NNP	bicarbonate	bicarbonate	bicarbon	Y	B-AdverseReaction
decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
56	CD	56	56	56	N	O
0	CD	0	0	0	N	O
40	CD	40	40	40	N	O
0	CD	0	0	0	N	O

Aspartate	NNP	aspartate	aspartate	aspart	N	B-AdverseReaction
transaminase	NN	transaminase	transaminase	transaminas	N	I-AdverseReaction
(	(	(	(	(	N	O
AST	NNP	ast	ast	ast	N	B-AdverseReaction
)	)	)	)	)	N	O
increased	VBD	increased	increased	increas	N	I-AdverseReaction
56	CD	56	56	56	N	O
4	CD	4	4	4	N	O
41	CD	41	41	41	N	O
4	CD	4	4	4	N	O

Alanine	NNP	alanine	alanine	alanin	N	B-AdverseReaction
transaminase	NN	transaminase	transaminase	transaminas	N	I-AdverseReaction
(	(	(	(	(	N	O
ALT	NNP	alt	alt	alt	N	B-AdverseReaction
)	)	)	)	)	N	O
increased	VBD	increased	increased	increas	N	I-AdverseReaction
48	CD	48	48	48	N	O
2	CD	2	2	2	N	O
35	CD	35	35	35	N	O
2	CD	2	2	2	N	O

Phosphate	NNP	phosphate	phosphate	phosphat	Y	B-AdverseReaction
decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
40	CD	40	40	40	N	O
10	CD	10	10	10	N	O
14	CD	14	14	14	N	O
3	CD	3	3	3	N	O

Triglycerides	NNS	triglycerides	triglyceride	triglycerid	Y	B-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
39	CD	39	39	39	N	O
0	CD	0	0	0	N	O
10	CD	10	10	10	N	O
0	CD	0	0	0	N	O

Calcium	NN	calcium	calcium	calcium	Y	B-AdverseReaction
decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
37	CD	37	37	37	N	O
0.5	CD	0.5	0.5	0.5	N	O
12	CD	12	12	12	N	O
0	CD	0	0	0	N	O

Potassium	NN	potassium	potassium	potassium	Y	B-AdverseReaction
decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
23	CD	23	23	23	N	O
4	CD	4	4	4	N	O
5	CD	5	5	5	N	O
0	CD	0	0	0	N	O

Creatinine	NNP	creatinine	creatinine	creatinin	Y	B-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
19	CD	19	19	19	N	O
2	CD	2	2	2	N	O
14	CD	14	14	14	N	O
0	CD	0	0	0	N	O

Sodium	NN	sodium	sodium	sodium	Y	B-AdverseReaction
decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
16	CD	16	16	16	N	O
1	CD	1	1	1	N	O
16	CD	16	16	16	N	O
1	CD	1	1	1	N	O

Albumin	NNP	albumin	albumin	albumin	Y	B-AdverseReaction
decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
13	CD	13	13	13	N	O
1	CD	1	1	1	N	O
8	CD	8	8	8	N	O
0	CD	0	0	0	N	O

Bilirubin	NNP	bilirubin	bilirubin	bilirubin	Y	B-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
10	CD	10	10	10	N	O
1	CD	1	1	1	N	O
14	CD	14	14	14	N	O
2	CD	2	2	2	N	O

Potassium	NN	potassium	potassium	potassium	Y	B-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
7	CD	7	7	7	N	O
0	CD	0	0	0	N	O
10	CD	10	10	10	N	O
0.5	CD	0.5	0.5	0.5	N	O

6.3	CD	6.3	6.3	6.3	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Study	NNP	study	study	studi	N	O
Experience	NNP	experience	experience	experi	N	O
in	IN	in	in	in	N	O
Advanced	NNP	advanced	advanced	advanc	N	O
Renal	NNP	renal	renal	renal	N	O
Cell	NNP	cell	cell	cell	N	O
Carcinoma	NNP	carcinoma	carcinoma	carcinoma	Y	O

The	DT	the	the	the	N	O
data	NNS	data	data	data	N	O
described	VBD	described	described	describ	N	O
below	IN	below	below	below	N	O
reflect	NN	reflect	reflect	reflect	N	O
exposure	NN	exposure	exposure	exposur	N	O
to	TO	to	to	to	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
274	CD	274	274	274	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
placebo	NN	placebo	placebo	placebo	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
137	CD	137	137	137	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
randomized	NN	randomized	randomized	random	N	O
,	,	,	,	,	N	O
controlled	VBN	controlled	controlled	control	N	O
trial	NN	trial	trial	trial	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
metastatic	JJ	metastatic	metastatic	metastat	N	O
renal	NN	renal	renal	renal	N	O
cell	NN	cell	cell	cell	N	O
carcinoma	NN	carcinoma	carcinoma	carcinoma	Y	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
prior	JJ	prior	prior	prior	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
sunitinib	NN	sunitinib	sunitinib	sunitinib	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
sorafenib	NN	sorafenib	sorafenib	sorafenib	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
median	JJ	median	median	median	N	O
age	NN	age	age	age	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
was	VBD	was	wa	wa	N	O
61	CD	61	61	61	N	O
years	NNS	years	year	year	N	O
(	(	(	(	(	N	O
range	NN	range	range	rang	N	O
27	CD	27	27	27	N	O
-	:	-	-	-	N	O
85	CD	85	85	85	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
88%	CD	88%	88%	88%	N	O
were	VBD	were	were	were	N	O
Caucasian	JJ	caucasian	caucasian	caucasian	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
78%	CD	78%	78%	78%	N	O
were	VBD	were	were	were	N	O
male	NN	male	male	male	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
median	JJ	median	median	median	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
blinded	JJ	blinded	blinded	blind	N	O
study	NN	study	study	studi	N	O
treatment	NN	treatment	treatment	treatment	N	O
was	VBD	was	wa	wa	N	O
141	CD	141	141	141	N	O
days	NNS	days	day	day	N	O
(	(	(	(	(	N	O
range	NN	range	range	rang	N	O
19	CD	19	19	19	N	O
-	:	-	-	-	N	O
451	CD	451	451	451	N	O
days	NNS	days	day	day	N	O
)	)	)	)	)	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
and	CC	and	and	and	N	O
60	CD	60	60	60	N	O
days	NNS	days	day	day	N	O
(	(	(	(	(	N	O
range	NN	range	range	rang	N	O
21	CD	21	21	21	N	O
-	:	-	-	-	N	O
295	CD	295	295	295	N	O
days	NNS	days	day	day	N	O
)	)	)	)	)	N	O
for	IN	for	for	for	N	O
those	DT	those	those	those	N	O
receiving	VBG	receiving	receiving	receiv	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
incidence	VB	incidence	incidence	incid	N	O
30%	CD	30%	30%	30%	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
stomatitis	VBN	stomatitis	stomatitis	stomat	Y	B-AdverseReaction
,	,	,	,	,	N	O
infections	NNS	infections	infection	infect	N	B-AdverseReaction
,	,	,	,	,	N	O
asthenia	NN	asthenia	asthenia	asthenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
,	,	,	,	,	N	O
cough	NN	cough	cough	cough	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
-	:	-	-	-	N	I-Severity
4	CD	4	4	4	N	I-Severity
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
incidence	VB	incidence	incidence	incid	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
infections	NNS	infections	infection	infect	N	B-AdverseReaction
,	,	,	,	,	N	O
dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
,	,	,	,	,	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
,	,	,	,	,	N	O
stomatitis	NN	stomatitis	stomatitis	stomat	Y	B-AdverseReaction
,	,	,	,	,	N	O
dehydration	NN	dehydration	dehydration	dehydr	Y	B-AdverseReaction
,	,	,	,	,	N	O
pneumonitis	NN	pneumonitis	pneumonitis	pneumon	Y	B-AdverseReaction
,	,	,	,	,	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
asthenia	NN	asthenia	asthenia	asthenia	Y	B-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
(	(	(	(	(	N	O
incidence	VB	incidence	incidence	incid	N	O
50%	CD	50%	50%	50%	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
anemia	JJ	anemia	anemia	anemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
hypercholesterolemia	NN	hypercholesterolemia	hypercholesterolemia	hypercholesterolemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
hypertriglyceridemia	NN	hypertriglyceridemia	hypertriglyceridemia	hypertriglyceridemia	Y	O
,	,	,	,	,	N	O
hyperglycemia	NN	hyperglycemia	hyperglycemia	hyperglycemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
lymphopenia	NN	lymphopenia	lymphopenia	lymphopenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
increased	VBD	increased	increased	increas	N	B-AdverseReaction
creatinine	NN	creatinine	creatinine	creatinin	Y	I-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
-	:	-	-	-	N	I-Severity
4	CD	4	4	4	N	I-Severity
laboratory	NN	laboratory	laboratory	laboratori	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
(	(	(	(	(	N	O
incidence	VB	incidence	incidence	incid	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
lymphopenia	JJ	lymphopenia	lymphopenia	lymphopenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
hyperglycemia	NN	hyperglycemia	hyperglycemia	hyperglycemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
anemia	NN	anemia	anemia	anemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
hypophosphatemia	NN	hypophosphatemia	hypophosphatemia	hypophosphatemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
hypercholesterolemia	NN	hypercholesterolemia	hypercholesterolemia	hypercholesterolemia	Y	B-AdverseReaction
.	.	.	.	.	N	O

Deaths	NNS	deaths	death	death	N	B-AdverseReaction
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
acute	VB	acute	acute	acut	N	B-AdverseReaction
respiratory	JJ	respiratory	respiratory	respiratori	N	I-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
(	(	(	(	(	N	O
0.7%	CD	0.7%	0.7%	0.7%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
infection	NN	infection	infection	infect	Y	B-AdverseReaction
(	(	(	(	(	N	O
0.7%	CD	0.7%	0.7%	0.7%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
acute	JJ	acute	acute	acut	N	B-AdverseReaction
renal	JJ	renal	renal	renal	N	I-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
(	(	(	(	(	N	O
0.4%	CD	0.4%	0.4%	0.4%	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
observed	VBN	observed	observed	observ	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
arm	NN	arm	arm	arm	N	O
but	CC	but	but	but	N	O
none	NN	none	none	none	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
arm	NN	arm	arm	arm	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
emergent	JJ	emergent	emergent	emerg	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
(	(	(	(	(	N	O
irrespective	NN	irrespective	irrespective	irrespect	N	O
of	IN	of	of	of	N	O
causality	NN	causality	causality	causal	N	O
)	)	)	)	)	N	O
resulting	VBG	resulting	resulting	result	N	O
in	IN	in	in	in	N	O
permanent	JJ	permanent	permanent	perman	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
were	VBD	were	were	were	N	O
14%	CD	14%	14%	14%	N	O
and	CC	and	and	and	N	O
3%	CD	3%	3%	3%	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
and	CC	and	and	and	N	O
placebo	VB	placebo	placebo	placebo	N	O
treatment	NN	treatment	treatment	treatment	N	O
groups	NNS	groups	group	group	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
irrespective	NN	irrespective	irrespective	irrespect	N	O
of	IN	of	of	of	N	O
causality	NN	causality	causality	causal	N	O
)	)	)	)	)	N	O
leading	VBG	leading	leading	lead	N	O
to	TO	to	to	to	N	O
treatment	NN	treatment	treatment	treatment	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
were	VBD	were	were	were	N	O
pneumonitis	NNS	pneumonitis	pneumonitis	pneumon	Y	B-AdverseReaction
and	CC	and	and	and	N	O
dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
.	.	.	.	.	N	O

Infections	NNS	infections	infection	infect	N	B-AdverseReaction
,	,	,	,	,	N	O
stomatitis	NN	stomatitis	stomatitis	stomat	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
pneumonitis	NN	pneumonitis	pneumonitis	pneumon	Y	B-AdverseReaction
were	VBD	were	were	were	N	O
the	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
reasons	NNS	reasons	reason	reason	N	O
for	IN	for	for	for	N	O
treatment	NN	treatment	treatment	treatment	N	O
delay	NN	delay	delay	delay	N	O
or	CC	or	or	or	N	O
dose	JJ	dose	dose	dose	N	O
reduction	NN	reduction	reduction	reduct	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
medical	JJ	medical	medical	medic	N	O
interventions	NNS	interventions	intervention	intervent	N	O
required	VBN	required	required	requir	N	O
during	IN	during	during	dure	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
treatment	NN	treatment	treatment	treatment	N	O
were	VBD	were	were	were	N	O
for	IN	for	for	for	N	O
infections	NNS	infections	infection	infect	N	B-AdverseReaction
,	,	,	,	,	N	O
anemia	NN	anemia	anemia	anemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
stomatitis	NN	stomatitis	stomatitis	stomat	Y	B-AdverseReaction
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
6	CD	6	6	6	N	O
compares	VBZ	compares	compare	compar	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
emergent	JJ	emergent	emergent	emerg	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
reported	VBN	reported	reported	report	N	O
with	IN	with	with	with	N	O
an	DT	an	an	an	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
10%	CD	10%	10%	10%	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
10	CD	10	10	10	N	O
mg	JJ	mg	mg	mg	N	O
daily	JJ	daily	daily	daili	N	O
versus	NN	versus	versus	versu	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

Within	IN	within	within	within	N	O
each	DT	each	each	each	N	O
MedDRA	NNP	meddra	meddra	meddra	N	O
system	NN	system	system	system	N	O
organ	JJ	organ	organ	organ	N	O
class	NN	class	class	class	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
presented	VBN	presented	presented	present	N	O
in	IN	in	in	in	N	O
order	NN	order	order	order	N	O
of	IN	of	of	of	N	O
decreasing	VBG	decreasing	decreasing	decreas	N	O
frequency	NN	frequency	frequency	frequenc	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
6	CD	6	6	6	N	O
:	:	:	:	:	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
Reported	VBD	reported	reported	report	N	O
in	IN	in	in	in	N	O
at	IN	at	at	at	N	O
Least	NNP	least	least	least	N	O
10%	CD	10%	10%	10%	N	O
of	IN	of	of	of	N	O
Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
RCC	NNP	rcc	rcc	rcc	N	O
and	CC	and	and	and	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
Higher	JJR	higher	higher	higher	N	O
Rate	NN	rate	rate	rate	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
Arm	NNP	arm	arm	arm	N	O
than	IN	than	than	than	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
Arm	NNP	arm	arm	arm	N	O

Grading	VBG	grading	grading	grade	N	O
according	VBG	according	according	accord	N	O
to	TO	to	to	to	N	O
CTCAE	NNP	ctcae	ctcae	ctcae	N	O
Version	NNP	version	version	version	N	O
3.0	CD	3.0	3.0	3.0	N	O
a	DT	a	a	a	N	O
Stomatitis	NNP	stomatitis	stomatitis	stomat	Y	B-AdverseReaction
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
aphthous	JJ	aphthous	aphthous	aphthou	N	B-AdverseReaction
stomatitis	NN	stomatitis	stomatitis	stomat	Y	I-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
mouth	NN	mouth	mouth	mouth	N	B-AdverseReaction
and	CC	and	and	and	N	O
tongue	NN	tongue	tongue	tongu	N	B-AdverseReaction
ulceration	NN	ulceration	ulceration	ulcer	N	I-AdverseReaction
.	.	.	.	.	N	O

b	SYM	b	b	b	N	O
Includes	VBZ	includes	includes	includ	N	O
all	DT	all	all	all	N	O
preferred	JJ	preferred	preferred	prefer	N	O
terms	NNS	terms	term	term	N	O
within	IN	within	within	within	N	O
the	DT	the	the	the	N	O
infections	NNS	infections	infection	infect	N	O
and	CC	and	and	and	N	O
infestations	NNS	infestations	infestation	infest	N	O
system	NN	system	system	system	N	O
organ	JJ	organ	organ	organ	N	O
class	NN	class	class	class	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
being	VBG	being	being	be	N	O
nasopharyngitis	NN	nasopharyngitis	nasopharyngitis	nasopharyng	Y	B-AdverseReaction
(	(	(	(	(	N	O
6%	CD	6%	6%	6%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
(	(	(	(	(	N	O
6%	CD	6%	6%	6%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
bronchitis	NN	bronchitis	bronchitis	bronchiti	Y	B-AdverseReaction
(	(	(	(	(	N	O
4%	CD	4%	4%	4%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
sinusitis	NN	sinusitis	sinusitis	sinus	Y	B-AdverseReaction
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
also	RB	also	also	also	N	O
including	VBG	including	including	includ	N	O
aspergillosis	NN	aspergillosis	aspergillosis	aspergillosi	Y	B-AdverseReaction
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
candidiasis	NN	candidiasis	candidiasis	candidiasi	Y	B-AdverseReaction
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
sepsis	NN	sepsis	sepsis	sepsi	Y	B-AdverseReaction
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

c	SYM	c	c	c	N	O
Includes	NNP	includes	includes	includ	N	O
pneumonitis	NN	pneumonitis	pneumonitis	pneumon	Y	B-AdverseReaction
,	,	,	,	,	N	O
interstitial	JJ	interstitial	interstitial	interstiti	N	B-AdverseReaction
lung	NN	lung	lung	lung	N	I-AdverseReaction
disease	NN	disease	disease	diseas	N	I-AdverseReaction
,	,	,	,	,	N	O
lung	NN	lung	lung	lung	N	B-AdverseReaction
infiltration	NN	infiltration	infiltration	infiltr	N	I-AdverseReaction
,	,	,	,	,	N	O
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	B-AdverseReaction
alveolar	JJ	alveolar	alveolar	alveolar	N	I-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
,	,	,	,	,	N	O
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	B-AdverseReaction
toxicity	NN	toxicity	toxicity	toxic	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
alveolitis	NN	alveolitis	alveolitis	alveol	Y	B-AdverseReaction
.	.	.	.	.	N	O

AFINITOR	NN	afinitor	afinitor	afinitor	N	O

10	CD	10	10	10	N	O
mg	JJ	mg	mg	mg	N	O
day	NN	day	day	day	N	O
N	NNP	n	n	n	N	O
274	CD	274	274	274	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
N	NNP	n	n	n	N	O
137	CD	137	137	137	N	O

All	DT	all	all	all	N	O
grades	NNS	grades	grade	grade	N	O
Grade	VBD	grade	grade	grade	N	O
3	CD	3	3	3	N	O
Grade	NNP	grade	grade	grade	N	O
4	CD	4	4	4	N	O
All	NNP	all	all	all	N	O
grades	NNS	grades	grade	grade	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
Grade	NNP	grade	grade	grade	N	O
4	CD	4	4	4	N	O

Any	DT	any	any	ani	N	O

a	DT	a	a	a	N	O
dverse	NN	dverse	dverse	dvers	N	O
r	NN	r	r	r	N	O
eaction	NN	eaction	eaction	eaction	N	O
97	CD	97	97	97	N	O
52	CD	52	52	52	N	O
13	CD	13	13	13	N	O
93	CD	93	93	93	N	O
23	CD	23	23	23	N	O
5	CD	5	5	5	N	O

Gastrointestinal	NNP	gastrointestinal	gastrointestinal	gastrointestin	N	O
d	NN	d	d	d	N	O
isorders	NNS	isorders	isorders	isord	N	O

Stomatitis	VB	stomatitis	stomatitis	stomat	Y	B-AdverseReaction
a	DT	a	a	a	N	O
44	CD	44	44	44	N	O
4	CD	4	4	4	N	O
1	CD	1	1	1	N	O
8	CD	8	8	8	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Diarrhea	NNP	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
30	CD	30	30	30	N	O
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O
7	CD	7	7	7	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
26	CD	26	26	26	N	O
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O
19	CD	19	19	19	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
20	CD	20	20	20	N	O
2	CD	2	2	2	N	O
0	CD	0	0	0	N	O
12	CD	12	12	12	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Infections	NNS	infections	infection	infect	N	O
and	CC	and	and	and	N	O
i	JJ	i	i	i	N	O
nfestations	NNS	nfestations	nfestations	nfestat	N	O
b	VBP	b	b	b	N	O
37	CD	37	37	37	N	O
7	CD	7	7	7	N	O
3	CD	3	3	3	N	O
18	CD	18	18	18	N	O
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O

General	NNP	general	general	gener	N	O
d	NN	d	d	d	N	O
isorders	NNS	isorders	isorders	isord	N	O
and	CC	and	and	and	N	O
a	DT	a	a	a	N	O
dministration	NN	dministration	dministration	dministr	N	O
s	NN	s	s	s	N	O
ite	JJ	ite	ite	ite	N	O
c	NN	c	c	c	N	O
onditions	NNS	onditions	onditions	ondit	N	O

Asthenia	NNP	asthenia	asthenia	asthenia	Y	B-AdverseReaction
33	CD	33	33	33	N	O
3	CD	3	3	3	N	O
1	CD	1	1	1	N	O
23	CD	23	23	23	N	O
4	CD	4	4	4	N	O
0	CD	0	0	0	N	O

Fatigue	NNP	fatigue	fatigue	fatigu	Y	B-AdverseReaction
31	CD	31	31	31	N	O
5	CD	5	5	5	N	O
0	CD	0	0	0	N	O
27	CD	27	27	27	N	O
3	CD	3	3	3	N	O
1	CD	1	1	1	N	O

Edema	NNP	edema	edema	edema	Y	B-AdverseReaction
peripheral	JJ	peripheral	peripheral	peripher	N	I-AdverseReaction
25	CD	25	25	25	N	O
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O
8	CD	8	8	8	N	O
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O

Pyrexia	NNP	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
20	CD	20	20	20	N	O
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O
9	CD	9	9	9	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Mucosal	NNP	mucosal	mucosal	mucos	N	B-AdverseReaction
inflammation	NN	inflammation	inflammation	inflamm	Y	I-AdverseReaction
19	CD	19	19	19	N	O
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Respiratory	NNP	respiratory	respiratory	respiratori	N	O
,	,	,	,	,	N	O
t	NN	t	t	t	N	O
horacic	NN	horacic	horacic	horac	N	O
and	CC	and	and	and	N	O
m	JJ	m	m	m	N	O
ediastinal	JJ	ediastinal	ediastinal	ediastin	N	O
d	NN	d	d	d	N	O
isorders	NNS	isorders	isorders	isord	N	O

Cough	NNP	cough	cough	cough	Y	B-AdverseReaction
30	CD	30	30	30	N	O
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O
16	CD	16	16	16	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Dyspnea	NNP	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
24	CD	24	24	24	N	O
6	CD	6	6	6	N	O
1	CD	1	1	1	N	O
15	CD	15	15	15	N	O
3	CD	3	3	3	N	O
0	CD	0	0	0	N	O

Epistaxis	NNP	epistaxis	epistaxis	epistaxi	Y	B-AdverseReaction
18	CD	18	18	18	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Pneumonitis	NNP	pneumonitis	pneumonitis	pneumon	Y	B-AdverseReaction
c	VBD	c	c	c	N	O
14	CD	14	14	14	N	O
4	CD	4	4	4	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Skin	NNP	skin	skin	skin	N	O
and	CC	and	and	and	N	O
s	RB	s	s	s	N	O
ubcutaneous	JJ	ubcutaneous	ubcutaneous	ubcutan	N	O
t	NNS	t	t	t	N	O
issue	NN	issue	issue	issu	N	O
d	VBZ	d	d	d	N	O
isorders	NNS	isorders	isorders	isord	N	O

Rash	NNP	rash	rash	rash	Y	B-AdverseReaction
29	CD	29	29	29	N	O
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O
7	CD	7	7	7	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Pruritus	NNP	pruritus	pruritus	pruritu	Y	B-AdverseReaction
14	CD	14	14	14	N	O
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O
7	CD	7	7	7	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Dry	NNP	dry	dry	dri	N	B-AdverseReaction
skin	VBD	skin	skin	skin	N	I-AdverseReaction
13	CD	13	13	13	N	O
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O
5	CD	5	5	5	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Metabolism	NN	metabolism	metabolism	metabol	N	O
and	CC	and	and	and	N	O
n	JJ	n	n	n	N	O
utrition	NN	utrition	utrition	utrit	N	O
d	NN	d	d	d	N	O
isorders	NNS	isorders	isorders	isord	N	O

Anorexia	NNP	anorexia	anorexia	anorexia	Y	B-AdverseReaction
25	CD	25	25	25	N	O
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O
14	CD	14	14	14	N	O
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O

Nervous	JJ	nervous	nervous	nervou	Y	O
s	NN	s	s	s	N	O
ystem	NN	ystem	ystem	ystem	N	O
d	NN	d	d	d	N	O
isorders	NNS	isorders	isorders	isord	N	O

Headache	NNP	headache	headache	headach	Y	B-AdverseReaction
19	CD	19	19	19	N	O
1	CD	1	1	1	N	O
1	CD	1	1	1	N	O
9	CD	9	9	9	N	O
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O

Dysgeusia	NNP	dysgeusia	dysgeusia	dysgeusia	Y	B-AdverseReaction
10	CD	10	10	10	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
2	CD	2	2	2	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Musculoskeletal	NNP	musculoskeletal	musculoskeletal	musculoskelet	N	O
and	CC	and	and	and	N	O
c	VB	c	c	c	N	O
onnective	JJ	onnective	onnective	onnect	N	O
t	NNS	t	t	t	N	O
issue	NN	issue	issue	issu	N	O
d	VBZ	d	d	d	N	O
isorders	NNS	isorders	isorders	isord	N	O

Pain	NN	pain	pain	pain	Y	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
extremity	NN	extremity	extremity	extrem	N	I-AdverseReaction
10	CD	10	10	10	N	O
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O
7	CD	7	7	7	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Medi	NNP	medi	medi	medi	N	O
an	DT	an	an	an	N	O
d	JJ	d	d	d	N	O
uration	NN	uration	uration	urat	N	O
of	IN	of	of	of	N	O
t	JJ	t	t	t	N	O
reatment	NN	reatment	reatment	reatment	N	O
(	(	(	(	(	N	O
d	NN	d	d	d	N	O
)	)	)	)	)	N	O
141	CD	141	141	141	N	O
60	CD	60	60	60	N	O

Other	JJ	other	other	other	N	O
notable	JJ	notable	notable	notabl	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
occurring	VBG	occurring	occurring	occur	N	O
more	RBR	more	more	more	N	O
frequently	RB	frequently	frequently	frequent	N	O
with	IN	with	with	with	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
than	IN	than	than	than	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
,	,	,	,	,	N	O
but	CC	but	but	but	N	O
with	IN	with	with	with	N	O
an	DT	an	an	an	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
10%	CD	10%	10%	10%	N	O
include	NN	include	include	includ	N	O
:	:	:	:	:	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O

disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Abdominal	NNP	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
(	(	(	(	(	N	O
9%	CD	9%	9%	9%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
dry	JJ	dry	dry	dri	N	B-AdverseReaction
mouth	NN	mouth	mouth	mouth	N	I-AdverseReaction
(	(	(	(	(	N	O
8%	CD	8%	8%	8%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
hemorrhoids	NNS	hemorrhoids	hemorrhoid	hemorrhoid	Y	B-AdverseReaction
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
dysphagia	NN	dysphagia	dysphagia	dysphagia	Y	B-AdverseReaction
(	(	(	(	(	N	O
4%	CD	4%	4%	4%	N	O
)	)	)	)	)	N	O

General	NNP	general	general	gener	N	O
disorders	NNS	disorders	disorder	disord	N	O
and	CC	and	and	and	N	O
administration	NN	administration	administration	administr	N	O
site	NN	site	site	site	N	O
conditions	NNS	conditions	condition	condit	N	O
:	:	:	:	:	N	O
Weight	NNP	weight	weight	weight	Y	B-AdverseReaction
decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
(	(	(	(	(	N	O
9%	CD	9%	9%	9%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
chest	JJS	chest	chest	chest	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
chills	NNS	chills	chill	chill	Y	B-AdverseReaction
(	(	(	(	(	N	O
4%	CD	4%	4%	4%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
impaired	VBN	impaired	impaired	impair	N	B-AdverseReaction
wound	IN	wound	wound	wound	Y	I-AdverseReaction
healing	NN	healing	healing	heal	N	I-AdverseReaction
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O

Respiratory	NNP	respiratory	respiratory	respiratori	N	O
,	,	,	,	,	N	O
thoracic	NN	thoracic	thoracic	thorac	N	O
and	CC	and	and	and	N	O
mediastinal	JJ	mediastinal	mediastinal	mediastin	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Pleural	JJ	pleural	pleural	pleural	N	B-AdverseReaction
effusion	NN	effusion	effusion	effus	Y	I-AdverseReaction
(	(	(	(	(	N	O
7%	CD	7%	7%	7%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
pharyngolaryngeal	JJ	pharyngolaryngeal	pharyngolaryngeal	pharyngolaryng	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
(	(	(	(	(	N	O
4%	CD	4%	4%	4%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
rhinorrhea	NN	rhinorrhea	rhinorrhea	rhinorrhea	Y	B-AdverseReaction
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O

Skin	NNP	skin	skin	skin	N	O
and	CC	and	and	and	N	O
subcutaneous	JJ	subcutaneous	subcutaneous	subcutan	N	O
tissue	NN	tissue	tissue	tissu	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Hand	NNP	hand	hand	hand	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
foot	NN	foot	foot	foot	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
(	(	(	(	(	N	O
reported	VBN	reported	reported	report	N	O
as	IN	as	a	as	N	O
palmar	NN	palmar	palmar	palmar	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
plantar	NN	plantar	plantar	plantar	N	I-AdverseReaction
erythrodysesthesia	JJ	erythrodysesthesia	erythrodysesthesia	erythrodysesthesia	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
)	)	)	)	)	N	O
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
nail	JJ	nail	nail	nail	N	B-AdverseReaction
disorder	NN	disorder	disorder	disord	N	I-AdverseReaction
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
erythema	FW	erythema	erythema	erythema	Y	B-AdverseReaction
(	(	(	(	(	N	O
4%	CD	4%	4%	4%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
onychoclasis	NN	onychoclasis	onychoclasis	onychoclasi	Y	B-AdverseReaction
(	(	(	(	(	N	O
4%	CD	4%	4%	4%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
skin	JJ	skin	skin	skin	N	B-AdverseReaction
lesion	NN	lesion	lesion	lesion	N	I-AdverseReaction
(	(	(	(	(	N	O
4%	CD	4%	4%	4%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
acneiform	JJ	acneiform	acneiform	acneiform	N	B-AdverseReaction
dermatitis	NN	dermatitis	dermatitis	dermat	Y	I-AdverseReaction
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
angioedema	NN	angioedema	angioedema	angioedema	Y	B-AdverseReaction
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O

Metabolism	NN	metabolism	metabolism	metabol	N	O
and	CC	and	and	and	N	O
nutrition	NN	nutrition	nutrition	nutrit	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Exacerbation	NN	exacerbation	exacerbation	exacerb	N	B-AdverseReaction
of	IN	of	of	of	N	O
pre	NN	pre	pre	pre	N	O
-	:	-	-	-	N	O
existing	VBG	existing	existing	exist	N	O
diabetes	NNS	diabetes	diabetes	diabet	Y	I-AdverseReaction
mellitus	NN	mellitus	mellitus	mellitu	N	I-AdverseReaction
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
new	JJ	new	new	new	N	B-AdverseReaction
onset	NN	onset	onset	onset	N	I-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
diabetes	NNS	diabetes	diabetes	diabet	Y	I-AdverseReaction
mellitus	NNS	mellitus	mellitus	mellitu	N	I-AdverseReaction
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O

Psychiatric	JJ	psychiatric	psychiatric	psychiatr	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Insomnia	NNP	insomnia	insomnia	insomnia	Y	B-AdverseReaction
(	(	(	(	(	N	O
9%	CD	9%	9%	9%	N	O
)	)	)	)	)	N	O

Nervous	JJ	nervous	nervous	nervou	Y	O
system	NN	system	system	system	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Dizziness	NNP	dizziness	dizziness	dizzi	Y	B-AdverseReaction
(	(	(	(	(	N	O
7%	CD	7%	7%	7%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
paresthesia	NN	paresthesia	paresthesia	paresthesia	Y	B-AdverseReaction
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O

Eye	JJ	eye	eye	eye	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Eyelid	NNP	eyelid	eyelid	eyelid	N	B-AdverseReaction
edema	NN	edema	edema	edema	Y	I-AdverseReaction
(	(	(	(	(	N	O
4%	CD	4%	4%	4%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
conjunctivitis	NN	conjunctivitis	conjunctivitis	conjunct	Y	B-AdverseReaction
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O

Vascular	JJ	vascular	vascular	vascular	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Hypertension	NNP	hypertension	hypertension	hypertens	Y	B-AdverseReaction
(	(	(	(	(	N	O
4%	CD	4%	4%	4%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
deep	JJ	deep	deep	deep	N	B-AdverseReaction
vein	NN	vein	vein	vein	N	I-AdverseReaction
thrombosis	NN	thrombosis	thrombosis	thrombosi	Y	I-AdverseReaction
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O

Renal	NNP	renal	renal	renal	N	O
and	CC	and	and	and	N	O
urinary	JJ	urinary	urinary	urinari	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Renal	JJ	renal	renal	renal	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O

Cardiac	JJ	cardiac	cardiac	cardiac	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Tachycardia	NNP	tachycardia	tachycardia	tachycardia	Y	B-AdverseReaction
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
congestive	JJ	congestive	congestive	congest	N	B-AdverseReaction
cardiac	JJ	cardiac	cardiac	cardiac	N	I-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O

Musculoskeletal	NNP	musculoskeletal	musculoskeletal	musculoskelet	N	O
and	CC	and	and	and	N	O
connective	JJ	connective	connective	connect	N	O
tissue	NN	tissue	tissue	tissu	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Jaw	NNP	jaw	jaw	jaw	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O

Hematologic	JJ	hematologic	hematologic	hematolog	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Hemorrhage	NNP	hemorrhage	hemorrhage	hemorrhag	Y	B-AdverseReaction
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O

Key	NNP	key	key	key	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
are	VBP	are	are	are	N	O
presented	VBN	presented	presented	present	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
7	CD	7	7	7	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
7	CD	7	7	7	N	O
:	:	:	:	:	N	O
Key	NNP	key	key	key	N	O
Laboratory	NNP	laboratory	laboratory	laboratori	N	O
Abnormalities	NNP	abnormalities	abnormality	abnorm	N	O
Reported	NNP	reported	reported	report	N	O
in	IN	in	in	in	N	O
Patients	NNP	patients	patient	patient	N	O
with	IN	with	with	with	N	O
RCC	NNP	rcc	rcc	rcc	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
Higher	JJR	higher	higher	higher	N	O
Rate	NN	rate	rate	rate	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
Arm	NNP	arm	arm	arm	N	O
than	IN	than	than	than	N	O
the	DT	the	the	the	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
Arm	NNP	arm	arm	arm	N	O

Grading	VBG	grading	grading	grade	N	O
according	VBG	according	according	accord	N	O
to	TO	to	to	to	N	O
CTCAE	NNP	ctcae	ctcae	ctcae	N	O
Version	NNP	version	version	version	N	O
3.0	CD	3.0	3.0	3.0	N	O
a	DT	a	a	a	N	O
Reflects	NNPS	reflects	reflects	reflect	N	O
corresponding	JJ	corresponding	corresponding	correspond	N	O
adverse	JJ	adverse	adverse	advers	N	O
drug	NN	drug	drug	drug	N	O
reaction	NN	reaction	reaction	reaction	N	O
reports	NNS	reports	report	report	N	O
of	IN	of	of	of	N	O
anemia	NN	anemia	anemia	anemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
leukopenia	NN	leukopenia	leukopenia	leukopenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
lymphopenia	NN	lymphopenia	lymphopenia	lymphopenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
thrombocytopenia	NN	thrombocytopenia	thrombocytopenia	thrombocytopenia	Y	B-AdverseReaction
(	(	(	(	(	N	O
collectively	RB	collectively	collectively	collect	N	O
pancytopenia	NN	pancytopenia	pancytopenia	pancytopenia	Y	B-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
which	WDT	which	which	which	N	O
occurred	VBD	occurred	occurred	occur	N	O
at	IN	at	at	at	N	O
lower	JJR	lower	lower	lower	N	O
frequency	NN	frequency	frequency	frequenc	N	O
.	.	.	.	.	N	O

Laboratory	NN	laboratory	laboratory	laboratori	N	O

p	NN	p	p	p	Y	O
arameter	NN	arameter	arameter	aramet	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
day	NN	day	day	day	N	O
N	NNP	n	n	n	N	O
274	CD	274	274	274	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
N	NNP	n	n	n	N	O
137	CD	137	137	137	N	O

All	DT	all	all	all	N	O
grades	NNS	grades	grade	grade	N	O
Grade	VBD	grade	grade	grade	N	O
3	CD	3	3	3	N	O
Grade	NNP	grade	grade	grade	N	O
4	CD	4	4	4	N	O
All	NNP	all	all	all	N	O
grades	NNS	grades	grade	grade	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
Grade	NNP	grade	grade	grade	N	O
4	CD	4	4	4	N	O

Hematology	NN	hematology	hematology	hematolog	N	O

a	DT	a	a	a	N	O

Hemoglobin	NNP	hemoglobin	hemoglobin	hemoglobin	Y	B-AdverseReaction
decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
92	CD	92	92	92	N	O
12	CD	12	12	12	N	O
1	CD	1	1	1	N	O
79	CD	79	79	79	N	O
5	CD	5	5	5	N	O
1	CD	1	1	1	N	O

Lymphocytes	NNS	lymphocytes	lymphocyte	lymphocyt	Y	B-AdverseReaction
decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
51	CD	51	51	51	N	O
16	CD	16	16	16	N	O
2	CD	2	2	2	N	O
28	CD	28	28	28	N	O
5	CD	5	5	5	N	O
0	CD	0	0	0	N	O

Platelets	NNS	platelets	platelet	platelet	N	B-AdverseReaction
decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
23	CD	23	23	23	N	O
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O
2	CD	2	2	2	N	O
0	CD	0	0	0	N	O
1	CD	1	1	1	N	O

Neutrophils	NNS	neutrophils	neutrophil	neutrophil	Y	B-AdverseReaction
decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
14	CD	14	14	14	N	O
0	CD	0	0	0	N	O
1	CD	1	1	1	N	O
4	CD	4	4	4	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Clinical	JJ	clinical	clinical	clinic	N	O
c	NNS	c	c	c	N	O
hemistry	NN	hemistry	hemistry	hemistri	N	O

Cholesterol	NNP	cholesterol	cholesterol	cholesterol	Y	B-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
77	CD	77	77	77	N	O
4	CD	4	4	4	N	O
0	CD	0	0	0	N	O
35	CD	35	35	35	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Triglycerides	NNS	triglycerides	triglyceride	triglycerid	Y	B-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
73	CD	73	73	73	N	O
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O
34	CD	34	34	34	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Glucose	NNP	glucose	glucose	glucos	Y	B-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
57	CD	57	57	57	N	O
15	CD	15	15	15	N	O
1	CD	1	1	1	N	O
25	CD	25	25	25	N	O
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O

Creatinine	NNP	creatinine	creatinine	creatinin	Y	B-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
50	CD	50	50	50	N	O
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O
34	CD	34	34	34	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Phosphate	NNP	phosphate	phosphate	phosphat	Y	B-AdverseReaction
decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
37	CD	37	37	37	N	O
6	CD	6	6	6	N	O
0	CD	0	0	0	N	O
8	CD	8	8	8	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Aspartate	NNP	aspartate	aspartate	aspart	N	B-AdverseReaction
transaminase	NN	transaminase	transaminase	transaminas	N	I-AdverseReaction
(	(	(	(	(	N	O
AST	NNP	ast	ast	ast	N	B-AdverseReaction
)	)	)	)	)	N	O
increased	VBD	increased	increased	increas	N	I-AdverseReaction
25	CD	25	25	25	N	O
1	CD	1	1	1	N	O
1	CD	1	1	1	N	O
7	CD	7	7	7	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Alanine	NNP	alanine	alanine	alanin	N	B-AdverseReaction
transaminase	NN	transaminase	transaminase	transaminas	N	I-AdverseReaction
(	(	(	(	(	N	O
ALT	NNP	alt	alt	alt	N	B-AdverseReaction
)	)	)	)	)	N	O
increased	VBD	increased	increased	increas	N	I-AdverseReaction
21	CD	21	21	21	N	O
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O
4	CD	4	4	4	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Bilirubin	NNP	bilirubin	bilirubin	bilirubin	Y	B-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
3	CD	3	3	3	N	O
1	CD	1	1	1	N	O
1	CD	1	1	1	N	O
2	CD	2	2	2	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

6.4	CD	6.4	6.4	6.4	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Study	NNP	study	study	studi	N	O
Experience	NNP	experience	experience	experi	N	O
in	IN	in	in	in	N	O
Renal	NNP	renal	renal	renal	N	O
Angiomyolipoma	NNP	angiomyolipoma	angiomyolipoma	angiomyolipoma	Y	O
with	IN	with	with	with	N	O
Tuberous	JJ	tuberous	tuberous	tuber	N	O
Sclerosis	NNP	sclerosis	sclerosis	sclerosi	N	O
Complex	NNP	complex	complex	complex	N	O

The	DT	the	the	the	N	O
data	NNS	data	data	data	N	O
described	VBN	described	described	describ	N	O
below	IN	below	below	below	N	O
are	VBP	are	are	are	N	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
a	DT	a	a	a	N	O
randomized	VBN	randomized	randomized	random	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
:	:	:	:	:	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
double	JJ	double	double	doubl	N	O
-	:	-	-	-	N	O
blind	NN	blind	blind	blind	Y	O
,	,	,	,	,	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trial	NN	trial	trial	trial	N	O
of	IN	of	of	of	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
in	IN	in	in	in	N	O
118	CD	118	118	118	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
renal	JJ	renal	renal	renal	N	O
angiomyolipoma	NN	angiomyolipoma	angiomyolipoma	angiomyolipoma	Y	O
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
feature	NN	feature	feature	featur	N	O
of	IN	of	of	of	N	O
TSC	NNP	tsc	tsc	tsc	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
113	CD	113	113	113	N	O
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
sporadic	JJ	sporadic	sporadic	sporad	N	O
lymphangioleiomyomatosis	NN	lymphangioleiomyomatosis	lymphangioleiomyomatosis	lymphangioleiomyomatosi	Y	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
5	CD	5	5	5	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
median	JJ	median	median	median	N	O
age	NN	age	age	age	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
was	VBD	was	wa	wa	N	O
31	CD	31	31	31	N	O
years	NNS	years	year	year	N	O
(	(	(	(	(	N	O
range	VB	range	range	rang	N	O
18	CD	18	18	18	N	O
to	TO	to	to	to	N	O
61	CD	61	61	61	N	O
years	NNS	years	year	year	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
89%	CD	89%	89%	89%	N	O
were	VBD	were	were	were	N	O
Caucasian	JJ	caucasian	caucasian	caucasian	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
34%	CD	34%	34%	34%	N	O
were	VBD	were	were	were	N	O
male	NN	male	male	male	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
median	JJ	median	median	median	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
blinded	JJ	blinded	blinded	blind	N	O
study	NN	study	study	studi	N	O
treatment	NN	treatment	treatment	treatment	N	O
was	VBD	was	wa	wa	N	O
48	CD	48	48	48	N	O
weeks	NNS	weeks	week	week	N	O
(	(	(	(	(	N	O
range	VB	range	range	rang	N	O
2	CD	2	2	2	N	O
to	TO	to	to	to	N	O
115	CD	115	115	115	N	O
weeks	NNS	weeks	week	week	N	O
)	)	)	)	)	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
and	CC	and	and	and	N	O
45	CD	45	45	45	N	O
weeks	NNS	weeks	week	week	N	O
(	(	(	(	(	N	O
range	VB	range	range	rang	N	O
9	CD	9	9	9	N	O
to	TO	to	to	to	N	O
115	CD	115	115	115	N	O
weeks	NNS	weeks	week	week	N	O
)	)	)	)	)	N	O
for	IN	for	for	for	N	O
those	DT	those	those	those	N	O
receiving	VBG	receiving	receiving	receiv	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
reported	VBD	reported	reported	report	N	O
for	IN	for	for	for	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
(	(	(	(	(	N	O
incidence	VB	incidence	incidence	incid	N	O
30%	CD	30%	30%	30%	N	O
)	)	)	)	)	N	O
was	VBD	was	wa	wa	N	O
stomatitis	NN	stomatitis	stomatitis	stomat	Y	B-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
4	CD	4	4	4	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
incidence	VB	incidence	incidence	incid	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
stomatitis	VBN	stomatitis	stomatitis	stomat	Y	B-AdverseReaction
and	CC	and	and	and	N	O
amenorrhea	NN	amenorrhea	amenorrhea	amenorrhea	Y	B-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
(	(	(	(	(	N	O
incidence	VB	incidence	incidence	incid	N	O
50%	CD	50%	50%	50%	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
hypercholesterolemia	VBN	hypercholesterolemia	hypercholesterolemia	hypercholesterolemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
hypertriglyceridemia	NN	hypertriglyceridemia	hypertriglyceridemia	hypertriglyceridemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
anemia	NN	anemia	anemia	anemia	Y	B-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
4	CD	4	4	4	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
abnormality	NN	abnormality	abnormality	abnorm	N	O
(	(	(	(	(	N	O
incidence	VB	incidence	incidence	incid	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
was	VBD	was	wa	wa	N	O
hypophosphatemia	NN	hypophosphatemia	hypophosphatemia	hypophosphatemia	Y	B-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
rate	NN	rate	rate	rate	N	O
of	IN	of	of	of	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
resulting	VBG	resulting	resulting	result	N	O
in	IN	in	in	in	N	O
permanent	JJ	permanent	permanent	perman	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
was	VBD	was	wa	wa	N	O
3.8%	CD	3.8%	3.8%	3.8%	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
leading	VBG	leading	leading	lead	N	O
to	TO	to	to	to	N	O
permanent	JJ	permanent	permanent	perman	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
arm	NN	arm	arm	arm	N	O
were	VBD	were	were	were	N	O
hypersensitivity	JJ	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
angioedema	NN	angioedema	angioedema	angioedema	Y	B-AdverseReaction
bronchospasm	NN	bronchospasm	bronchospasm	bronchospasm	Y	B-AdverseReaction
,	,	,	,	,	N	O
convulsion	NN	convulsion	convulsion	convuls	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
hypophosphatemia	NN	hypophosphatemia	hypophosphatemia	hypophosphatemia	Y	B-AdverseReaction
.	.	.	.	.	N	O

Dose	JJ	dose	dose	dose	N	O
adjustments	NNS	adjustments	adjustment	adjust	N	O
(	(	(	(	(	N	O
interruptions	NNS	interruptions	interruption	interrupt	N	O
or	CC	or	or	or	N	O
reductions	NNS	reductions	reduction	reduct	N	O
)	)	)	)	)	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
52%	CD	52%	52%	52%	N	O
of	IN	of	of	of	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
leading	VBG	leading	leading	lead	N	O
to	TO	to	to	to	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
dose	JJ	dose	dose	dose	N	O
adjustment	NN	adjustment	adjustment	adjust	N	O
was	VBD	was	wa	wa	N	O
stomatitis	NN	stomatitis	stomatitis	stomat	Y	B-AdverseReaction
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
8	CD	8	8	8	N	O
compares	VBZ	compares	compare	compar	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
reported	VBN	reported	reported	report	N	O
with	IN	with	with	with	N	O
an	DT	an	an	an	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
10%	CD	10%	10%	10%	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
and	CC	and	and	and	N	O
occurring	VBG	occurring	occurring	occur	N	O
more	RBR	more	more	more	N	O
frequently	RB	frequently	frequently	frequent	N	O
with	IN	with	with	with	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
than	IN	than	than	than	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

Laboratory	NN	laboratory	laboratory	laboratori	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
are	VBP	are	are	are	N	O
described	VBN	described	described	describ	N	O
separately	RB	separately	separately	separ	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
9	CD	9	9	9	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
8	CD	8	8	8	N	O
:	:	:	:	:	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
Reported	VBD	reported	reported	report	N	O
in	IN	in	in	in	N	O
10%	CD	10%	10%	10%	N	O
of	IN	of	of	of	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Renal	NNP	renal	renal	renal	N	O
Angiomyolipoma	NNP	angiomyolipoma	angiomyolipoma	angiomyolipoma	Y	O

Grading	VBG	grading	grading	grade	N	O
according	VBG	according	according	accord	N	O
to	TO	to	to	to	N	O
CTCAE	NNP	ctcae	ctcae	ctcae	N	O
Version	NNP	version	version	version	N	O
3.0	CD	3.0	3.0	3.0	N	O
a	DT	a	a	a	N	O
Includes	NNP	includes	includes	includ	N	O
stomatitis	NN	stomatitis	stomatitis	stomat	Y	B-AdverseReaction
,	,	,	,	,	N	O
aphthous	JJ	aphthous	aphthous	aphthou	N	B-AdverseReaction
stomatitis	NN	stomatitis	stomatitis	stomat	Y	I-AdverseReaction
,	,	,	,	,	N	O
mouth	JJ	mouth	mouth	mouth	N	B-AdverseReaction
ulceration	NN	ulceration	ulceration	ulcer	N	I-AdverseReaction
,	,	,	,	,	N	O
gingival	NN	gingival	gingival	gingiv	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
glossitis	NN	glossitis	glossitis	glossiti	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
glossodynia	NN	glossodynia	glossodynia	glossodynia	Y	B-AdverseReaction
.	.	.	.	.	N	O

AFINITOR	NN	afinitor	afinitor	afinitor	N	O

N	NNP	n	n	n	N	O
79	CD	79	79	79	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
N	NNP	n	n	n	N	O
39	CD	39	39	39	N	O

All	DT	all	all	all	N	O
grades	NNS	grades	grade	grade	N	O
Grade	VBD	grade	grade	grade	N	O
3	CD	3	3	3	N	O
Grade	NNP	grade	grade	grade	N	O
4	CD	4	4	4	N	O
All	NNP	all	all	all	N	O
grades	NNS	grades	grade	grade	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
Grade	NNP	grade	grade	grade	N	O
4	CD	4	4	4	N	O

Any	DT	any	any	ani	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
100	CD	100	100	100	N	O
25	CD	25	25	25	N	O
5	CD	5	5	5	N	O
97	CD	97	97	97	N	O
8	CD	8	8	8	N	O
5	CD	5	5	5	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
disorders	NNS	disorders	disorder	disord	N	O

Stomatitis	VB	stomatitis	stomatitis	stomat	Y	B-AdverseReaction
a	DT	a	a	a	N	O
78	CD	78	78	78	N	O
6	CD	6	6	6	N	O
0	CD	0	0	0	N	O
23	CD	23	23	23	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
15	CD	15	15	15	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
5	CD	5	5	5	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Diarrhea	NNP	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
14	CD	14	14	14	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
5	CD	5	5	5	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

General	NNP	general	general	gener	N	O
disorders	NNS	disorders	disorder	disord	N	O
and	CC	and	and	and	N	O
administration	NN	administration	administration	administr	N	O
site	NN	site	site	site	N	O
conditions	NNS	conditions	condition	condit	N	O

Peripheral	NNP	peripheral	peripheral	peripher	N	B-AdverseReaction
edema	VBD	edema	edema	edema	Y	I-AdverseReaction
13	CD	13	13	13	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
8	CD	8	8	8	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Infections	NNS	infections	infection	infect	N	O
and	CC	and	and	and	N	O
infestations	NNS	infestations	infestation	infest	N	O

Upper	NNP	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
11	CD	11	11	11	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
5	CD	5	5	5	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Musculoskeletal	NNP	musculoskeletal	musculoskeletal	musculoskelet	N	O
and	CC	and	and	and	N	O
connective	JJ	connective	connective	connect	N	O
tissue	NN	tissue	tissue	tissu	N	O
disorders	NNS	disorders	disorder	disord	N	O

Arthralgia	NNP	arthralgia	arthralgia	arthralgia	Y	B-AdverseReaction
13	CD	13	13	13	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
5	CD	5	5	5	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Respiratory	NNP	respiratory	respiratory	respiratori	N	O
,	,	,	,	,	N	O
thoracic	NN	thoracic	thoracic	thorac	N	O
and	CC	and	and	and	N	O
mediastinal	JJ	mediastinal	mediastinal	mediastin	N	O
disorders	NNS	disorders	disorder	disord	N	O

Cough	NNP	cough	cough	cough	Y	B-AdverseReaction
20	CD	20	20	20	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
13	CD	13	13	13	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Skin	NNP	skin	skin	skin	N	O
and	CC	and	and	and	N	O
subcutaneous	JJ	subcutaneous	subcutaneous	subcutan	N	O
tissue	NN	tissue	tissue	tissu	N	O
disorders	NNS	disorders	disorder	disord	N	O

Acne	NNP	acne	acne	acn	Y	B-AdverseReaction
22	CD	22	22	22	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
5	CD	5	5	5	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Amenorrhea	NNP	amenorrhea	amenorrhea	amenorrhea	Y	B-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
15%	CD	15%	15%	15%	N	O
of	IN	of	of	of	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
females	NNS	females	female	femal	N	O
(	(	(	(	(	N	O
8	CD	8	8	8	N	O
of	IN	of	of	of	N	O
52	CD	52	52	52	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
4%	CD	4%	4%	4%	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
of	IN	of	of	of	N	O
26	CD	26	26	26	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
females	NNS	females	female	femal	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
group	NN	group	group	group	N	O
.	.	.	.	.	N	O

Other	JJ	other	other	other	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
involving	VBG	involving	involving	involv	N	O
the	DT	the	the	the	N	O
female	JJ	female	female	femal	N	O
reproductive	JJ	reproductive	reproductive	reproduct	N	O
system	NN	system	system	system	N	O
were	VBD	were	were	were	N	O
menorrhagia	NNS	menorrhagia	menorrhagia	menorrhagia	Y	B-AdverseReaction
(	(	(	(	(	N	O
10%	CD	10%	10%	10%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
menstrual	JJ	menstrual	menstrual	menstrual	N	B-AdverseReaction
irregularities	NNS	irregularities	irregularity	irregular	N	I-AdverseReaction
(	(	(	(	(	N	O
10%	CD	10%	10%	10%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
vaginal	JJ	vaginal	vaginal	vagin	N	B-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
(	(	(	(	(	N	O
8%	CD	8%	8%	8%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O

following	VBG	following	following	follow	N	O
additional	JJ	additional	additional	addit	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
10%	CD	10%	10%	10%	N	O
of	IN	of	of	of	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
:	:	:	:	:	N	O
epistaxis	NN	epistaxis	epistaxis	epistaxi	Y	B-AdverseReaction
(	(	(	(	(	N	O
9%	CD	9%	9%	9%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
decreased	VBN	decreased	decreased	decreas	N	B-AdverseReaction
appetite	NN	appetite	appetite	appetit	N	I-AdverseReaction
(	(	(	(	(	N	O
6%	CD	6%	6%	6%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
otitis	JJ	otitis	otitis	otiti	Y	B-AdverseReaction
media	NNS	media	medium	media	N	I-AdverseReaction
(	(	(	(	(	N	O
6%	CD	6%	6%	6%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
depression	NN	depression	depression	depress	Y	B-AdverseReaction
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
abnormal	JJ	abnormal	abnormal	abnorm	N	B-AdverseReaction
taste	NN	taste	taste	tast	N	I-AdverseReaction
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
increased	VBD	increased	increased	increas	N	B-AdverseReaction
blood	NN	blood	blood	blood	N	I-AdverseReaction
luteinizing	VBG	luteinizing	luteinizing	lutein	N	I-AdverseReaction
hormone	NN	hormone	hormone	hormon	N	I-AdverseReaction
(	(	(	(	(	N	O
LH	NNP	lh	lh	lh	Y	I-AdverseReaction
)	)	)	)	)	N	O
levels	NNS	levels	level	level	N	I-AdverseReaction
(	(	(	(	(	N	O
4%	CD	4%	4%	4%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
increased	VBD	increased	increased	increas	N	B-AdverseReaction
blood	NN	blood	blood	blood	N	I-AdverseReaction
follicle	NN	follicle	follicle	follicl	N	I-AdverseReaction
stimulating	VBG	stimulating	stimulating	stimul	N	I-AdverseReaction
hormone	NN	hormone	hormone	hormon	N	I-AdverseReaction
(	(	(	(	(	N	O
FSH	NNP	fsh	fsh	fsh	Y	I-AdverseReaction
)	)	)	)	)	N	O
levels	NNS	levels	level	level	N	I-AdverseReaction
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
ovarian	JJ	ovarian	ovarian	ovarian	N	B-AdverseReaction
cyst	NN	cyst	cyst	cyst	Y	I-AdverseReaction
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
pneumonitis	NN	pneumonitis	pneumonitis	pneumon	Y	B-AdverseReaction
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
angioedema	NN	angioedema	angioedema	angioedema	Y	B-AdverseReaction
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
9	CD	9	9	9	N	O
:	:	:	:	:	N	O
Key	NNP	key	key	key	N	O
Laboratory	NNP	laboratory	laboratory	laboratori	N	O
Abnormalities	NNP	abnormalities	abnormality	abnorm	N	O
Reported	NNP	reported	reported	report	N	O
in	IN	in	in	in	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Renal	NNP	renal	renal	renal	N	O
Angiomyolipoma	NNP	angiomyolipoma	angiomyolipoma	angiomyolipoma	Y	O

Grading	VBG	grading	grading	grade	N	O
according	VBG	according	according	accord	N	O
to	TO	to	to	to	N	O
CTCAE	NNP	ctcae	ctcae	ctcae	N	O
Version	NNP	version	version	version	N	O
3.0	CD	3.0	3.0	3.0	N	O

AFINITOR	NN	afinitor	afinitor	afinitor	N	O

N	NNP	n	n	n	N	O
79	CD	79	79	79	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
N	NNP	n	n	n	N	O
39	CD	39	39	39	N	O

All	DT	all	all	all	N	O
grades	NNS	grades	grade	grade	N	O
Grade	VBD	grade	grade	grade	N	O
3	CD	3	3	3	N	O
Grade	NNP	grade	grade	grade	N	O
4	CD	4	4	4	N	O
All	NNP	all	all	all	N	O
grades	NNS	grades	grade	grade	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
Grade	NNP	grade	grade	grade	N	O
4	CD	4	4	4	N	O

Hematology	NN	hematology	hematology	hematolog	N	O

Anemia	NNP	anemia	anemia	anemia	Y	O
61	CD	61	61	61	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
49	CD	49	49	49	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Leucopenia	NNP	leucopenia	leucopenia	leucopenia	Y	B-AdverseReaction
37	CD	37	37	37	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
21	CD	21	21	21	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Neutropenia	NNP	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
25	CD	25	25	25	N	O
0	CD	0	0	0	N	O
1	CD	1	1	1	N	O
26	CD	26	26	26	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Lymphopenia	NNP	lymphopenia	lymphopenia	lymphopenia	Y	B-AdverseReaction
20	CD	20	20	20	N	O
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O
8	CD	8	8	8	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Thrombocytopenia	NNP	thrombocytopenia	thrombocytopenia	thrombocytopenia	Y	B-AdverseReaction
19	CD	19	19	19	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
3	CD	3	3	3	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Clinical	JJ	clinical	clinical	clinic	N	O

chemistry	NN	chemistry	chemistry	chemistri	N	O

Hypercholesterolemia	NNP	hypercholesterolemia	hypercholesterolemia	hypercholesterolemia	Y	B-AdverseReaction
85	CD	85	85	85	N	O
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O
46	CD	46	46	46	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Hypertriglyceridemia	NNP	hypertriglyceridemia	hypertriglyceridemia	hypertriglyceridemia	Y	B-AdverseReaction
52	CD	52	52	52	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
10	CD	10	10	10	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Hypophosphatemia	NNP	hypophosphatemia	hypophosphatemia	hypophosphatemia	Y	B-AdverseReaction
49	CD	49	49	49	N	O
5	CD	5	5	5	N	O
0	CD	0	0	0	N	O
15	CD	15	15	15	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Alkaline	JJ	alkaline	alkaline	alkalin	N	B-AdverseReaction
phosphatase	NN	phosphatase	phosphatase	phosphatas	N	I-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
32	CD	32	32	32	N	O
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O
10	CD	10	10	10	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Elevated	VBN	elevated	elevated	elev	N	B-AdverseReaction
aspartate	JJ	aspartate	aspartate	aspart	N	I-AdverseReaction
transaminase	NN	transaminase	transaminase	transaminas	N	I-AdverseReaction
(	(	(	(	(	N	O
AST	NNP	ast	ast	ast	N	I-AdverseReaction
)	)	)	)	)	N	O
23	CD	23	23	23	N	O
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O
8	CD	8	8	8	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Elevated	VBN	elevated	elevated	elev	N	B-AdverseReaction
alanine	JJ	alanine	alanine	alanin	N	I-AdverseReaction
transaminase	NN	transaminase	transaminase	transaminas	N	I-AdverseReaction
(	(	(	(	(	N	O
ALT	NNP	alt	alt	alt	N	I-AdverseReaction
)	)	)	)	)	N	O
20	CD	20	20	20	N	O
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O
15	CD	15	15	15	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Fasting	VBG	fasting	fasting	fast	Y	B-AdverseReaction
hyperglycemia	NN	hyperglycemia	hyperglycemia	hyperglycemia	Y	I-AdverseReaction
14	CD	14	14	14	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
8	CD	8	8	8	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

6.5	CD	6.5	6.5	6.5	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Study	NNP	study	study	studi	N	O
Experience	NNP	experience	experience	experi	N	O
in	IN	in	in	in	N	O
Subependymal	NNP	subependymal	subependymal	subependym	N	O
Giant	NNP	giant	giant	giant	N	O
Cell	NNP	cell	cell	cell	N	O
Astrocytoma	NNP	astrocytoma	astrocytoma	astrocytoma	Y	O
with	IN	with	with	with	N	O
Tuberous	JJ	tuberous	tuberous	tuber	N	O
Sclerosis	NNP	sclerosis	sclerosis	sclerosi	N	O
Complex	NNP	complex	complex	complex	N	O

The	DT	the	the	the	N	O
data	NNS	data	data	data	N	O
described	VBN	described	described	describ	N	O
below	IN	below	below	below	N	O
are	VBP	are	are	are	N	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
a	DT	a	a	a	N	O
randomized	VBN	randomized	randomized	random	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
:	:	:	:	:	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
double	JJ	double	double	doubl	N	O
-	:	-	-	-	N	O
blind	NN	blind	blind	blind	Y	O
,	,	,	,	,	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trial	NN	trial	trial	trial	N	O
(	(	(	(	(	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
in	IN	in	in	in	N	O
117	CD	117	117	117	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
subependymal	JJ	subependymal	subependymal	subependym	N	O
giant	NN	giant	giant	giant	N	O
cell	NN	cell	cell	cell	N	O
astrocytoma	NN	astrocytoma	astrocytoma	astrocytoma	Y	O
(	(	(	(	(	N	O
SEGA	NNP	sega	sega	sega	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
tuberous	JJ	tuberous	tuberous	tuber	N	O
sclerosis	NN	sclerosis	sclerosis	sclerosi	N	O
complex	NN	complex	complex	complex	N	O
(	(	(	(	(	N	O
TSC	NNP	tsc	tsc	tsc	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
median	JJ	median	median	median	N	O
age	NN	age	age	age	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
was	VBD	was	wa	wa	N	O
9.5	CD	9.5	9.5	9.5	N	O
years	NNS	years	year	year	N	O
(	(	(	(	(	N	O
range	VB	range	range	rang	N	O
0.8	CD	0.8	0.8	0.8	N	O
to	TO	to	to	to	N	O
26	CD	26	26	26	N	O
years	NNS	years	year	year	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
93%	CD	93%	93%	93%	N	O
were	VBD	were	were	were	N	O
Caucasian	JJ	caucasian	caucasian	caucasian	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
57%	CD	57%	57%	57%	N	O
were	VBD	were	were	were	N	O
male	NN	male	male	male	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
median	JJ	median	median	median	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
blinded	JJ	blinded	blinded	blind	N	O
study	NN	study	study	studi	N	O
treatment	NN	treatment	treatment	treatment	N	O
was	VBD	was	wa	wa	N	O
52	CD	52	52	52	N	O
weeks	NNS	weeks	week	week	N	O
(	(	(	(	(	N	O
range	VB	range	range	rang	N	O
24	CD	24	24	24	N	O
to	TO	to	to	to	N	O
89	CD	89	89	89	N	O
weeks	NNS	weeks	week	week	N	O
)	)	)	)	)	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
and	CC	and	and	and	N	O
47	CD	47	47	47	N	O
weeks	NNS	weeks	week	week	N	O
(	(	(	(	(	N	O
range	VB	range	range	rang	N	O
14	CD	14	14	14	N	O
to	TO	to	to	to	N	O
88	CD	88	88	88	N	O
weeks	NNS	weeks	week	week	N	O
)	)	)	)	)	N	O
for	IN	for	for	for	N	O
those	DT	those	those	those	N	O
receiving	VBG	receiving	receiving	receiv	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
reported	VBD	reported	reported	report	N	O
for	IN	for	for	for	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
(	(	(	(	(	N	O
incidence	VB	incidence	incidence	incid	N	O
30%	CD	30%	30%	30%	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
stomatitis	VBN	stomatitis	stomatitis	stomat	Y	B-AdverseReaction
and	CC	and	and	and	N	O
respiratory	JJ	respiratory	respiratory	respiratori	N	B-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
-	:	-	-	-	N	I-Severity
4	CD	4	4	4	N	I-Severity
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
incidence	VB	incidence	incidence	incid	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
stomatitis	VBN	stomatitis	stomatitis	stomat	Y	B-AdverseReaction
,	,	,	,	,	N	O
pyrexia	NN	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
,	,	,	,	,	N	O
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
,	,	,	,	,	N	O
gastroenteritis	NN	gastroenteritis	gastroenteritis	gastroenter	Y	B-AdverseReaction
,	,	,	,	,	N	O
aggression	NN	aggression	aggression	aggress	Y	B-AdverseReaction
,	,	,	,	,	N	O
agitation	NN	agitation	agitation	agit	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
amenorrhea	NN	amenorrhea	amenorrhea	amenorrhea	Y	B-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
key	JJ	key	key	key	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
(	(	(	(	(	N	O
incidence	VB	incidence	incidence	incid	N	O
50%	CD	50%	50%	50%	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
hypercholesterolemia	JJ	hypercholesterolemia	hypercholesterolemia	hypercholesterolemia	Y	B-AdverseReaction
and	CC	and	and	and	N	O
elevated	VBD	elevated	elevated	elev	N	B-AdverseReaction
partial	JJ	partial	partial	partial	N	I-AdverseReaction
thromboplastin	NN	thromboplastin	thromboplastin	thromboplastin	Y	I-AdverseReaction
time	NN	time	time	time	N	I-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
-	:	-	-	-	N	I-Severity
4	CD	4	4	4	N	I-Severity
laboratory	NN	laboratory	laboratory	laboratori	N	O
abnormality	NN	abnormality	abnormality	abnorm	N	O
(	(	(	(	(	N	O
incidence	VB	incidence	incidence	incid	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
was	VBD	was	wa	wa	N	O
neutropenia	VBN	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
.	.	.	.	.	N	O

There	EX	there	there	there	N	O
were	VBD	were	were	were	N	O
no	DT	no	no	no	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
resulting	VBG	resulting	resulting	result	N	O
in	IN	in	in	in	N	O
permanent	JJ	permanent	permanent	perman	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
.	.	.	.	.	N	O

Dose	JJ	dose	dose	dose	N	O
adjustments	NNS	adjustments	adjustment	adjust	N	O
(	(	(	(	(	N	O
interruptions	NNS	interruptions	interruption	interrupt	N	O
or	CC	or	or	or	N	O
reductions	NNS	reductions	reduction	reduct	N	O
)	)	)	)	)	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
55%	CD	55%	55%	55%	N	O
of	IN	of	of	of	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
leading	VBG	leading	leading	lead	N	O
to	TO	to	to	to	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
dose	JJ	dose	dose	dose	N	O
adjustment	NN	adjustment	adjustment	adjust	N	O
was	VBD	was	wa	wa	N	O
stomatitis	NN	stomatitis	stomatitis	stomat	Y	B-AdverseReaction
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
10	CD	10	10	10	N	O
compares	VBZ	compares	compare	compar	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
reported	VBN	reported	reported	report	N	O
with	IN	with	with	with	N	O
an	DT	an	an	an	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
10%	CD	10%	10%	10%	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
and	CC	and	and	and	N	O
occurring	VBG	occurring	occurring	occur	N	O
more	RBR	more	more	more	N	O
frequently	RB	frequently	frequently	frequent	N	O
with	IN	with	with	with	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
than	IN	than	than	than	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

Laboratory	NN	laboratory	laboratory	laboratori	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
are	VBP	are	are	are	N	O
described	VBN	described	described	describ	N	O
separately	RB	separately	separately	separ	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
11	CD	11	11	11	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
10	CD	10	10	10	N	O
:	:	:	:	:	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
Reported	VBD	reported	reported	report	N	O
in	IN	in	in	in	N	O
10%	CD	10%	10%	10%	N	O
of	IN	of	of	of	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
SEGA	NNP	sega	sega	sega	N	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O

Grading	VBG	grading	grading	grade	N	O
according	VBG	according	according	accord	N	O
to	TO	to	to	to	N	O
CTCAE	NNP	ctcae	ctcae	ctcae	N	O
Version	NNP	version	version	version	N	O
3.0	CD	3.0	3.0	3.0	N	O
a	DT	a	a	a	N	O
Includes	NNP	includes	includes	includ	N	O
mouth	NN	mouth	mouth	mouth	N	B-AdverseReaction
ulceration	NN	ulceration	ulceration	ulcer	N	I-AdverseReaction
,	,	,	,	,	N	O
stomatitis	NN	stomatitis	stomatitis	stomat	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
lip	JJS	lip	lip	lip	N	B-AdverseReaction
ulceration	NN	ulceration	ulceration	ulcer	N	I-AdverseReaction
b	NN	b	b	b	N	O
Includes	NNP	includes	includes	includ	N	O
respiratory	NN	respiratory	respiratory	respiratori	N	B-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
upper	JJ	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
respiratory	JJ	respiratory	respiratory	respiratori	N	B-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
viral	JJ	viral	viral	viral	N	I-AdverseReaction
c	NN	c	c	c	N	O
Includes	NNP	includes	includes	includ	N	O
gastroenteritis	NN	gastroenteritis	gastroenteritis	gastroenter	Y	B-AdverseReaction
,	,	,	,	,	N	O
gastroenteritis	NN	gastroenteritis	gastroenteritis	gastroenter	Y	B-AdverseReaction
viral	NN	viral	viral	viral	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	B-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
d	NN	d	d	d	N	O
Includes	NNP	includes	includes	includ	N	O
agitation	NN	agitation	agitation	agit	Y	B-AdverseReaction
,	,	,	,	,	N	O
anxiety	NN	anxiety	anxiety	anxieti	Y	B-AdverseReaction
,	,	,	,	,	N	O
panic	JJ	panic	panic	panic	N	B-AdverseReaction
attack	NN	attack	attack	attack	N	I-AdverseReaction
,	,	,	,	,	N	O
aggression	NN	aggression	aggression	aggress	Y	B-AdverseReaction
,	,	,	,	,	N	O
abnormal	JJ	abnormal	abnormal	abnorm	N	B-AdverseReaction
behavior	NN	behavior	behavior	behavior	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
obsessive	JJ	obsessive	obsessive	obsess	N	B-AdverseReaction
compulsive	JJ	compulsive	compulsive	compuls	N	I-AdverseReaction
disorder	NN	disorder	disorder	disord	N	I-AdverseReaction
e	NN	e	e	e	N	O
Includes	NNP	includes	includes	includ	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
,	,	,	,	,	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
generalized	VBD	generalized	generalized	gener	N	I-AdverseReaction
,	,	,	,	,	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
macular	NN	macular	macular	macular	N	I-AdverseReaction
,	,	,	,	,	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
maculo	SYM	maculo	maculo	maculo	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
papular	NN	papular	papular	papular	N	I-AdverseReaction
,	,	,	,	,	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
papular	NN	papular	papular	papular	N	I-AdverseReaction
,	,	,	,	,	N	O
dermatitis	NN	dermatitis	dermatitis	dermat	Y	B-AdverseReaction
allergic	NN	allergic	allergic	allerg	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
urticaria	NNS	urticaria	urticaria	urticaria	Y	B-AdverseReaction

AFINITOR	NN	afinitor	afinitor	afinitor	N	O

N	NNP	n	n	n	N	O
78	CD	78	78	78	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
N	NNP	n	n	n	N	O
39	CD	39	39	39	N	O

All	DT	all	all	all	N	O
grades	NNS	grades	grade	grade	N	O
Grade	VBD	grade	grade	grade	N	O
3	CD	3	3	3	N	O
Grade	NNP	grade	grade	grade	N	O
4	CD	4	4	4	N	O
All	NNP	all	all	all	N	O
grades	NNS	grades	grade	grade	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
Grade	NNP	grade	grade	grade	N	O
4	CD	4	4	4	N	O

Any	DT	any	any	ani	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
97	CD	97	97	97	N	O
36	CD	36	36	36	N	O
3	CD	3	3	3	N	O
92	CD	92	92	92	N	O
23	CD	23	23	23	N	O
3	CD	3	3	3	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
disorders	NNS	disorders	disorder	disord	N	O

Stomatitis	VB	stomatitis	stomatitis	stomat	Y	B-AdverseReaction
a	DT	a	a	a	N	O
62	CD	62	62	62	N	O
9	CD	9	9	9	N	O
0	CD	0	0	0	N	O
26	CD	26	26	26	N	O
3	CD	3	3	3	N	O
0	CD	0	0	0	N	O

Vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
22	CD	22	22	22	N	O
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O
13	CD	13	13	13	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Diarrhea	NNP	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
17	CD	17	17	17	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
5	CD	5	5	5	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Constipation	NN	constipation	constipation	constip	Y	B-AdverseReaction
10	CD	10	10	10	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
3	CD	3	3	3	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Infections	NNS	infections	infection	infect	N	O
and	CC	and	and	and	N	O
infestations	NNS	infestations	infestation	infest	N	O

Respiratory	NNP	respiratory	respiratory	respiratori	N	B-AdverseReaction
tract	JJ	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
b	VBD	b	b	b	N	O
31	CD	31	31	31	N	O
1	CD	1	1	1	N	O
1	CD	1	1	1	N	O
23	CD	23	23	23	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Gastroenteritis	NNP	gastroenteritis	gastroenteritis	gastroenter	Y	B-AdverseReaction
c	VBD	c	c	c	N	O
10	CD	10	10	10	N	O
4	CD	4	4	4	N	O
1	CD	1	1	1	N	O
3	CD	3	3	3	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Pharyngitis	NNP	pharyngitis	pharyngitis	pharyng	Y	O
streptococcal	JJ	streptococcal	streptococcal	streptococc	N	O
10	CD	10	10	10	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
3	CD	3	3	3	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

General	NNP	general	general	gener	N	O
disorders	NNS	disorders	disorder	disord	N	O
and	CC	and	and	and	N	O
administration	NN	administration	administration	administr	N	O
site	NN	site	site	site	N	O
conditions	NNS	conditions	condition	condit	N	O

Pyrexia	NNP	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
23	CD	23	23	23	N	O
6	CD	6	6	6	N	O
0	CD	0	0	0	N	O
18	CD	18	18	18	N	O
3	CD	3	3	3	N	O
0	CD	0	0	0	N	O

Fatigue	NNP	fatigue	fatigue	fatigu	Y	B-AdverseReaction
14	CD	14	14	14	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
3	CD	3	3	3	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Psychiatric	JJ	psychiatric	psychiatric	psychiatr	N	O
disorders	NNS	disorders	disorder	disord	N	O

Anxiety	NN	anxiety	anxiety	anxieti	Y	B-AdverseReaction
,	,	,	,	,	N	O
aggression	NN	aggression	aggression	aggress	Y	B-AdverseReaction
or	CC	or	or	or	N	O
other	JJ	other	other	other	N	O
behavioral	JJ	behavioral	behavioral	behavior	N	B-AdverseReaction
disturbance	NN	disturbance	disturbance	disturb	N	I-AdverseReaction
d	VBD	d	d	d	N	O
21	CD	21	21	21	N	O
5	CD	5	5	5	N	O
0	CD	0	0	0	N	O
3	CD	3	3	3	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Skin	NNP	skin	skin	skin	N	O
and	CC	and	and	and	N	O
subcutaneous	JJ	subcutaneous	subcutaneous	subcutan	N	O
tissue	NN	tissue	tissue	tissu	N	O
disorders	NNS	disorders	disorder	disord	N	O

Rash	NNP	rash	rash	rash	Y	B-AdverseReaction
e	VBD	e	e	e	N	O
21	CD	21	21	21	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
8	CD	8	8	8	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Acne	NNP	acne	acne	acn	Y	B-AdverseReaction
10	CD	10	10	10	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
5	CD	5	5	5	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Amenorrhea	NNP	amenorrhea	amenorrhea	amenorrhea	Y	B-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
17%	CD	17%	17%	17%	N	O
of	IN	of	of	of	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
females	NNS	females	female	femal	N	O
aged	VBN	aged	aged	age	N	O
10	CD	10	10	10	N	O
to	TO	to	to	to	N	O
55	CD	55	55	55	N	O
years	NNS	years	year	year	N	O
(	(	(	(	(	N	O
3	CD	3	3	3	N	O
of	IN	of	of	of	N	O
18	CD	18	18	18	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
none	NN	none	none	none	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
females	NNS	females	female	femal	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
group	NN	group	group	group	N	O
.	.	.	.	.	N	O

For	IN	for	for	for	N	O
this	DT	this	this	thi	N	O
same	JJ	same	same	same	N	O
group	NN	group	group	group	N	O
of	IN	of	of	of	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
females	NNS	females	female	femal	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
following	VBG	following	following	follow	N	O
menstrual	JJ	menstrual	menstrual	menstrual	N	B-AdverseReaction
abnormalities	NNS	abnormalities	abnormality	abnorm	N	I-AdverseReaction
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
:	:	:	:	:	N	O
dysmenorrhea	NN	dysmenorrhea	dysmenorrhea	dysmenorrhea	Y	B-AdverseReaction
(	(	(	(	(	N	O
6%	CD	6%	6%	6%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
menorrhagia	FW	menorrhagia	menorrhagia	menorrhagia	Y	B-AdverseReaction
(	(	(	(	(	N	O
6%	CD	6%	6%	6%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
metrorrhagia	FW	metrorrhagia	metrorrhagia	metrorrhagia	Y	B-AdverseReaction
(	(	(	(	(	N	O
6%	CD	6%	6%	6%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
unspecified	JJ	unspecified	unspecified	unspecifi	N	B-AdverseReaction
menstrual	JJ	menstrual	menstrual	menstrual	N	I-AdverseReaction
irregularity	NN	irregularity	irregularity	irregular	N	I-AdverseReaction
(	(	(	(	(	N	O
6%	CD	6%	6%	6%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O

following	VBG	following	following	follow	N	O
additional	JJ	additional	additional	addit	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
10%	CD	10%	10%	10%	N	O
of	IN	of	of	of	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
:	:	:	:	:	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
(	(	(	(	(	N	O
8%	CD	8%	8%	8%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
pain	VBP	pain	pain	pain	Y	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
extremity	NN	extremity	extremity	extrem	N	I-AdverseReaction
(	(	(	(	(	N	O
8%	CD	8%	8%	8%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
insomnia	NN	insomnia	insomnia	insomnia	Y	B-AdverseReaction
(	(	(	(	(	N	O
6%	CD	6%	6%	6%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
(	(	(	(	(	N	O
6%	CD	6%	6%	6%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
epistaxis	FW	epistaxis	epistaxis	epistaxi	Y	B-AdverseReaction
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
increased	VBD	increased	increased	increas	N	B-AdverseReaction
blood	NN	blood	blood	blood	N	I-AdverseReaction
luteinizing	VBG	luteinizing	luteinizing	lutein	N	I-AdverseReaction
hormone	NN	hormone	hormone	hormon	N	I-AdverseReaction
(	(	(	(	(	N	O
LH	NNP	lh	lh	lh	Y	I-AdverseReaction
)	)	)	)	)	N	O
levels	NNS	levels	level	level	N	I-AdverseReaction
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
pneumonitis	NN	pneumonitis	pneumonitis	pneumon	Y	B-AdverseReaction
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
11	CD	11	11	11	N	O
:	:	:	:	:	N	O
Key	NNP	key	key	key	N	O
Laboratory	NNP	laboratory	laboratory	laboratori	N	O
Abnormalities	NNP	abnormalities	abnormality	abnorm	N	O
Reported	NNP	reported	reported	report	N	O
in	IN	in	in	in	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
SEGA	NNP	sega	sega	sega	N	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O

Grading	VBG	grading	grading	grade	N	O
according	VBG	according	according	accord	N	O
to	TO	to	to	to	N	O
CTCAE	NNP	ctcae	ctcae	ctcae	N	O
Version	NNP	version	version	version	N	O
3.0	CD	3.0	3.0	3.0	N	O

AFINITOR	NN	afinitor	afinitor	afinitor	N	O

N	NNP	n	n	n	N	O
78	CD	78	78	78	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
N	NNP	n	n	n	N	O
39	CD	39	39	39	N	O

All	DT	all	all	all	N	O
grades	NNS	grades	grade	grade	N	O
Grade	VBD	grade	grade	grade	N	O
3	CD	3	3	3	N	O
Grade	NNP	grade	grade	grade	N	O
4	CD	4	4	4	N	O
All	NNP	all	all	all	N	O
grades	NNS	grades	grade	grade	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
Grade	NNP	grade	grade	grade	N	O
4	CD	4	4	4	N	O

Hematology	NN	hematology	hematology	hematolog	N	O

Elevated	VBN	elevated	elevated	elev	N	B-AdverseReaction
partial	JJ	partial	partial	partial	N	I-AdverseReaction
thromboplastin	NN	thromboplastin	thromboplastin	thromboplastin	Y	I-AdverseReaction
time	NN	time	time	time	N	I-AdverseReaction
72	CD	72	72	72	N	O
3	CD	3	3	3	N	O
0	CD	0	0	0	N	O
44	CD	44	44	44	N	O
5	CD	5	5	5	N	O
0	CD	0	0	0	N	O

Neutropenia	NNP	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
46	CD	46	46	46	N	O
9	CD	9	9	9	N	O
0	CD	0	0	0	N	O
41	CD	41	41	41	N	O
3	CD	3	3	3	N	O
0	CD	0	0	0	N	O

Anemia	NNP	anemia	anemia	anemia	Y	B-AdverseReaction
41	CD	41	41	41	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
21	CD	21	21	21	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Clinical	JJ	clinical	clinical	clinic	N	O
chemistry	NN	chemistry	chemistry	chemistri	N	O

Hypercholesterolemia	NNP	hypercholesterolemia	hypercholesterolemia	hypercholesterolemia	Y	B-AdverseReaction
81	CD	81	81	81	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
39	CD	39	39	39	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Elevated	VBN	elevated	elevated	elev	N	B-AdverseReaction
aspartate	JJ	aspartate	aspartate	aspart	N	I-AdverseReaction
transaminase	NN	transaminase	transaminase	transaminas	N	I-AdverseReaction
(	(	(	(	(	N	O
AST	NNP	ast	ast	ast	N	I-AdverseReaction
)	)	)	)	)	N	O
33	CD	33	33	33	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Hypertriglyceridemia	NNP	hypertriglyceridemia	hypertriglyceridemia	hypertriglyceridemia	Y	B-AdverseReaction
27	CD	27	27	27	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
15	CD	15	15	15	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Elevated	VBN	elevated	elevated	elev	N	B-AdverseReaction
alanine	JJ	alanine	alanine	alanin	N	I-AdverseReaction
transaminase	NN	transaminase	transaminase	transaminas	N	I-AdverseReaction
(	(	(	(	(	N	O
ALT	NNP	alt	alt	alt	N	I-AdverseReaction
)	)	)	)	)	N	O
18	CD	18	18	18	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
3	CD	3	3	3	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Hypophosphatemia	NNP	hypophosphatemia	hypophosphatemia	hypophosphatemia	Y	B-AdverseReaction
9	CD	9	9	9	N	O
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O
3	CD	3	3	3	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Longer	JJR	longer	longer	longer	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
follow	SYM	follow	follow	follow	N	O
-	:	-	-	-	N	O
up	IN	up	up	up	N	O
of	IN	of	of	of	N	O
34.2	CD	34.2	34.2	34.2	N	O
months	NNS	months	month	month	N	O
(	(	(	(	(	N	O
range	VB	range	range	rang	N	O
4.7	CD	4.7	4.7	4.7	N	O
to	TO	to	to	to	N	O
47.1	CD	47.1	47.1	47.1	N	O
months	NNS	months	month	month	N	O
)	)	)	)	)	N	O
from	IN	from	from	from	N	O
a	DT	a	a	a	N	O
non	JJ	non	non	non	N	O
-	:	-	-	-	N	O
randomized	VBN	randomized	randomized	random	N	O
,	,	,	,	,	N	O
open	JJ	open	open	open	N	O
-	:	-	-	-	N	O
label	NN	label	label	label	N	O
,	,	,	,	,	N	O
28	CD	28	28	28	N	O
-	:	-	-	-	N	O
patient	NN	patient	patient	patient	N	O
trial	NN	trial	trial	trial	N	O
resulted	VBD	resulted	resulted	result	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
additional	JJ	additional	additional	addit	N	O
notable	JJ	notable	notable	notabl	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
and	CC	and	and	and	N	O
key	JJ	key	key	key	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
:	:	:	:	:	N	O
cellulitis	NN	cellulitis	cellulitis	cellul	Y	B-AdverseReaction
(	(	(	(	(	N	O
29%	CD	29%	29%	29%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
hyperglycemia	NN	hyperglycemia	hyperglycemia	hyperglycemia	Y	B-AdverseReaction
(	(	(	(	(	N	O
25%	CD	25%	25%	25%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
elevated	VBD	elevated	elevated	elev	N	B-AdverseReaction
creatinine	NN	creatinine	creatinine	creatinin	Y	I-AdverseReaction
(	(	(	(	(	N	O
14%	CD	14%	14%	14%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

6.6	CD	6.6	6.6	6.6	N	O

Postmarketing	VBG	postmarketing	postmarketing	postmarket	N	O
Experience	NN	experience	experience	experi	N	O

The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
identified	VBN	identified	identified	identifi	N	O
during	IN	during	during	dure	N	O
post	NN	post	post	post	N	O
approval	NN	approval	approval	approv	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	O
these	DT	these	these	these	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
reported	VBN	reported	reported	report	N	O
voluntarily	RB	voluntarily	voluntarily	voluntarili	N	O
from	IN	from	from	from	N	O
a	DT	a	a	a	N	O
population	NN	population	population	popul	N	O
of	IN	of	of	of	N	O
uncertain	JJ	uncertain	uncertain	uncertain	N	O
size	NN	size	size	size	N	O
,	,	,	,	,	N	O
it	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
always	RB	always	always	alway	N	O
possible	JJ	possible	possible	possibl	N	O
to	TO	to	to	to	N	O
reliably	VB	reliably	reliably	reliabl	N	O
estimate	JJ	estimate	estimate	estim	N	O
frequency	NN	frequency	frequency	frequenc	N	O
or	CC	or	or	or	N	O
establish	VB	establish	establish	establish	N	O
a	DT	a	a	a	N	O
causal	NN	causal	causal	causal	N	O
relationship	NN	relationship	relationship	relationship	N	O
to	TO	to	to	to	N	O
drug	NN	drug	drug	drug	N	O
exposure	NN	exposure	exposure	exposur	N	O
:	:	:	:	:	N	O
acute	NN	acute	acute	acut	N	B-AdverseReaction
pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	I-AdverseReaction
,	,	,	,	,	N	O
cholecystitis	NN	cholecystitis	cholecystitis	cholecyst	Y	B-AdverseReaction
,	,	,	,	,	N	O
cholelithiasis	NN	cholelithiasis	cholelithiasis	cholelithiasi	Y	B-AdverseReaction
,	,	,	,	,	N	O
arterial	JJ	arterial	arterial	arteri	N	B-AdverseReaction
thrombotic	JJ	thrombotic	thrombotic	thrombot	N	I-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
and	CC	and	and	and	N	O
reflex	JJ	reflex	reflex	reflex	N	B-AdverseReaction
sympathetic	JJ	sympathetic	sympathetic	sympathet	N	I-AdverseReaction
dystrophy	NN	dystrophy	dystrophy	dystrophi	N	I-AdverseReaction
.	.	.	.	.	N	O
5	CD	5	5	5	N	O
WARNINGS	NNP	warnings	warning	warn	N	O
AND	NNP	and	and	and	N	O
PRECAUTIONS	NNP	precautions	precaution	precaut	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Non	NNP	non	non	non	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
infectious	JJ	infectious	infectious	infecti	N	I-AdverseReaction
pneumonitis	NN	pneumonitis	pneumonitis	pneumon	Y	I-AdverseReaction
:	:	:	:	:	N	O
Monitor	NN	monitor	monitor	monitor	N	O
for	IN	for	for	for	N	O
clinical	JJ	clinical	clinical	clinic	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
or	CC	or	or	or	N	O
radiological	JJ	radiological	radiological	radiolog	N	O
changes	NNS	changes	change	chang	N	O
;	:	;	;	;	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
cases	NNS	cases	case	case	N	O
have	VBP	have	have	have	N	O
occurred	VBN	occurred	occurred	occur	N	O
.	.	.	.	.	N	O

Manage	NN	manage	manage	manag	N	O
by	IN	by	by	by	N	O
dose	JJ	dose	dose	dose	N	O
reduction	NN	reduction	reduction	reduct	N	O
or	CC	or	or	or	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
until	IN	until	until	until	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
resolve	VBP	resolve	resolve	resolv	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
consider	VB	consider	consider	consid	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O

Infections	NNS	infections	infection	infect	N	B-AdverseReaction
:	:	:	:	:	N	O
Increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
infections	NNS	infections	infection	infect	N	B-AdverseReaction
,	,	,	,	,	N	O
some	DT	some	some	some	N	O
fatal	NN	fatal	fatal	fatal	N	B-AdverseReaction
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
for	IN	for	for	for	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
treat	NN	treat	treat	treat	N	O
promptly	RB	promptly	promptly	promptli	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O

Angioedema	NN	angioedema	angioedema	angioedema	Y	B-AdverseReaction
:	:	:	:	:	N	O
Patients	NNS	patients	patient	patient	N	O
taking	VBG	taking	taking	take	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
ACE	NNP	ace	ace	ace	N	O
inhibitor	NN	inhibitor	inhibitor	inhibitor	N	O
therapy	NN	therapy	therapy	therapi	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
at	IN	at	at	at	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
for	IN	for	for	for	N	O
angioedema	NN	angioedema	angioedema	angioedema	Y	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O

Oral	JJ	oral	oral	oral	N	B-AdverseReaction
ulceration	NN	ulceration	ulceration	ulcer	N	I-AdverseReaction
:	:	:	:	:	N	O
Mouth	NNP	mouth	mouth	mouth	N	B-AdverseReaction
ulcers	NNS	ulcers	ulcer	ulcer	N	I-AdverseReaction
,	,	,	,	,	N	O
stomatitis	NN	stomatitis	stomatitis	stomat	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
oral	JJ	oral	oral	oral	N	B-AdverseReaction
mucositis	NN	mucositis	mucositis	mucos	Y	I-AdverseReaction
are	VBP	are	are	are	N	O
common	JJ	common	common	common	N	O
.	.	.	.	.	N	O

Management	NNP	management	management	manag	N	O
includes	VBZ	includes	includes	includ	N	O
mouthwashes	NNS	mouthwashes	mouthwash	mouthwash	N	O
and	CC	and	and	and	N	O
topical	JJ	topical	topical	topic	N	O
treatments	NNS	treatments	treatment	treatment	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O

Renal	JJ	renal	renal	renal	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
:	:	:	:	:	N	O
Cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
renal	JJ	renal	renal	renal	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
acute	JJ	acute	acute	acut	N	B-AdverseReaction
renal	JJ	renal	renal	renal	N	I-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
some	DT	some	some	some	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
outcome	NN	outcome	outcome	outcom	N	O
,	,	,	,	,	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
observed	VBN	observed	observed	observ	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O

Impaired	NNP	impaired	impaired	impair	N	B-AdverseReaction
wound	VBD	wound	wound	wound	Y	I-AdverseReaction
healing	NN	healing	healing	heal	N	I-AdverseReaction
:	:	:	:	:	N	O
Increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
wound	WP	wound	wound	wound	Y	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
related	JJ	related	related	relat	N	I-AdverseReaction
complications	NNS	complications	complication	complic	N	I-AdverseReaction
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
.	.	.	.	.	N	O

Exercise	NN	exercise	exercise	exercis	N	O
caution	NN	caution	caution	caution	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
peri	NN	peri	peri	peri	N	O
-	:	-	-	-	N	O
surgical	JJ	surgical	surgical	surgic	N	O
period	NN	period	period	period	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
)	)	)	)	)	N	O

Laboratory	JJ	laboratory	laboratory	laboratori	N	O
test	NN	test	test	test	N	O
alterations	NNS	alterations	alteration	alter	N	O
:	:	:	:	:	N	O
Elevations	NNS	elevations	elevation	elev	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
serum	NN	serum	serum	serum	N	I-AdverseReaction
creatinine	NN	creatinine	creatinine	creatinin	Y	I-AdverseReaction
,	,	,	,	,	N	O
urinary	JJ	urinary	urinary	urinari	N	I-AdverseReaction
protein	NN	protein	protein	protein	Y	I-AdverseReaction
,	,	,	,	,	N	O
blood	NN	blood	blood	blood	N	I-AdverseReaction
glucose	NN	glucose	glucose	glucos	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
lipids	NNS	lipids	lipid	lipid	Y	I-AdverseReaction
may	MD	may	may	may	N	O
occur	VB	occur	occur	occur	N	O
.	.	.	.	.	N	O

Decreases	NNS	decreases	decrease	decreas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
hemoglobin	NN	hemoglobin	hemoglobin	hemoglobin	Y	I-AdverseReaction
,	,	,	,	,	N	O
neutrophils	NNS	neutrophils	neutrophil	neutrophil	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
platelets	NNS	platelets	platelet	platelet	N	I-AdverseReaction
may	MD	may	may	may	N	B-Factor
also	RB	also	also	also	N	O
occur	VB	occur	occur	occur	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
renal	JJ	renal	renal	renal	N	O
function	NN	function	function	function	N	O
,	,	,	,	,	N	O
blood	NN	blood	blood	blood	N	O
glucose	NN	glucose	glucose	glucos	Y	O
,	,	,	,	,	N	O
lipids	NNS	lipids	lipid	lipid	Y	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
hematologic	JJ	hematologic	hematologic	hematolog	N	O
parameters	NNS	parameters	parameter	paramet	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
treatment	NN	treatment	treatment	treatment	N	O
and	CC	and	and	and	N	O
periodically	RB	periodically	periodically	period	N	O
thereafter	RB	thereafter	thereafter	thereaft	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.8	CD	5.8	5.8	5.8	N	O
)	)	)	)	)	N	O

Vaccinations	NNS	vaccinations	vaccination	vaccin	N	O
:	:	:	:	:	N	O
Avoid	NNP	avoid	avoid	avoid	N	O
live	VBP	live	live	live	N	O
vaccines	NNS	vaccines	vaccine	vaccin	N	O
and	CC	and	and	and	N	O
close	JJ	close	close	close	N	O
contact	NN	contact	contact	contact	N	O
with	IN	with	with	with	N	O
those	DT	those	those	those	N	O
who	WP	who	who	who	N	O
have	VBP	have	have	have	N	O
received	VBN	received	received	receiv	N	O
live	JJ	live	live	live	N	O
vaccines	NNS	vaccines	vaccine	vaccin	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.11	CD	5.11	5.11	5.11	N	O
)	)	)	)	)	N	O

Embryo	NNP	embryo	embryo	embryo	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
fetal	JJ	fetal	fetal	fetal	N	I-AdverseReaction
toxicity	NN	toxicity	toxicity	toxic	N	I-AdverseReaction
:	:	:	:	:	N	O
Fetal	JJ	fetal	fetal	fetal	N	B-AdverseReaction
harm	NN	harm	harm	harm	N	I-AdverseReaction
can	MD	can	can	can	N	B-Factor
occur	VB	occur	occur	occur	N	O
when	WRB	when	when	when	N	O
administered	VBN	administered	administered	administ	N	O
to	TO	to	to	to	N	O
a	DT	a	a	a	N	O
pregnant	JJ	pregnant	pregnant	pregnant	Y	O
woman	NN	woman	woman	woman	N	O
.	.	.	.	.	N	O

Apprise	NNP	apprise	apprise	appris	N	O
women	NNS	women	woman	women	N	O
of	IN	of	of	of	N	O
potential	JJ	potential	potential	potenti	N	O
harm	NN	harm	harm	harm	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
fetus	NN	fetus	fetus	fetu	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.12	CD	5.12	5.12	5.12	N	O
,	,	,	,	,	N	O
8.1	CD	8.1	8.1	8.1	N	O
)	)	)	)	)	N	O

5.1	CD	5.1	5.1	5.1	N	O

Non	NN	non	non	non	N	O

-	:	-	-	-	N	O
infectious	JJ	infectious	infectious	infecti	N	O
Pneumonitis	NN	pneumonitis	pneumonitis	pneumon	Y	O

Non	NNP	non	non	non	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
infectious	JJ	infectious	infectious	infecti	N	I-AdverseReaction
pneumonitis	NN	pneumonitis	pneumonitis	pneumon	Y	I-AdverseReaction
is	VBZ	is	is	is	N	O
a	DT	a	a	a	N	O
class	NN	class	class	class	N	O
effect	NN	effect	effect	effect	N	O
of	IN	of	of	of	N	O
rapamycin	NN	rapamycin	rapamycin	rapamycin	N	O
derivatives	NNS	derivatives	derivative	deriv	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
.	.	.	.	.	N	O

Non	NNP	non	non	non	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
infectious	JJ	infectious	infectious	infecti	N	I-AdverseReaction
pneumonitis	NN	pneumonitis	pneumonitis	pneumon	Y	I-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
up	IN	up	up	up	N	O
to	TO	to	to	to	N	O
19%	CD	19%	19%	19%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
Common	NNP	common	common	common	N	O
Terminology	NNP	terminology	terminology	terminolog	N	O
Criteria	NNP	criteria	criterion	criteria	N	O
(	(	(	(	(	N	O
CTC	NNP	ctc	ctc	ctc	N	O
)	)	)	)	)	N	O
Grade	VBD	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
and	CC	and	and	and	N	O
4	CD	4	4	4	N	I-Severity
non	JJ	non	non	non	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
infectious	JJ	infectious	infectious	infecti	N	I-AdverseReaction
pneumonitis	NN	pneumonitis	pneumonitis	pneumon	Y	I-AdverseReaction
was	VBD	was	wa	wa	N	O
up	RB	up	up	up	N	O
to	TO	to	to	to	N	O
4.0%	CD	4.0%	4.0%	4.0%	N	O
and	CC	and	and	and	N	O
up	RB	up	up	up	N	O
to	TO	to	to	to	N	O
0.2%	CD	0.2%	0.2%	0.2%	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
[	JJ	[	[	[	N	O
see	VBP	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
,	,	,	,	,	N	O
6.2	CD	6.2	6.2	6.2	N	O
,	,	,	,	,	N	O
6.3	CD	6.3	6.3	6.3	N	O
,	,	,	,	,	N	O
6.4	CD	6.4	6.4	6.4	N	O
,	,	,	,	,	N	O
6.5	CD	6.5	6.5	6.5	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
outcomes	NNS	outcomes	outcome	outcom	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
observed	VBN	observed	observed	observ	N	O
.	.	.	.	.	N	O

Consider	VB	consider	consider	consid	N	B-Factor
a	DT	a	a	a	N	O
diagnosis	NN	diagnosis	diagnosis	diagnosi	N	O
of	IN	of	of	of	N	O
non	JJ	non	non	non	N	O
-	:	-	-	-	N	O
infectious	JJ	infectious	infectious	infecti	N	O
pneumonitis	NN	pneumonitis	pneumonitis	pneumon	Y	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
presenting	VBG	presenting	presenting	present	N	O
with	IN	with	with	with	N	O
non	JJ	non	non	non	N	O
-	:	-	-	-	N	O
specific	JJ	specific	specific	specif	N	O
respiratory	NN	respiratory	respiratory	respiratori	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
hypoxia	NN	hypoxia	hypoxia	hypoxia	Y	O
,	,	,	,	,	N	O
pleural	JJ	pleural	pleural	pleural	N	O
effusion	NN	effusion	effusion	effus	Y	O
,	,	,	,	,	N	O
cough	NN	cough	cough	cough	Y	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
whom	WP	whom	whom	whom	N	O
infectious	JJ	infectious	infectious	infecti	N	O
,	,	,	,	,	N	O
neoplastic	JJ	neoplastic	neoplastic	neoplast	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
other	JJ	other	other	other	N	O
causes	NNS	causes	cause	caus	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
excluded	VBN	excluded	excluded	exclud	N	O
by	IN	by	by	by	N	O
means	NNS	means	mean	mean	N	O
of	IN	of	of	of	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
investigations	NNS	investigations	investigation	investig	N	O
.	.	.	.	.	N	O

Opportunistic	JJ	opportunistic	opportunistic	opportunist	N	O
infections	NNS	infections	infection	infect	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
pneumocystis	NN	pneumocystis	pneumocystis	pneumocysti	N	O
jiroveci	NN	jiroveci	jiroveci	jiroveci	N	O
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	O
(	(	(	(	(	N	O
PJP	NNP	pjp	pjp	pjp	N	O
)	)	)	)	)	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
considered	VBN	considered	considered	consid	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
differential	JJ	differential	differential	differenti	N	O
diagnosis	NN	diagnosis	diagnosis	diagnosi	N	O
.	.	.	.	.	N	O

Advise	NN	advise	advise	advis	N	O
patients	NNS	patients	patient	patient	N	O
to	TO	to	to	to	N	O
report	VB	report	report	report	N	O
promptly	RB	promptly	promptly	promptli	N	O
any	DT	any	any	ani	N	O
new	JJ	new	new	new	N	O
or	CC	or	or	or	N	O
worsening	VBG	worsening	worsening	worsen	N	O
respiratory	NN	respiratory	respiratory	respiratori	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
develop	VBP	develop	develop	develop	N	O
radiological	JJ	radiological	radiological	radiolog	N	O
changes	NNS	changes	change	chang	N	O
suggestive	VBP	suggestive	suggestive	suggest	N	O
of	IN	of	of	of	N	O
non	JJ	non	non	non	N	O
-	:	-	-	-	N	O
infectious	JJ	infectious	infectious	infecti	N	O
pneumonitis	NN	pneumonitis	pneumonitis	pneumon	Y	O
and	CC	and	and	and	N	O
have	VBP	have	have	have	N	O
few	JJ	few	few	few	N	O
or	CC	or	or	or	N	O
no	DT	no	no	no	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
may	MD	may	may	may	N	O
continue	VB	continue	continue	continu	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
therapy	NN	therapy	therapy	therapi	N	O
without	IN	without	without	without	N	O
dose	JJ	dose	dose	dose	N	O
alteration	NN	alteration	alteration	alter	N	O
.	.	.	.	.	N	O

Imaging	VBG	imaging	imaging	imag	N	O
appears	VBZ	appears	appears	appear	N	O
to	TO	to	to	to	N	O
overestimate	VB	overestimate	overestimate	overestim	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
clinical	JJ	clinical	clinical	clinic	N	O
pneumonitis	NN	pneumonitis	pneumonitis	pneumon	Y	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
are	VBP	are	are	are	N	O
moderate	JJ	moderate	moderate	moder	N	O
,	,	,	,	,	N	O
consider	VB	consider	consider	consid	N	O
interrupting	VBG	interrupting	interrupting	interrupt	N	O
therapy	NN	therapy	therapy	therapi	N	O
until	IN	until	until	until	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
improve	VBP	improve	improve	improv	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
indicated	VBN	indicated	indicated	indic	N	B-Factor
.	.	.	.	.	N	O

AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
reintroduced	VBN	reintroduced	reintroduced	reintroduc	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
daily	JJ	daily	daily	daili	N	O
dose	NN	dose	dose	dose	N	O
approximately	RB	approximately	approximately	approxim	N	O
50%	CD	50%	50%	50%	N	O
lower	JJR	lower	lower	lower	N	O
than	IN	than	than	than	N	O
the	DT	the	the	the	N	O
dose	JJ	dose	dose	dose	N	O
previously	RB	previously	previously	previous	N	O
administered	VBN	administered	administered	administ	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
in	IN	in	in	in	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

For	IN	for	for	for	N	O
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
non	SYM	non	non	non	N	O
-	:	-	-	-	N	O
infectious	JJ	infectious	infectious	infecti	N	O
pneumonitis	NN	pneumonitis	pneumonitis	pneumon	Y	O
interrupt	JJ	interrupt	interrupt	interrupt	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
until	IN	until	until	until	N	O
resolution	NN	resolution	resolution	resolut	N	O
to	TO	to	to	to	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
or	CC	or	or	or	N	O
equal	JJ	equal	equal	equal	N	O
to	TO	to	to	to	N	O
Grade	VB	grade	grade	grade	N	O
1	CD	1	1	1	N	O
.	.	.	.	.	N	O

AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
re	VBN	re	re	re	N	O
-	:	-	-	-	N	O
introduced	VBN	introduced	introduced	introduc	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
daily	JJ	daily	daily	daili	N	O
dose	NN	dose	dose	dose	N	O
approximately	RB	approximately	approximately	approxim	N	O
50%	CD	50%	50%	50%	N	O
lower	JJR	lower	lower	lower	N	O
than	IN	than	than	than	N	O
the	DT	the	the	the	N	O
dose	JJ	dose	dose	dose	N	O
previously	RB	previously	previously	previous	N	O
administered	VBN	administered	administered	administ	N	O
depending	VBG	depending	depending	depend	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
individual	JJ	individual	individual	individu	N	O
clinical	JJ	clinical	clinical	clinic	N	O
circumstances	NNS	circumstances	circumstance	circumst	N	O
[	VBP	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
toxicity	NN	toxicity	toxicity	toxic	N	O
recurs	VBP	recurs	recurs	recur	N	O
at	IN	at	at	at	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
,	,	,	,	,	N	O
consider	JJR	consider	consider	consid	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
.	.	.	.	.	N	O

For	IN	for	for	for	N	O
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
Grade	NNP	grade	grade	grade	N	O
4	CD	4	4	4	N	O
non	SYM	non	non	non	N	O
-	:	-	-	-	N	O
infectious	JJ	infectious	infectious	infecti	N	O
pneumonitis	NN	pneumonitis	pneumonitis	pneumon	Y	O
,	,	,	,	,	N	O
discontinue	NN	discontinue	discontinue	discontinu	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
.	.	.	.	.	N	O

Corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
indicated	VBN	indicated	indicated	indic	N	O
until	IN	until	until	until	N	O
clinical	JJ	clinical	clinical	clinic	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
resolve	VBP	resolve	resolve	resolv	N	O
.	.	.	.	.	N	O

For	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
require	VBP	require	require	requir	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
for	IN	for	for	for	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
non	JJ	non	non	non	N	O
-	:	-	-	-	N	O
infectious	JJ	infectious	infectious	infecti	N	O
pneumonitis	NN	pneumonitis	pneumonitis	pneumon	Y	O
,	,	,	,	,	N	O
prophylaxis	NN	prophylaxis	prophylaxis	prophylaxi	Y	O
for	IN	for	for	for	N	O
PJP	NNP	pjp	pjp	pjp	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
considered	VBN	considered	considered	consid	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
development	NN	development	development	develop	N	O
of	IN	of	of	of	N	O
pneumonitis	NN	pneumonitis	pneumonitis	pneumon	Y	B-AdverseReaction
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
even	RB	even	even	even	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
reduced	JJ	reduced	reduced	reduc	N	O
dose	NN	dose	dose	dose	N	O
.	.	.	.	.	N	O

5.2	CD	5.2	5.2	5.2	N	O
Infections	NNS	infections	infection	infect	N	O

AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
has	VBZ	has	ha	ha	N	O
immunosuppressive	JJ	immunosuppressive	immunosuppressive	immunosuppress	N	O
properties	NNS	properties	property	properti	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	B-Factor
predispose	VB	predispose	predispose	predispos	N	O
patients	NNS	patients	patient	patient	N	O
to	TO	to	to	to	N	O
bacterial	JJ	bacterial	bacterial	bacteri	N	B-AdverseReaction
,	,	,	,	,	N	O
fungal	JJ	fungal	fungal	fungal	N	B-AdverseReaction
,	,	,	,	,	N	O
viral	JJ	viral	viral	viral	N	B-AdverseReaction
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
protozoal	NN	protozoal	protozoal	protozo	N	B-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
infections	NNS	infections	infection	infect	N	B-AdverseReaction
with	IN	with	with	with	N	I-AdverseReaction
opportunistic	JJ	opportunistic	opportunistic	opportunist	N	I-AdverseReaction
pathogens	NNS	pathogens	pathogen	pathogen	N	I-AdverseReaction
[	MD	[	[	[	N	O
see	VB	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
,	,	,	,	,	N	O
6.2	CD	6.2	6.2	6.2	N	O
,	,	,	,	,	N	O
6.3	CD	6.3	6.3	6.3	N	O
,	,	,	,	,	N	O
6.4	CD	6.4	6.4	6.4	N	O
,	,	,	,	,	N	O
6.5	CD	6.5	6.5	6.5	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Localized	VBN	localized	localized	local	N	O
and	CC	and	and	and	N	O
systemic	JJ	systemic	systemic	system	N	O
infections	NNS	infections	infection	infect	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
,	,	,	,	,	N	O
mycobacterial	JJ	mycobacterial	mycobacterial	mycobacteri	N	B-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
,	,	,	,	,	N	O
other	JJ	other	other	other	N	O
bacterial	JJ	bacterial	bacterial	bacteri	N	B-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
,	,	,	,	,	N	O
invasive	JJ	invasive	invasive	invas	N	B-AdverseReaction
fungal	JJ	fungal	fungal	fungal	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
,	,	,	,	,	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
aspergillosis	NN	aspergillosis	aspergillosis	aspergillosi	Y	B-AdverseReaction
,	,	,	,	,	N	O
candidiasis	NN	candidiasis	candidiasis	candidiasi	Y	B-AdverseReaction
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
pneumocystis	NN	pneumocystis	pneumocystis	pneumocysti	N	B-AdverseReaction
jiroveci	NN	jiroveci	jiroveci	jiroveci	N	I-AdverseReaction
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	I-AdverseReaction
(	(	(	(	(	N	O
PJP	NNP	pjp	pjp	pjp	N	B-AdverseReaction
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
viral	JJ	viral	viral	viral	N	B-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
including	VBG	including	including	includ	N	O
reactivation	NN	reactivation	reactivation	reactiv	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
hepatitis	NN	hepatitis	hepatitis	hepat	Y	I-AdverseReaction
B	NNP	b	b	b	N	I-AdverseReaction
virus	NN	virus	virus	viru	N	I-AdverseReaction
have	VBP	have	have	have	N	O
occurred	VBN	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
taking	VBG	taking	taking	take	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
.	.	.	.	.	N	O

Some	DT	some	some	some	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
infections	NNS	infections	infection	infect	N	B-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
severe	JJ	severe	severe	sever	N	B-Severity
(	(	(	(	(	N	O
e	JJ	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
leading	VBG	leading	leading	lead	N	O
to	TO	to	to	to	N	O
sepsis	VB	sepsis	sepsis	sepsi	Y	B-AdverseReaction
,	,	,	,	,	N	O
respiratory	NN	respiratory	respiratory	respiratori	N	B-AdverseReaction
or	CC	or	or	or	N	O
hepatic	JJ	hepatic	hepatic	hepat	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
.	.	.	.	.	N	O

Physicians	NNS	physicians	physician	physician	N	O
and	CC	and	and	and	N	O
patients	NNS	patients	patient	patient	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
aware	JJ	aware	aware	awar	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
infection	NN	infection	infection	infect	Y	O
with	IN	with	with	with	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
.	.	.	.	.	N	O

Complete	JJ	complete	complete	complet	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
pre	NN	pre	pre	pre	N	O
-	:	-	-	-	N	O
existing	VBG	existing	existing	exist	N	O
invasive	JJ	invasive	invasive	invas	N	O
fungal	JJ	fungal	fungal	fungal	N	O
infections	NNS	infections	infection	infect	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
starting	VBG	starting	starting	start	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
.	.	.	.	.	N	O

While	IN	while	while	while	N	O
taking	VBG	taking	taking	take	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
,	,	,	,	,	N	O
be	VB	be	be	be	N	O
vigilant	JJ	vigilant	vigilant	vigil	N	O
for	IN	for	for	for	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
infection	NN	infection	infection	infect	Y	O
;	:	;	;	;	N	O
if	IN	if	if	if	N	O
a	DT	a	a	a	N	O
diagnosis	NN	diagnosis	diagnosis	diagnosi	N	O
of	IN	of	of	of	N	O
an	DT	an	an	an	N	O
infection	NN	infection	infection	infect	Y	O
is	VBZ	is	is	is	N	O
made	VBN	made	made	made	N	O
,	,	,	,	,	N	O
institute	JJ	institute	institute	institut	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
treatment	NN	treatment	treatment	treatment	N	O
promptly	RB	promptly	promptly	promptli	N	O
and	CC	and	and	and	N	O
consider	VB	consider	consider	consid	N	O
interruption	NN	interruption	interruption	interrupt	N	O
or	CC	or	or	or	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
a	DT	a	a	a	N	O
diagnosis	NN	diagnosis	diagnosis	diagnosi	N	O
of	IN	of	of	of	N	O
invasive	JJ	invasive	invasive	invas	N	O
systemic	JJ	systemic	systemic	system	N	O
fungal	JJ	fungal	fungal	fungal	N	O
infection	NN	infection	infection	infect	Y	O
is	VBZ	is	is	is	N	O
made	VBN	made	made	made	N	O
,	,	,	,	,	N	O
discontinue	VB	discontinue	discontinue	discontinu	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
and	CC	and	and	and	N	O
treat	NN	treat	treat	treat	N	O
with	IN	with	with	with	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
antifungal	JJ	antifungal	antifungal	antifung	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

Pneumocystis	NNP	pneumocystis	pneumocystis	pneumocysti	N	B-AdverseReaction
jiroveci	NN	jiroveci	jiroveci	jiroveci	N	I-AdverseReaction
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	I-AdverseReaction
,	,	,	,	,	N	O
some	DT	some	some	some	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
outcome	NN	outcome	outcome	outcom	N	O
,	,	,	,	,	N	O
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
everolimus	NN	everolimus	everolimus	everolimu	N	O
.	.	.	.	.	N	O

This	DT	this	this	thi	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
or	CC	or	or	or	N	O
other	JJ	other	other	other	N	O
immunosuppressive	JJ	immunosuppressive	immunosuppressive	immunosuppress	N	O
agents	NNS	agents	agent	agent	N	O
.	.	.	.	.	N	O

Prophylaxis	NNP	prophylaxis	prophylaxis	prophylaxi	Y	O
for	IN	for	for	for	N	O
PJP	NNP	pjp	pjp	pjp	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
considered	VBN	considered	considered	consid	N	O
when	WRB	when	when	when	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
or	CC	or	or	or	N	O
other	JJ	other	other	other	N	O
immunosuppressive	JJ	immunosuppressive	immunosuppressive	immunosuppress	N	O
agents	NNS	agents	agent	agent	N	O
are	VBP	are	are	are	N	O
required	VBN	required	required	requir	N	O
.	.	.	.	.	N	O

5.3	CD	5.3	5.3	5.3	N	O
Angioedema	NNP	angioedema	angioedema	angioedema	Y	O
with	IN	with	with	with	N	O
Concomitant	NNP	concomitant	concomitant	concomit	N	O
Use	NNP	use	use	use	N	O
of	IN	of	of	of	N	O
Angiotensin	NNP	angiotensin	angiotensin	angiotensin	N	O
-	:	-	-	-	N	O
Converting	VBG	converting	converting	convert	N	O
Enzyme	NNP	enzyme	enzyme	enzym	N	O
(	(	(	(	(	N	O
ACE	NNP	ace	ace	ace	N	O
)	)	)	)	)	N	O
Inhibitors	NNS	inhibitors	inhibitor	inhibitor	N	O

Patients	NNS	patients	patient	patient	N	O
taking	VBG	taking	taking	take	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
ACE	NNP	ace	ace	ace	N	O
inhibitor	NN	inhibitor	inhibitor	inhibitor	N	O
therapy	NN	therapy	therapy	therapi	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
at	IN	at	at	at	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	B-Factor
for	IN	for	for	for	N	O
angioedema	NN	angioedema	angioedema	angioedema	Y	B-AdverseReaction
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
swelling	VBG	swelling	swelling	swell	Y	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
airways	NNS	airways	airway	airway	N	I-AdverseReaction
or	CC	or	or	or	N	O
tongue	NN	tongue	tongue	tongu	N	I-AdverseReaction
,	,	,	,	,	N	O
with	IN	with	with	with	N	O
or	CC	or	or	or	N	O
without	IN	without	without	without	N	O
respiratory	JJ	respiratory	respiratory	respiratori	N	B-AdverseReaction
impairment	NN	impairment	impairment	impair	N	I-AdverseReaction
)	)	)	)	)	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
a	DT	a	a	a	N	O
pooled	JJ	pooled	pooled	pool	N	O
analysis	NN	analysis	analysis	analysi	N	O
of	IN	of	of	of	N	O
randomized	VBN	randomized	randomized	random	N	O
double	JJ	double	double	doubl	N	O
-	:	-	-	-	N	O
blind	NN	blind	blind	blind	Y	O
oncology	JJ	oncology	oncology	oncolog	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
angioedema	NN	angioedema	angioedema	angioedema	Y	B-AdverseReaction
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
taking	VBG	taking	taking	take	N	O
everolimus	NN	everolimus	everolimus	everolimu	N	O
with	IN	with	with	with	N	O
an	DT	an	an	an	N	O
ACE	NNP	ace	ace	ace	N	O
inhibitor	NN	inhibitor	inhibitor	inhibitor	N	O
was	VBD	was	wa	wa	N	O
6.8%	CD	6.8%	6.8%	6.8%	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
1.3%	CD	1.3%	1.3%	1.3%	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
control	NN	control	control	control	N	O
arm	NN	arm	arm	arm	N	O
with	IN	with	with	with	N	O
an	DT	an	an	an	N	O
ACE	NNP	ace	ace	ace	N	O
inhibitor	NN	inhibitor	inhibitor	inhibitor	N	O
.	.	.	.	.	N	O

5.4	CD	5.4	5.4	5.4	N	O
Oral	JJ	oral	oral	oral	N	O
Ulceration	NN	ulceration	ulceration	ulcer	N	O

Mouth	NNP	mouth	mouth	mouth	N	B-AdverseReaction
ulcers	NNS	ulcers	ulcer	ulcer	N	I-AdverseReaction
,	,	,	,	,	N	O
stomatitis	NN	stomatitis	stomatitis	stomat	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
oral	JJ	oral	oral	oral	N	B-AdverseReaction
mucositis	NN	mucositis	mucositis	mucos	Y	I-AdverseReaction
have	VBP	have	have	have	N	O
occurred	VBN	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
at	IN	at	at	at	N	O
an	DT	an	an	an	N	O
incidence	NN	incidence	incidence	incid	N	O
ranging	VBG	ranging	ranging	rang	N	O
from	IN	from	from	from	N	O
44%	CD	44%	44%	44%	N	O
-	:	-	-	-	N	O
78%	CD	78%	78%	78%	N	O
across	IN	across	across	across	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trial	NN	trial	trial	trial	N	O
experience	NN	experience	experience	experi	N	O
.	.	.	.	.	N	O

Grade	VB	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
or	CC	or	or	or	N	O
4	CD	4	4	4	N	I-Severity
stomatitis	NN	stomatitis	stomatitis	stomat	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
4%	CD	4%	4%	4%	N	O
-	:	-	-	-	N	O
9%	CD	9%	9%	9%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
[	JJ	[	[	[	N	O
see	VBP	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
,	,	,	,	,	N	O
6.2	CD	6.2	6.2	6.2	N	O
,	,	,	,	,	N	O
6.3	CD	6.3	6.3	6.3	N	O
,	,	,	,	,	N	O
6.4	CD	6.4	6.4	6.4	N	O
,	,	,	,	,	N	O
6.5	CD	6.5	6.5	6.5	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
such	JJ	such	such	such	N	O
cases	NNS	cases	case	case	N	O
,	,	,	,	,	N	O
topical	JJ	topical	topical	topic	N	O
treatments	NNS	treatments	treatment	treatment	N	O
are	VBP	are	are	are	N	O
recommended	VBN	recommended	recommended	recommend	N	O
,	,	,	,	,	N	O
but	CC	but	but	but	N	O
alcohol	SYM	alcohol	alcohol	alcohol	N	O
-	:	-	-	-	N	O
,	,	,	,	,	N	O
hydrogen	NN	hydrogen	hydrogen	hydrogen	N	O
peroxide	NN	peroxide	peroxide	peroxid	N	O
-	:	-	-	-	N	O
,	,	,	,	,	N	O
iodine	JJ	iodine	iodine	iodin	N	O
-	:	-	-	-	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
thyme	SYM	thyme	thyme	thyme	N	O
-	:	-	-	-	N	O
containing	VBG	containing	containing	contain	N	O
mouthwashes	NNS	mouthwashes	mouthwash	mouthwash	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
avoided	VBN	avoided	avoided	avoid	N	O
as	IN	as	a	as	N	O
they	PRP	they	they	they	N	O
may	MD	may	may	may	N	O
exacerbate	VB	exacerbate	exacerbate	exacerb	N	O
the	DT	the	the	the	N	O
condition	NN	condition	condition	condit	N	O
.	.	.	.	.	N	O

Antifungal	JJ	antifungal	antifungal	antifung	N	O
agents	NNS	agents	agent	agent	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
used	VBN	used	used	use	N	O
unless	IN	unless	unless	unless	N	O
fungal	JJ	fungal	fungal	fungal	N	O
infection	NN	infection	infection	infect	Y	O
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
diagnosed	VBN	diagnosed	diagnosed	diagnos	N	O
[	JJ	[	[	[	N	O
see	VBP	see	see	see	N	O
Drug	JJ	drug	drug	drug	N	O
Interactions	NNP	interactions	interaction	interact	N	O
(	(	(	(	(	N	O
7.1	CD	7.1	7.1	7.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

5.5	CD	5.5	5.5	5.5	N	O
Renal	JJ	renal	renal	renal	N	O
Failure	NN	failure	failure	failur	N	O

Cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
renal	JJ	renal	renal	renal	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
acute	JJ	acute	acute	acut	N	B-AdverseReaction
renal	JJ	renal	renal	renal	N	I-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
some	DT	some	some	some	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
outcome	NN	outcome	outcome	outcom	N	O
,	,	,	,	,	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Laboratory	JJ	laboratory	laboratory	laboratori	N	O
Tests	NNS	tests	test	test	N	O
and	CC	and	and	and	N	O
Monitoring	NNP	monitoring	monitoring	monitor	N	O
(	(	(	(	(	N	O
5.8	CD	5.8	5.8	5.8	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

5.6	CD	5.6	5.6	5.6	N	O
Impaired	NNP	impaired	impaired	impair	N	O
Wound	NNP	wound	wound	wound	Y	O
Healing	NNP	healing	healing	heal	N	O

Everolimus	NNP	everolimus	everolimus	everolimu	N	O
delays	VBZ	delays	delay	delay	N	B-AdverseReaction
wound	IN	wound	wound	wound	Y	I-AdverseReaction
healing	VBG	healing	healing	heal	N	I-AdverseReaction
and	CC	and	and	and	N	O
increases	VBZ	increases	increase	increas	N	O
the	DT	the	the	the	N	O
occurrence	NN	occurrence	occurrence	occurr	N	O
of	IN	of	of	of	N	O
wound	NN	wound	wound	wound	Y	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
related	JJ	related	related	relat	N	I-AdverseReaction
complications	NNS	complications	complication	complic	N	I-AdverseReaction
like	IN	like	like	like	N	O
wound	NN	wound	wound	wound	Y	B-AdverseReaction
dehiscence	NN	dehiscence	dehiscence	dehisc	N	I-AdverseReaction
,	,	,	,	,	N	O
wound	JJ	wound	wound	wound	Y	B-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
incisional	JJ	incisional	incisional	incision	N	B-AdverseReaction
hernia	NN	hernia	hernia	hernia	Y	I-AdverseReaction
,	,	,	,	,	N	O
lymphocele	NN	lymphocele	lymphocele	lymphocel	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
seroma	NN	seroma	seroma	seroma	Y	B-AdverseReaction
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
wound	SYM	wound	wound	wound	Y	O
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
complications	NNS	complications	complication	complic	N	O
may	MD	may	may	may	N	O
require	VB	require	require	requir	N	O
surgical	JJ	surgical	surgical	surgic	N	O
intervention	NN	intervention	intervention	intervent	N	O
.	.	.	.	.	N	O

Exercise	NN	exercise	exercise	exercis	N	O
caution	NN	caution	caution	caution	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
peri	NN	peri	peri	peri	N	O
-	:	-	-	-	N	O
surgical	JJ	surgical	surgical	surgic	N	O
period	NN	period	period	period	N	O
.	.	.	.	.	N	O

5.7	CD	5.7	5.7	5.7	N	O
Geriatric	JJ	geriatric	geriatric	geriatr	N	O
Patients	NNS	patients	patient	patient	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
randomized	NN	randomized	randomized	random	N	O
advanced	VBD	advanced	advanced	advanc	N	O
hormone	NN	hormone	hormone	hormon	N	O
receptor	NN	receptor	receptor	receptor	N	O
-	:	-	-	-	N	O
positive	JJ	positive	positive	posit	N	O
,	,	,	,	,	N	O
HER2	NNP	her2	her2	her2	N	O
-	:	-	-	-	N	O
negative	JJ	negative	negative	neg	N	O
breast	NN	breast	breast	breast	N	O
cancer	NN	cancer	cancer	cancer	Y	O
study	NN	study	study	studi	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
deaths	NNS	deaths	death	death	N	B-AdverseReaction
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
any	DT	any	any	ani	N	O
cause	NN	cause	cause	caus	N	O
within	IN	within	within	within	N	O
28	CD	28	28	28	N	O
days	NNS	days	day	day	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
last	JJ	last	last	last	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
dose	NN	dose	dose	dose	N	O
was	VBD	was	wa	wa	N	O
6%	CD	6%	6%	6%	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
65	CD	65	65	65	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
age	NN	age	age	age	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
2%	CD	2%	2%	2%	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
65	CD	65	65	65	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
age	NN	age	age	age	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
leading	VBG	leading	leading	lead	N	O
to	TO	to	to	to	N	O
permanent	JJ	permanent	permanent	perman	N	O
treatment	NN	treatment	treatment	treatment	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
33%	CD	33%	33%	33%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
65	CD	65	65	65	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
age	NN	age	age	age	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
17%	CD	17%	17%	17%	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
65	CD	65	65	65	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
age	NN	age	age	age	N	O
.	.	.	.	.	N	O

Careful	JJ	careful	careful	care	N	O
monitoring	NN	monitoring	monitoring	monitor	N	O
and	CC	and	and	and	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
dose	NN	dose	dose	dose	N	O
adjustments	NNS	adjustments	adjustment	adjust	N	O
for	IN	for	for	for	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
recommended	VBN	recommended	recommended	recommend	N	O
[	JJ	[	[	[	N	O
see	NN	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
Use	NNP	use	use	use	N	O
in	IN	in	in	in	N	O
Specific	NNP	specific	specific	specif	N	O
Populations	NNP	populations	population	popul	N	O
(	(	(	(	(	N	O
8.5	CD	8.5	8.5	8.5	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

5.8	CD	5.8	5.8	5.8	N	O
Laboratory	JJ	laboratory	laboratory	laboratori	N	O
Tests	NNS	tests	test	test	N	O
and	CC	and	and	and	N	O
Monitoring	VBG	monitoring	monitoring	monitor	N	O

Renal	JJ	renal	renal	renal	N	O
Function	NN	function	function	function	N	O

Elevations	NNS	elevations	elevation	elev	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
serum	JJ	serum	serum	serum	N	I-AdverseReaction
creatinine	NN	creatinine	creatinine	creatinin	Y	I-AdverseReaction
and	CC	and	and	and	N	O
proteinuria	NNS	proteinuria	proteinuria	proteinuria	Y	B-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
taking	VBG	taking	taking	take	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
,	,	,	,	,	N	O
6.2	CD	6.2	6.2	6.2	N	O
,	,	,	,	,	N	O
6.3	CD	6.3	6.3	6.3	N	O
,	,	,	,	,	N	O
6.4	CD	6.4	6.4	6.4	N	O
,	,	,	,	,	N	O
6.5	CD	6.5	6.5	6.5	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Monitoring	NN	monitoring	monitoring	monitor	N	O
of	IN	of	of	of	N	O
renal	JJ	renal	renal	renal	N	O
function	NN	function	function	function	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
measurement	NN	measurement	measurement	measur	N	O
of	IN	of	of	of	N	O
blood	NN	blood	blood	blood	N	O
urea	JJ	urea	urea	urea	Y	O
nitrogen	NN	nitrogen	nitrogen	nitrogen	N	O
(	(	(	(	(	N	O
BUN	NNP	bun	bun	bun	Y	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
urinary	JJ	urinary	urinary	urinari	N	O
protein	NN	protein	protein	protein	Y	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
serum	JJ	serum	serum	serum	N	O
creatinine	NN	creatinine	creatinine	creatinin	Y	O
,	,	,	,	,	N	O
is	VBZ	is	is	is	N	O
recommended	VBN	recommended	recommended	recommend	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
start	NN	start	start	start	N	O
of	IN	of	of	of	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
therapy	NN	therapy	therapy	therapi	N	O
and	CC	and	and	and	N	O
periodically	RB	periodically	periodically	period	N	O
thereafter	RB	thereafter	thereafter	thereaft	N	O
.	.	.	.	.	N	O

Renal	JJ	renal	renal	renal	N	O
function	NN	function	function	function	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
monitored	VBN	monitored	monitored	monitor	N	O
particularly	RB	particularly	particularly	particularli	N	O
where	WRB	where	where	where	N	O
patients	NNS	patients	patient	patient	N	O
have	VBP	have	have	have	N	O
additional	JJ	additional	additional	addit	N	O
risk	NN	risk	risk	risk	N	O
factors	NNS	factors	factor	factor	N	O
that	WDT	that	that	that	N	O
may	MD	may	may	may	N	O
further	RB	further	further	further	N	O
impair	VB	impair	impair	impair	N	O
renal	JJ	renal	renal	renal	N	O
function	NN	function	function	function	N	O
.	.	.	.	.	N	O

Blood	NNP	blood	blood	blood	N	O
Glucose	NNP	glucose	glucose	glucos	Y	O
and	CC	and	and	and	N	O
Lipids	NNP	lipids	lipid	lipid	Y	O

Hyperglycemia	NNP	hyperglycemia	hyperglycemia	hyperglycemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
hyperlipidemia	NN	hyperlipidemia	hyperlipidemia	hyperlipidemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
hypertriglyceridemia	NN	hypertriglyceridemia	hypertriglyceridemia	hypertriglyceridemia	Y	B-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
taking	VBG	taking	taking	take	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
,	,	,	,	,	N	O
6.2	CD	6.2	6.2	6.2	N	O
,	,	,	,	,	N	O
6.3	CD	6.3	6.3	6.3	N	O
,	,	,	,	,	N	O
6.4	CD	6.4	6.4	6.4	N	O
,	,	,	,	,	N	O
6.5	CD	6.5	6.5	6.5	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Monitoring	NN	monitoring	monitoring	monitor	N	O
of	IN	of	of	of	N	O
fasting	VBG	fasting	fasting	fast	Y	O
serum	NN	serum	serum	serum	N	O
glucose	NN	glucose	glucose	glucos	Y	O
and	CC	and	and	and	N	O
lipid	JJ	lipid	lipid	lipid	N	O
profile	NN	profile	profile	profil	N	O
is	VBZ	is	is	is	N	O
recommended	VBN	recommended	recommended	recommend	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
start	NN	start	start	start	N	O
of	IN	of	of	of	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
therapy	NN	therapy	therapy	therapi	N	O
and	CC	and	and	and	N	O
periodically	RB	periodically	periodically	period	N	O
thereafter	RB	thereafter	thereafter	thereaft	N	O
as	RB	as	a	as	N	O
well	RB	well	well	well	N	O
as	IN	as	a	as	N	O
management	NN	management	management	manag	N	O
with	IN	with	with	with	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
medical	JJ	medical	medical	medic	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

More	RBR	more	more	more	N	O
frequent	JJ	frequent	frequent	frequent	N	O
monitoring	NN	monitoring	monitoring	monitor	N	O
is	VBZ	is	is	is	N	O
recommended	VBN	recommended	recommended	recommend	N	O
when	WRB	when	when	when	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
is	VBZ	is	is	is	N	O
co	JJ	co	co	co	N	O
-	:	-	-	-	N	O
administered	VBN	administered	administered	administ	N	O
with	IN	with	with	with	N	O
other	JJ	other	other	other	N	O
drugs	NNS	drugs	drug	drug	N	O
that	WDT	that	that	that	N	O
may	MD	may	may	may	N	O
induce	VB	induce	induce	induc	N	O
hyperglycemia	NN	hyperglycemia	hyperglycemia	hyperglycemia	Y	O
.	.	.	.	.	N	O

When	WRB	when	when	when	N	O
possible	JJ	possible	possible	possibl	N	O
,	,	,	,	,	N	O
optimal	JJ	optimal	optimal	optim	N	O
glucose	NN	glucose	glucose	glucos	Y	O
and	CC	and	and	and	N	O
lipid	JJ	lipid	lipid	lipid	N	O
control	NN	control	control	control	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
achieved	VBN	achieved	achieved	achiev	N	O
before	IN	before	before	befor	N	O
starting	VBG	starting	starting	start	N	O
a	DT	a	a	a	N	O
patient	NN	patient	patient	patient	N	O
on	IN	on	on	on	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
.	.	.	.	.	N	O

Hematologic	NNP	hematologic	hematologic	hematolog	N	O
Parameters	NNS	parameters	parameter	paramet	N	O

Decreased	VBN	decreased	decreased	decreas	N	B-AdverseReaction
hemoglobin	NN	hemoglobin	hemoglobin	hemoglobin	Y	I-AdverseReaction
,	,	,	,	,	N	O
lymphocytes	VBZ	lymphocytes	lymphocyte	lymphocyt	Y	I-AdverseReaction
,	,	,	,	,	N	O
neutrophils	NNS	neutrophils	neutrophil	neutrophil	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
platelets	NNS	platelets	platelet	platelet	N	I-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
taking	VBG	taking	taking	take	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
,	,	,	,	,	N	O
6.2	CD	6.2	6.2	6.2	N	O
,	,	,	,	,	N	O
6.3	CD	6.3	6.3	6.3	N	O
,	,	,	,	,	N	O
6.4	CD	6.4	6.4	6.4	N	O
,	,	,	,	,	N	O
6.5	CD	6.5	6.5	6.5	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Monitoring	NN	monitoring	monitoring	monitor	N	O
of	IN	of	of	of	N	O
complete	JJ	complete	complete	complet	N	O
blood	NN	blood	blood	blood	N	O
count	NN	count	count	count	N	O
is	VBZ	is	is	is	N	O
recommended	VBN	recommended	recommended	recommend	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
start	NN	start	start	start	N	O
of	IN	of	of	of	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
therapy	NN	therapy	therapy	therapi	N	O
and	CC	and	and	and	N	O
periodically	RB	periodically	periodically	period	N	O
thereafter	RB	thereafter	thereafter	thereaft	N	O
.	.	.	.	.	N	O

5.9	CD	5.9	5.9	5.9	N	O
Drug	NNP	drug	drug	drug	N	O
-	:	-	-	-	N	O
drug	NN	drug	drug	drug	N	O
Interactions	NNS	interactions	interaction	interact	N	O

Due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
significant	JJ	significant	significant	signific	N	O
increases	NNS	increases	increase	increas	N	O
in	IN	in	in	in	N	O
exposure	NN	exposure	exposure	exposur	N	O
of	IN	of	of	of	N	O
everolimus	NN	everolimus	everolimus	everolimu	N	O
,	,	,	,	,	N	O
co	SYM	co	co	co	N	O
-	:	-	-	-	N	O
administration	NN	administration	administration	administr	N	O
with	IN	with	with	with	N	O
strong	JJ	strong	strong	strong	N	O
CYP3A4	NNP	cyp3a4	cyp3a4	cyp3a4	N	O
PgP	NNP	pgp	pgp	pgp	N	O
inhibitors	NNS	inhibitors	inhibitor	inhibitor	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
avoided	VBN	avoided	avoided	avoid	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
,	,	,	,	,	N	O
2.5	CD	2.5	2.5	2.5	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Drug	NNP	drug	drug	drug	N	O
Interactions	NNP	interactions	interaction	interact	N	O
(	(	(	(	(	N	O
7.1	CD	7.1	7.1	7.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

A	DT	a	a	a	N	O
reduction	NN	reduction	reduction	reduct	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
dose	NN	dose	dose	dose	N	O
is	VBZ	is	is	is	N	O
recommended	VBN	recommended	recommended	recommend	N	O
when	WRB	when	when	when	N	O
co	JJ	co	co	co	N	O
-	:	-	-	-	N	O
administered	VBN	administered	administered	administ	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
moderate	JJ	moderate	moderate	moder	N	O
CYP3A4	NNP	cyp3a4	cyp3a4	cyp3a4	N	O
PgP	NNP	pgp	pgp	pgp	N	O
inhibitor	NN	inhibitor	inhibitor	inhibitor	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
,	,	,	,	,	N	O
2.5	CD	2.5	2.5	2.5	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Drug	NNP	drug	drug	drug	N	O
Interactions	NNP	interactions	interaction	interact	N	O
(	(	(	(	(	N	O
7.1	CD	7.1	7.1	7.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

An	DT	an	an	an	N	O
increase	NN	increase	increase	increas	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
dose	NN	dose	dose	dose	N	O
is	VBZ	is	is	is	N	O
recommended	VBN	recommended	recommended	recommend	N	O
when	WRB	when	when	when	N	O
co	JJ	co	co	co	N	O
-	:	-	-	-	N	O
administered	VBN	administered	administered	administ	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
strong	JJ	strong	strong	strong	N	O
CYP3A4	NNP	cyp3a4	cyp3a4	cyp3a4	N	O
PgP	NNP	pgp	pgp	pgp	N	O
inducer	NN	inducer	inducer	induc	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
,	,	,	,	,	N	O
2.5	CD	2.5	2.5	2.5	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Drug	NNP	drug	drug	drug	N	O
Interactions	NNP	interactions	interaction	interact	N	O
(	(	(	(	(	N	O
7.2	CD	7.2	7.2	7.2	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

5.10	CD	5.10	5.10	5.10	N	O
Hepatic	JJ	hepatic	hepatic	hepat	N	O
Impairment	NN	impairment	impairment	impair	N	O

Exposure	NN	exposure	exposure	exposur	N	O
to	TO	to	to	to	N	O
everolimus	VB	everolimus	everolimus	everolimu	N	O
was	VBD	was	wa	wa	N	O
increased	VBN	increased	increased	increas	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
hepatic	JJ	hepatic	hepatic	hepat	N	B-AdverseReaction
impairment	NN	impairment	impairment	impair	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Pharmacology	NNP	pharmacology	pharmacology	pharmacolog	N	O
(	(	(	(	(	N	O
12.3	CD	12.3	12.3	12.3	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

For	IN	for	for	for	N	O
advanced	JJ	advanced	advanced	advanc	N	O
HR	NNP	hr	hr	hr	N	O
BC	NNP	bc	bc	bc	N	O
,	,	,	,	,	N	O
advanced	VBD	advanced	advanced	advanc	N	O
PNET	NNP	pnet	pnet	pnet	N	O
,	,	,	,	,	N	O
advanced	VBD	advanced	advanced	advanc	N	O
RCC	NNP	rcc	rcc	rcc	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
renal	JJ	renal	renal	renal	N	O
angiomyolipoma	NN	angiomyolipoma	angiomyolipoma	angiomyolipoma	Y	O
with	IN	with	with	with	N	O
TSC	NNP	tsc	tsc	tsc	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
severe	JJ	severe	severe	sever	N	B-Severity
hepatic	JJ	hepatic	hepatic	hepat	N	B-AdverseReaction
impairment	NN	impairment	impairment	impair	N	I-AdverseReaction
(	(	(	(	(	N	O
Child	NNP	child	child	child	N	O
-	:	-	-	-	N	O
Pugh	NNP	pugh	pugh	pugh	N	O
class	NN	class	class	class	N	O
C	NNP	c	c	c	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
used	VBN	used	used	use	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
reduced	VBN	reduced	reduced	reduc	N	O
dose	NN	dose	dose	dose	N	O
if	IN	if	if	if	N	O
the	DT	the	the	the	N	O
desired	JJ	desired	desired	desir	N	O
benefit	NN	benefit	benefit	benefit	N	O
outweighs	VBZ	outweighs	outweighs	outweigh	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
.	.	.	.	.	N	O

For	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
mild	JJ	mild	mild	mild	N	O
(	(	(	(	(	N	O
Child	NNP	child	child	child	N	O
-	:	-	-	-	N	O
Pugh	NNP	pugh	pugh	pugh	N	O
class	NN	class	class	class	N	O
A	NNP	a	a	a	N	O
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
moderate	JJ	moderate	moderate	moder	N	O
(	(	(	(	(	N	O
Child	NNP	child	child	child	N	O
-	:	-	-	-	N	O
Pugh	NNP	pugh	pugh	pugh	N	O
class	NN	class	class	class	N	O
B	NNP	b	b	b	N	O
)	)	)	)	)	N	O
hepatic	JJ	hepatic	hepatic	hepat	N	O
impairment	NN	impairment	impairment	impair	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
dose	JJ	dose	dose	dose	N	O
reduction	NN	reduction	reduction	reduct	N	O
is	VBZ	is	is	is	N	O
recommended	VBN	recommended	recommended	recommend	N	O
[	JJ	[	[	[	N	O
see	NN	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Pharmacology	NNP	pharmacology	pharmacology	pharmacolog	N	O
(	(	(	(	(	N	O
12.3	CD	12.3	12.3	12.3	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

For	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
SEGA	NNP	sega	sega	sega	N	O
and	CC	and	and	and	N	O
mild	VB	mild	mild	mild	N	O
or	CC	or	or	or	N	O
moderate	VB	moderate	moderate	moder	N	O
hepatic	JJ	hepatic	hepatic	hepat	N	O
impairment	NN	impairment	impairment	impair	N	O
,	,	,	,	,	N	O
adjust	VBP	adjust	adjust	adjust	N	O
the	DT	the	the	the	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
Tablets	NNPS	tablets	tablet	tablet	N	O
or	CC	or	or	or	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
DISPERZ	NNP	disperz	disperz	disperz	N	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
therapeutic	JJ	therapeutic	therapeutic	therapeut	N	O
drug	NN	drug	drug	drug	N	O
monitoring	NN	monitoring	monitoring	monitor	N	O
.	.	.	.	.	N	O

For	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
SEGA	NNP	sega	sega	sega	N	O
and	CC	and	and	and	N	O
severe	JJ	severe	severe	sever	N	O
hepatic	JJ	hepatic	hepatic	hepat	N	O
impairment	NN	impairment	impairment	impair	N	O
,	,	,	,	,	N	O
reduce	VB	reduce	reduce	reduc	N	O
the	DT	the	the	the	N	O
starting	VBG	starting	starting	start	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
Tablets	NNPS	tablets	tablet	tablet	N	O
or	CC	or	or	or	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
DISPERZ	NNP	disperz	disperz	disperz	N	O
by	IN	by	by	by	N	O
approximately	RB	approximately	approximately	approxim	N	O
50%	CD	50%	50%	50%	N	O
and	CC	and	and	and	N	O
adjust	JJ	adjust	adjust	adjust	N	O
subsequent	NN	subsequent	subsequent	subsequ	N	O
doses	NNS	doses	dos	dose	N	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
therapeutic	JJ	therapeutic	therapeutic	therapeut	N	O
drug	NN	drug	drug	drug	N	O
monitoring	NN	monitoring	monitoring	monitor	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.4	CD	2.4	2.4	2.4	N	O
,	,	,	,	,	N	O
2.5	CD	2.5	2.5	2.5	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

5.11	CD	5.11	5.11	5.11	N	O
Vaccinations	NNS	vaccinations	vaccination	vaccin	N	O

During	IN	during	during	dure	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
treatment	NN	treatment	treatment	treatment	N	O
,	,	,	,	,	N	O
avoid	VBP	avoid	avoid	avoid	N	O
the	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
live	JJ	live	live	live	N	O
vaccines	NNS	vaccines	vaccine	vaccin	N	O
and	CC	and	and	and	N	O
avoid	VBP	avoid	avoid	avoid	N	O
close	JJ	close	close	close	N	O
contact	NN	contact	contact	contact	N	O
with	IN	with	with	with	N	O
individuals	NNS	individuals	individual	individu	N	O
who	WP	who	who	who	N	O
have	VBP	have	have	have	N	O
received	VBN	received	received	receiv	N	O
live	JJ	live	live	live	N	O
vaccines	NNS	vaccines	vaccine	vaccin	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
intranasal	JJ	intranasal	intranasal	intranas	N	O
influenza	NN	influenza	influenza	influenza	Y	O
,	,	,	,	,	N	O
measles	NNS	measles	measles	measl	Y	O
,	,	,	,	,	N	O
mumps	NNS	mumps	mumps	mump	Y	O
,	,	,	,	,	N	O
rubella	NN	rubella	rubella	rubella	Y	O
,	,	,	,	,	N	O
oral	JJ	oral	oral	oral	N	O
polio	NN	polio	polio	polio	Y	O
,	,	,	,	,	N	O
BCG	NNP	bcg	bcg	bcg	N	O
,	,	,	,	,	N	O
yellow	JJ	yellow	yellow	yellow	N	O
fever	NN	fever	fever	fever	Y	O
,	,	,	,	,	N	O
varicella	NN	varicella	varicella	varicella	Y	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
TY21a	NNP	ty21a	ty21a	ty21a	N	O
typhoid	NNP	typhoid	typhoid	typhoid	Y	O
vaccines	NNS	vaccines	vaccine	vaccin	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

For	IN	for	for	for	N	O
pediatric	JJ	pediatric	pediatric	pediatr	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
SEGA	NNP	sega	sega	sega	N	O
that	WDT	that	that	that	N	O
do	VBP	do	do	do	N	O
not	RB	not	not	not	N	O
require	VB	require	require	requir	N	O
immediate	JJ	immediate	immediate	immedi	N	O
treatment	NN	treatment	treatment	treatment	N	O
,	,	,	,	,	N	O
complete	VB	complete	complete	complet	N	O
the	DT	the	the	the	N	O
recommended	JJ	recommended	recommended	recommend	N	O
childhood	NN	childhood	childhood	childhood	Y	O
series	NN	series	series	seri	N	O
of	IN	of	of	of	N	O
live	JJ	live	live	live	N	O
virus	NN	virus	virus	viru	N	O
vaccinations	NNS	vaccinations	vaccination	vaccin	N	O
according	VBG	according	according	accord	N	O
to	TO	to	to	to	N	O
American	NNP	american	american	american	N	O
Council	NNP	council	council	council	N	O
on	IN	on	on	on	N	O
Immunization	NNP	immunization	immunization	immun	Y	O
Practices	NNP	practices	practice	practic	N	O
(	(	(	(	(	N	O
ACIP	NNP	acip	acip	acip	N	O
)	)	)	)	)	N	O
guidelines	NNS	guidelines	guideline	guidelin	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
start	NN	start	start	start	N	O
of	IN	of	of	of	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

An	DT	an	an	an	N	O
accelerated	JJ	accelerated	accelerated	acceler	N	O
vaccination	NN	vaccination	vaccination	vaccin	Y	O
schedule	NN	schedule	schedule	schedul	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
.	.	.	.	.	N	O

5.12	CD	5.12	5.12	5.12	N	O
Embryo	NNP	embryo	embryo	embryo	N	O
-	:	-	-	-	N	O
fetal	JJ	fetal	fetal	fetal	N	O
Toxicity	NN	toxicity	toxicity	toxic	N	O

Based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
mechanism	NN	mechanism	mechanism	mechan	N	O
of	IN	of	of	of	N	O
action	NN	action	action	action	N	O
,	,	,	,	,	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
can	MD	can	can	can	N	B-Factor
cause	VB	cause	cause	caus	N	O
fetal	JJ	fetal	fetal	fetal	N	B-AdverseReaction
harm	NN	harm	harm	harm	N	I-AdverseReaction
.	.	.	.	.	N	O

Everolimus	NNP	everolimus	everolimus	everolimu	N	O
caused	VBD	caused	caused	caus	N	O
embryo	SYM	embryo	embryo	embryo	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
fetal	JJ	fetal	fetal	fetal	N	I-AdverseReaction
toxicities	NNS	toxicities	toxicity	toxic	N	I-AdverseReaction
in	IN	in	in	in	N	O
animals	NNS	animals	animal	anim	N	B-Animal
at	IN	at	at	at	N	O
maternal	JJ	maternal	maternal	matern	N	O
exposures	NNS	exposures	exposure	exposur	N	O
that	WDT	that	that	that	N	O
were	VBD	were	were	were	N	O
lower	JJR	lower	lower	lower	N	O
than	IN	than	than	than	N	O
human	JJ	human	human	human	N	O
exposures	NNS	exposures	exposure	exposur	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
this	DT	this	this	thi	N	O
drug	NN	drug	drug	drug	N	O
is	VBZ	is	is	is	N	O
used	VBN	used	used	use	N	O
during	IN	during	during	dure	N	O
pregnancy	NN	pregnancy	pregnancy	pregnanc	Y	O
or	CC	or	or	or	N	O
if	IN	if	if	if	N	O
the	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
becomes	VBZ	becomes	becomes	becom	N	O
pregnant	JJ	pregnant	pregnant	pregnant	Y	O
while	IN	while	while	while	N	O
taking	VBG	taking	taking	take	N	O
this	DT	this	this	thi	N	O
drug	NN	drug	drug	drug	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
apprised	VBN	apprised	apprised	appris	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
potential	JJ	potential	potential	potenti	N	O
hazard	NN	hazard	hazard	hazard	N	O
to	TO	to	to	to	N	O
a	DT	a	a	a	N	O
fetus	NN	fetus	fetus	fetu	N	O
[	NNP	[	[	[	N	O
see	NN	see	see	see	N	O
Use	NNP	use	use	use	N	O
in	IN	in	in	in	N	O
Specific	NNP	specific	specific	specif	N	O
Populations	NNP	populations	population	popul	N	O
(	(	(	(	(	N	O
8.1	CD	8.1	8.1	8.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Advise	NNP	advise	advise	advis	N	O
female	JJ	female	female	femal	N	O
patients	NNS	patients	patient	patient	N	O
of	IN	of	of	of	N	O
reproductive	JJ	reproductive	reproductive	reproduct	N	O
potential	NN	potential	potential	potenti	N	O
to	TO	to	to	to	N	O
avoid	VB	avoid	avoid	avoid	N	O
becoming	VBG	becoming	becoming	becom	N	O
pregnant	JJ	pregnant	pregnant	pregnant	Y	O
and	CC	and	and	and	N	O
to	TO	to	to	to	N	O
use	VB	use	use	use	N	O
highly	RB	highly	highly	highli	N	O
effective	JJ	effective	effective	effect	N	O
contraception	NN	contraception	contraception	contracept	Y	O
while	IN	while	while	while	N	O
using	VBG	using	using	use	N	O
AFINITOR	NNP	afinitor	afinitor	afinitor	N	O
and	CC	and	and	and	N	O
for	IN	for	for	for	N	O
up	RB	up	up	up	N	O
to	TO	to	to	to	N	O
8	CD	8	8	8	N	O
weeks	NNS	weeks	week	week	N	O
after	IN	after	after	after	N	O
ending	VBG	ending	ending	end	N	O
treatment	NN	treatment	treatment	treatment	N	O
[	NNP	[	[	[	N	O
see	NN	see	see	see	N	O
Use	NNP	use	use	use	N	O
in	IN	in	in	in	N	O
Specific	NNP	specific	specific	specif	N	O
Populations	NNP	populations	population	popul	N	O
(	(	(	(	(	N	O
8.6	CD	8.6	8.6	8.6	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

